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 ABSTRACT 
 
Diabetes is a chronic disease affecting approximately 250 million people. To date, 
transplantation-based therapy is the therapy of choice; however, its success is hampered by 
the scarcity of transplantable human material. An alternative strategy is the promotion of 
regeneration in the pancreas. Endothelial progenitor cells (EPCs), a subpopulation of bone 
marrow (BM) cells, can contribute to tissue repair in various pathological conditions via 
the formation of new blood vessels. In this thesis, I review and discuss the role and 
regenerative potential of EPCs in diabetes using non-obese diabetic (NOD) mice, a model 
of type 1 diabetes (T1D). Flow cytometry analyses of the EPC population in BM and blood 
of both diabetic and pre-diabetic NOD mice suggested that at the onset of diabetes, BM-
derived EPCs are stimulated to enter the systemic circulation in response to signals from 
the pancreas. To further investigate the contribution of EPCs to β-cell regeneration, whole 
BM and cultured EPCs were transplanted into pre-diabetic and diabetic NOD mice soon 
after diabetes was diagnosed. Our data imply that BM cells from wild type mice 
administered before the onset of diabetes may have an effect in delaying β-cell destruction 
evidenced by glycaemic control, reduced inflammation and increased number of 
proliferating Ki-67+ Insulin+ cells. EPCs transplanted into early diabetic NOD mice had 
reduced inflammation and a higher survival rate compared to control mice that did not 
receive EPCs. I therefore believe that both BM and EPCs show great promise in 
regenerating the damaged pancreas of NOD mice. 
 
In addition to promoting endogenous β-cell regeneration using EPCs, I have investigated a 
strategy to protect β-cell death via apoptosis, using a protease peptide XG-102 developed 
by Xigen. Since apoptosis of β-cells is one of the putative mechanisms involved in the 
cascade of events leading to T1D, we tested XG-102, for prevention of β-cell loss in the 
NOD mouse. Treated mice had a larger number of islets and inflammation was less 
prevalent compared to control mice. Additionally, XG-102 treated mice showed better 
control of their blood glucose.  
 
In conclusion, both therapeutic strategies showed great promise in regenerating the 
damaged pancreas of NOD mice. While these strategies are still under further 
investigation, they offer encouragement in the quest for the treatment of early diabetes in 
the future. 
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CHAPTER 1: INTRODUCTION 
 
1.1. BACKGROUND 
 
Diabetes is a debilitating condition where the glucose level in the body is high due to 
impairment of the body’s ability to process it properly. This disease affects nearly 250 
million people worldwide and its number is estimated to increase to 380 million in 
approximately 20 years time (The International Diabetes Federation, 2006)(Table1.1.). 
Diabetes causes various complications such as kidney failure, heart attacks and stroke 
which have a significant impact on quality of life.  
 
 2007 2025 
Total world population (billions) 6.6 7.9 
Adult population (age 20-79, billions) 4.1 5.2 
WORLD DIABETES (20-70 age group)   
Comparative prevalence (%) 6.0 7.3 
Number of people with diabetes (millions) 246 380 
 
 
 
 
Diabetes is a multigenic disorder that is divided into two groups; type 1 and type 2 
diabetes. ‘Type 1 diabetes (T1D) is a chronic disease that occurs when the pancreas 
produces too little insulin to regulate blood sugar levels appropriately’ (American Diabetes 
Association, 2003). This form of diabetes occurs approximately in 5-10% of diabetics. 
T1D is further subdivided into two types, type 1A (immune-mediated diabetes) which 
involves autodestruction of β-cells and type 1B (idiopathic diabetes) which causes 
permanent insulin deficiency and up to now its aetiology is still unknown (American 
Diabetes Association, 2003). Type 2 diabetes (T2D) is the more common form of diabetes, 
where the peripheral tissues are resistant to insulin due to the insufficient release of insulin 
by the pancreatic β-cells. Insulin plays a role in maintaining glucose homeostasis, 
converting excess glucose to glycogen which is stored, until glucose levels in the body 
drop drastically, which activates the conversion of glycogen back to glucose. 
Table 1.1 Estimated statistics for type 1 diabetes prevalence worldwide. 
(Modified from Diabetes Atlas third edition, International Diabetes Federation; 2009) 
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Transplantation therapies which include whole-organ pancreas and islet transplantation 
have been in practice since the 1990s as evidenced by the successes of treatments using the 
Edmonton Protocol developed by Shapiro and colleagues (Shapiro et al., 2000). The 
Edmonton Protocol consists of techniques for the isolation and preservation of islets with 
steroid-free immunosuppressive treatment for transplant of pancreatic islet cells in patients 
with diabetes (Kordella, 2003). However, due to an insufficient supply of donor pancreata 
and islets and reported immune system rejection, researchers now are looking for 
alternative treatments.  
 
Embryonic stem cells (ESCs) are pluripotent cells which have the ability to give rise to 
numerous specialised cells. They are capable of unlimited self-renewal and have recently 
attracted public attention as a viable source for replacement of insulin-secreting cells. The 
use of ESCs in clinical application is not viable to date as various issues such as teratoma 
formation and immune rejection might occur when transplanted into patients. Unlike 
ESCs, adult stem cells are multipotent cells and can only differentiate to a limited range of 
cell types. Although ESCs seem to have more potential in producing insulin-secreting 
cells, there were some successes reported where adult stem cells in the rat liver have been 
cultured under certain conditions and it was found they were able to differentiate into β-
cells (Yang et al., 2002). Other extra-pancreatic cell sources for their transdifferentiation 
into insulin-secreting cells are bone marrow mesenchymal stem cells (Ianus et al., 2003; 
Moriscot et al., 2005), mouse intestinal epithelium (Suzuki et al., 2003) and monocytes 
from human peripheral blood (Ruhnke et al., 2005).  
 
Another therapeutic strategy that has gained interest in recent years is the promotion of 
regeneration in the pancreas without the need to worry about immunorejection. Based on 
the knowledge that there are still some residual functioning β-cells in patients with diabetes 
(may vary, depends on severity of disease), studies have tried inducing replication and 
neogenesis of existing β-cells using glucagon-like peptide (GLP-1) or exendin-4 (Rolin et 
al., 2002; Xu et al., 1999) and reported a significant increase in β-cell mass, reduced 
apoptosis and improved glucose tolerance in both diabetic rat and mice models. Excessive 
β-cell destruction by apoptosis and defective autoimmune regulation have been implicated 
in the pathogenesis of T1D. The infusion of major histocompatibility complex class-1 
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matched spleen cells was shown to attenuate the autoimmune process as well as contribute 
to islet regeneration, possibly in a paracrine manner (Kodama et al., 2003). 
  
A subset of cells from the bone marrow (BM) called endothelial progenitor cells (EPCs) 
can contribute to tissue repair in various pathological conditions via the formation of new 
blood vessels i.e. neovascularization (Dome et al., 2006; Hilbe et al., 2004; Mathews et al., 
2004). In the STZ-induced model of T1D, several studies have demonstrated that BM-
derived EPCs could be stimulated to enter the systemic circulation in response to signals 
from the pancreas (Hasegawa et al., 2007; Hess et al., 2003; Mathews et al., 2004). Apart 
from contributing to neovascularization, it is highly likely that BM-derived EPCs have 
indirectly contributed to islet regeneration by releasing factors that act in a paracrine 
manner, reducing inflammation and promoting cell survival and proliferation. While this 
discovery is still under further investigation, it offers hope and brings us a step forward for 
the treatment of diabetes in the future.  
 
In this thesis, I review and discuss the role and regenerative potential of EPCs in diabetes. 
Equally important is to understand the mechanisms of β-cell death to prevent excessive β-
cell death. 
 
1.2. ANATOMY AND THE EMBRYOLOGY OF THE PANCREAS  
 
The pancreas plays a role in the digestive system. It is divided into two types of tissues; the 
endocrine and exocrine tissue. Clusters of endocrine cells known as the Islets of 
Langerhans, are embedded in the exocrine tissue and secrete hormones, including insulin 
directly into the blood system. The Islets of Langerhans consist of 4 types of cells with β-
cells being the majority (Figure 1.1). In contrast, exocrine cells (namely acinar cells) 
secrete various digestive enzymes. The pancreatic β-cells are important as they secrete 
insulin which helps maintain blood glucose levels in the body. β-cells also influence the 
functioning of neighbouring cells via autocrine and paracrine interactions (Ishihara et al., 
2003) .  
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Figure 1.1. Anatomy of the pancreas depicting location of islets of Langerhans 
in the human body (Picture from Encyclopaedia Brittanica Online, 2003 ) 
 
 
 
1.3. STAGES OF PANCREATIC DEVELOPMENT IN MOUSE AND HUMAN  
 
The pancreas is derived from the gut (endodermal germ layer). Pancreatic development in 
the mouse can be divided into four key stages (Gu et al., 2004): - (i) embryonic day (E) 7.5 
where groups of cells envelope the mesoderm and ectoderm forming an ‘unspecified 
endoderm’; (ii) E10.5 where pancreatic cells start to express the transcription factor Pdx1; 
(iii) E13.5 where endocrine progenitor cells start to express another transcription factor 
Ngn3 and (iv) mature islets of Langerhans form (occurs shortly after birth) by aggregation 
of endocrine cells migrated from the ducts. Pancreatic development in humans however is 
divided into five distinct stages (Portela-Gomes et al., 1999) :- (i) embryonic day (E) E24 
where the dorsal pancreatic bud first appears then the ventral pancreatic bud, a day later (ii) 
embryonic week (EW) 5-6 where differential growth of the foregut is followed by fusion 
of dorsal and ventral pancreatic rudiments (iii) EW 10 to EW 15 where endocrine cells 
start to assemble and form islets; (iv) EW 16 to EW 20 where islets develop into a more 
vascular form and (v) EW 21 to EW26, period of development of islet innervations. 
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Golosow and Grobstein (1962) used murine models to propose that the pancreas was 
developed as a consequence of the interaction between the pancreatic epithelium and 
mesenchyme and occurs at E10 onwards. It was shown in vivo in rodent models that the 
associated mesenchyme surrounding the pancreatic epithelium modulates the proliferation 
of immature pancreatic epithelial cells, instructing differentiation into endocrine or 
exocrine tissue (Polak et al., 2000; Scharfmann, 2000). 
 
Human and mouse pancreatic development follows a general trend; dorsal and ventral bud 
appear from midgut (Hill, 2005). Pancreatic epithelial cells differentiate into pancreatic β-
cells. The continuous development of the pancreas is mainly mediated by active 
interactions between endoderm and blood vessels (Lammert et al., 2000). The population 
of insulin-secreting cells rapidly expands and becomes more defined; this indicates the 
formation of the endocrine pancreas, which eventually leads to the formation of mature 
islets. 
 
1.4. TYPE 1 DIABETES (T1D) 
 
T1D is an autoimmune disorder with onset occurring mainly in children. Its onset is due to 
both genetic and external factors where the exposure of a genetically susceptible individual 
to specific allergens triggers the body’s immune response to immunologically destroy 
pancreatic β-cells (Fig. 1.2). Islet cell autoantibodies form, demonstrating the initial stage 
of β-cell destruction. The loss of the first phase of insulin secretion follows and β-cell 
destruction progresses (Imagawa et al., 1999). The immunologic destruction of pancreatic 
β-cells results in a significant reduction in β-cell mass, preventing the maintenance of 
normal blood glucose levels due to the inadequate amount of insulin being secreted. 
Currently, patients with T1D are treated with insulin injections (Zimmet et al., 2001).  
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Figure 1.2. Natural history of Type 1 diabetes (adapted from Tisch and McDevitt, 
1996) 
The pathogenesis of autoimmune T1D is complex and involves the interplay between 
genetics and environment (Tisch and McDevitt, 1996) (Figure 1.2). Various genes have 
been implicated in different stages of T1D development including centrally located MHC-
HLA class II. In the 1970’s, candidate gene studies have identified  HLA on chromosome 
6 and it was the first locus shown to be associated with T1D (Cudworth and Woodrow, 
1975; Nerup et al., 1974), contributing half of the familial basis of T1D (Todd, 1995). The 
second most important genetic susceptibility factor is the insulin gene on chromosome 11 
contributing 10% of susceptibility to T1D (Bell et al., 1984; Gillespie, 2006). In addition, 
environmental factors play a role in the development of T1D. Some environmental factors 
that have been implicated include infectious agents (viruses-congenital rubella, 
enteroviruses), early life factors (cow’s milk protein, vitamin D deficiency, rapid growth) 
and toxins, vaccinations, stress and climatic influences (Dahlquist, 1997; Knip and 
Akerblom, 1999). 
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1.5. β-CELL DESTRUCTION  
 
T1D is characterized by selective destruction of β-cells by the immune system, which 
results in insufficient insulin production to regulate blood glucose level leading to 
hyperglycaemia. Immunodysregulation in T1D leads to the development of autoantibodies 
against islet cell components such as glutamic acid decarboxylase antibodies (GAD-65), 
insulinoma antigen 2 (IA-2), insulin autoantibodies (IAA). The expression of 
autoantibodies are good markers for prediction of T1D in first degree relatives (Verge et 
al., 1996), reflecting the magnitude of ongoing β-cell destruction (Lernmark, 1999; 
Maclaren et al., 2003)  
 
1.5.1. Autoimmunity 
 
T1D occurs in early life due to rapid immune-mediated loss of β-cells. Early studies using 
spontaneous models of T1D such as the non-obese diabetic (NOD) mouse and the 
BioBreeding (BB) diabetes-prone rat revealed that T1D  is caused by infiltration of T- and 
B-lymphocytes, a process commonly known as insulitis (Yang and Santamaria, 2006). This 
is followed by active destruction of β-cells which leads to diabetes onset. Based on a vast 
number of studies on the pathogenesis of diabetes, there is consensus that the progression 
of autoimmune β-cell destruction is a T-lymphocyte-mediated event, where CD8+ cells 
initiate the process while CD4+ lymphocytes mediate the islet destructive process (Dotta et 
al., 2005). Macrophages and/or dendritic cells have also been implicated in the insulitis 
stage in the NOD mouse and BB rat (Dotta et al., 2005) (Figure 1.3, Table 1.2). 
Characteristics Human T1D NOD STZ-induce 
(low dose) 
BB-rat 
Sex predominance Female = Male Female > >Male Female = Male Female = Male 
Insulitis Medium 
severity, mainly 
T-cells 
Destructive, T-
cells, 
macrophages 
/dendritic cells 
Non-specific, T-
cells 
Destructive, 
macrophages 
/dendritic cells 
Diabetes onset Spontaneous Spontaneous Induced Spontaneous 
Successful 
intervention 
therapies 
In progress Yes Yes Yes 
 Table 1.2. Summary of the characteristics of human T1D and animal models (the NOD 
mouse model, STZ-induced diabetes (low-dose) and BB-rat. 
(Abbreviations: T1D, type 1 diabetes; NOD, non-obese diabetic; STZ, streptozotocin; 
BB-rat, BioBreeding-rat)  
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Figure 1.3. Autoimmune response  in the NOD mouse (adapted from Yang and 
Santamaria, 2006) 
 
Environmental factors such as viral infection and stress can trigger the start of β-cell 
autoimmunity. In the NOD mouse, macrophages and dendritic cells or antigen-presenting 
cells (APCs) are recruited to the periphery of pancreatic ducts and islets cells around 
weaning (Homo-Delarche and Drexhage, 2004) (Figure 1.3, 1.4). APCs ingest the β-cell 
antigens and migrate to the pancreatic lymph node (Mathis et al., 2001). Subsequently, 
APCs display β-cell antigens to naive β-cell reactive T-cells and activate them. Activated 
T-cells migrate into the pancreas and re-encounter β-cell antigen marking the initiation of 
insulitis. Infiltration of T-cells around islets progresses with age, releasing cytokines and 
other soluble death mediators. 
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Figure 1.4. Proposed scheme for the initiation of T1D (Adapted from Kaufman, 
2003). Environmental factors trigger the start of β-cell autoimmunity in genetically 
susceptible individuals. β-cell-specific antigens are released and subsequently, T-
lymphocytes are mobilized that specifically recognize these antigens resulting in 
widespread β-cell killing in several stages; peri-insulitis, intra-islet insulitis and finally 
severe insulitis. 
 
Immunological abnormalities observed in diabetic NOD mice and humans could contribute 
to the autoimmune process of diabetes, such as dysfunctional natural killer and regulatory 
T-cells (Brusko et al., 2005; Lindley et al., 2005; Shi et al., 2001). It is further 
demonstrated in NOD mice that they have a decreased number of helper T-cells (Th1 and 
Th2 cells), an imbalanced ratio of Th1 effector to Th2 suppressor cells and defective APC 
mediated co-stimulation that can affect onset and rate of diabetes development (Salomon et 
al., 2000; Trembleau et al., 2003). In T1D, there is a loss of self-tolerance believed to be 
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due to defective antigen presentation by APCs to T-lymphocytes resulting in inappropriate 
T-lymphocyte activation (Kubach et al., 2005).  
 
1.5.2. Apoptosis 
 
Apoptosis is a form of programmed cell death, important in developmental remodelling 
and/or to maintain homeostasis of the β-cell mass (Trudeau et al., 2000). Many studies to 
date have suggested that apoptosis is probably the main form of β-cell death in T1D 
causing gradual β-cell depletion (Reviewed in (Cnop et al., 2005; Eizirik and Mandrup-
Poulsen, 2001). β-cell death by apoptosis is easily identifiable, characterized by plasma 
membrane blebbing, cytoplasmic and organelle contraction and shrinkage, nuclear 
chromatin condenzation and DNA fragmentation/cleavage (Grodzicky and Elkon, 2002). 
Apoptosis is a multi-step process involving :- (i) induction stage; initiated by extracellular 
death signals; (ii) effector phase; activation of one or more signal transduction pathways 
and (iii) degradation phase; where signal transduction pathways converge to a few final 
death pathways carried out usually by proteases-caspases and caspase-activated DNAse 
(Dotta et al., 2005). 
 
Several signalling pathways have been implicated in apoptosis, mainly divided into (i) 
extrinsic pathway (death-receptor induced pathway) (ii) intrinsic pathway (reviewed in 
Grodzicky and Elkon, 2002). The extrinsic pathway is stimulated by death receptor 
engagement such as Fas and Fas ligand binding which initiates a signalling caspase 
cascade. Cell surface receptor Fas and Fas ligand (FasL) are expressed on β-cells and 
CD8+ T-cells respectively (Kawasaki et al., 2004). Once FAS is activated upon binding of 
FasL, Fas trimerizes and recruits Fas-associated death domain (FADD) to its cytoplasmic 
part forming a death-inducing signalling complex (DISC). DISC associates with caspase-8 
which subsequently gets activated and released, initiating the caspase cascade 
(Emamaullee and Shapiro, 2006). 
 
The intrinsic pathway occurs when various apoptotic stimuli such as DNA damage or 
hypoxia activates pro-apoptotic proteins such as Bax and Bad. These translocate to the 
mitochondria, binding or inactivating anti-apoptotic Bcl-2 proteins (Bcl-2 or Bcl-xl). Bax 
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and Bad can form pores in the mitochondria membrane, releasing cytochrome c from the 
mitochondria. Cytochrome c interacts with Apaf-1 and caspase-9 to promote the activation 
of caspase-3. 
 
1.5.3. Cytokine induced apoptosis 
 
Under basal conditions, apoptosis plays a role in eliminating activated B-and T-cells 
beyond the course of an infection, to terminate immune responses. Defects in apoptosis 
regulatory mechanisms have been implicated in T1D pathogenesis, causing excessive 
apoptosis of β-cells of the pancreas (Mauricio and Mandrup-Poulsen, 1998). Some of the 
defects that have been reported include defective regulation of apoptosis in lymphoid cells 
(Watanabe-Fukunaga et al., 1992), and defects in surface expression of the Fas receptor in 
B-and T-cells (Giordano et al., 1995).  
 
IFN-γ
STAT-1
Gene regulation
APOPTOSIS
IL-1β
Caspase-3
FasL
MAPK -
JNK/ p38
NFĸβ
Endoplasmic 
reticulum (ER)
Mitochondria
TNFα
MAPK -
JNK/ p38
 
Figure 1.5. Proposed model of cytokine-induced apoptosis. During insulitis, 
infiltration of immune cells produces inflammatory cytokines such as IL-1β, IFN-γ 
and TNF-α which in turn induce β-cell apoptosis via the activation of β-cell gene 
network under the control of transcription factors such as NFĸB and STAT-1. β-cell 
death is finally executed by the activation of MAPK (JNK or p38) via release of 
mitochondrial death signals and ER stress trigger (Abbreviations: MAPK, mitogen 
activated protein kinase; JNK, c-Jun N-terminal kinase; STAT-1, signal transduction 
and transcription-1) (adapted from Cnop et al., 2005) 
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Members of the JNK family, JNK2 and JNK1 have also been implicated in T2D and T1D 
progression respectively (Jaeschke et al., 2005). Extracellular stimuli such as growth 
factors, cytokines and radiation activate the JNK pathway (Tawadros et al., 2005). 
Activated JNK can phosphorylate transcription factors such as c-Jun that play a critical 
part in controlling the expression of genes involved in apoptosis (Figure 1.5).  
 
1.5.4. β-cell apoptosis and T1D autoimmunity  
 
Apoptosis and autoimmunity in T1D are traditionally thought to initiate destruction of β-
cells as two separate entities. However there is increasing evidence of a relationship 
between apoptosis and autoimmunity. 
 
a) Apoptosis in the initiation or triggering of immune activation  
 
Apoptosis has traditionally been thought to be a non-inflammatory process. However it has 
been demonstrated that apoptosis can initiate β-cell directed autoimmunity, followed by 
uptake of β-cell antigens by islet APCs, inducing the formation of autoantibodies against 
such as GAD-65, a known target in young NOD mice (Tian et al., 2001). In NOD mice, 
apoptosis of β-cells initiates antigen uptake by APCs, activating T-cells in pancreatic 
lymph node. Immune cells accumulate around islets, invade islets and spread, destroying 
β-cells  (Mathis et al., 2001). Trudeau et al. demonstrated that a neonatal wave of β-cell 
apoptosis occurring around 2-3 weeks of age in BB rats and NOD mice causes these 
apoptotic cells to display autoreactive antigens in their surface blebs eventually leading to 
more β-cell apoptosis and insulitis (Trudeau et al., 2000). A higher incidence of β-cell 
apoptosis was observed in both BB rats and NOD mice compared to different strains that 
do not develop diabetes.  
 
b) Massive destruction of the islets  
 
Apoptosis is also involved in the direct destruction of islet β-cells through contact 
dependent CD8 T-cells, Fas/FasL and cytokine mediated pathways. In the NOD mouse and 
BB rat, macrophages and/or dendritic cells interact with T-cells and infiltrate the 
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pancreatic islets leading to an inflammatory response releasing proinflammatory cytokines 
– interleukin 1β (IL-1β), tumour necrosis factor α (TNF-α ) and interferon γ (IFN-γ). The 
high concentration of cytokines in the islets leads to the induction of apoptotic signalling 
cascades such as perforin/granzyme and Fas-mediated apoptosis which cause massive 
destruction of β-cells (Cnop et al., 2005; Dotta et al., 2005) 
 
Defects in apoptosis regulatory mechanisms have been implicated in T1D pathogenesis, 
causing excessive apoptosis of β-islet cells of the pancreas. Activation of native T-cells 
results in massive expansion of Ag-specific T-cells, the majority of which die by natural 
apoptosis and the remaining cells may survive and differentiate into memory cells. The 
excessive apoptosis due to a defect in the regulation of apoptosis may trigger an 
autoimmune reaction through presentation of autoantigens to the lymphocytes and 
production of autoreactive antibodies (Božič and Rozman, 2006). The failure of β-cells to 
clear apoptotic fragments is another key pathogenic factor leading to diabetic 
autoimmunity (Savill, 2000). 
 
1.5.5. Current strategies to block β-cell destruction 
 
a) Strategy 1: Direct inhibition of death receptor interaction 
 
Studies have shown that the Fas-mediated cytotoxicity pathway is one of the common 
inducers of β-cell apoptosis in humans and the NOD mouse model (Grewal et al., 1996; 
Itoh et al., 1997). Fas-Fas ligand interaction initiates a signalling cascade mediated by 
caspase-8 or Fas-associated death domain–like interleukin 1β-converting enzyme (FLICE) 
activation. In 1990s, cellular FLICE-inhibitory protein (FLIP) was developed which 
functions by blocking protein-protein interaction between caspase-8 and FADD, thus 
preventing the activation of caspase-8 and downstream caspases (Irmler et al., 1997). 
Newly diagnosed T1D patients have increased surface expression of Fas (CD95) on β-cells 
where the apoptotic signal is delivered via FasL (CD95L) present on infiltrating CD8+T-
cells. Neutralizing antibodies to Fas (CD95) successfully block apoptosis and preserve β-
cells function (Allison et al., 2005). 
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The overexpression of Bcl-2 in human islets results in functioning insulin secretion and 
full protection from IL-1, TNF-, IFN- cytokine induced β-cell destruction (Rabinovitch 
et al., 1999). Another important gene target is cytokine response modifier A (CrmA) where 
NOD transgenic mice with target expression of CrmA have reduced spontaneous 
development of autoimmune diabetes, and pancreatic β-cells were protected from 
cytokine-mediated cytotoxicity. In addition, β-cells from NOD CrmA mice were 
significantly protected from the destruction by diabetogenic T-cells after adoptive transfer. 
During apoptosis, anti-apoptotic Bcl-2 proteins such as Bcl-XL are inactivated by Bax. 
Klein et al. showed that Bcl-XL is effective in preventing apoptosis triggered by IL-1, 
staurosporine and serum withdrawal in vitro (Klein et al., 2004). 
 
b) Strategy 3: Combination of inhibiting extrinsic and intrinsic pathways  
 
The majority of inhibitors developed so far, specifically target either the extrinsic or 
intrinsic pathway, but do not inhibit both pathways due to difficulties in efficiently and 
reproducibly delivering and regulating multiple genes at the same time. Recently, a potent 
inhibitor of apoptosis was developed known as X-linked inhibitor of apoptosis protein 
(XIAP), and it was demonstrated that its overexpression could block cell apoptosis beyond 
the convergence point of most apoptotic pathways. XIAP acts by binding to the active site 
of all the main effector caspases (caspase 3, 7, and 9), thus preventing apoptosis 
(Schimmer, 2004; Schratzberger et al., 2001). 
 
c) Strategy 4: Modulation of cytokine signalling  
 
Studies have shown that two groups of cytokines exist where one group enhances β-cell 
destruction such as the Th1 subset of CD4 T-cells and Th1 cytokines; IFN- γ , TNF-α, IL-
1, Il-12 and Il-18, whereas the other group inhibits β-cell destruction consisting of Th2 and 
Th3 cytokines; IL-4, IL-5, IL-10 and TGF- β. Administration of antigen-specific regulatory 
T-cells (Tregs) can induce tolerance by releasing cytokines that inhibits β-cell destruction 
(Cernea and Pozzilli, 2008). Candidate autoantigens include insulin, glutamic acid 
decarboxylase (GAD65) and heat shock protein 60 (HSP60). 
 
 
Chapter 1                                                                                                         Introduction 
 
 
 
Cheen Khoo                                                                                                                           29             
 
e) Strategy 5: Inhibition of JNK-c-Jun interaction  
 
JNK inhibitors have been discovered by high throughput screening of compound libraries 
and subsequent structure-activity studies and cell culture testing (reviewed by 
(Bogoyevitch and Arthur, 2008). JNK peptide inhibitors are preferable to the JNK 
knockout model, due to their reported high specificity in disrupting only the interaction 
between their target and a small subset of potential binding partners (Waetzig and 
Herdegen, 2005). JNK inhibitors are divided into two groups (i) ATP-competitive JNK 
inhibitors which directly interfere and target highly conserved ATP binding sites and, (ii) 
ATP-non-competitive JNK inhibitory peptides which function by competing with protein 
substrate specific docking sites. Although these JNK inhibitors are highly specific, their 
cell permeability and rapid breakdown are problematic. To address these issues, Holzberg 
et al. discovered and developed a cell-permeable peptide that contains the JNK-binding 
(delta) domain (JBD) of human c-Jun, which selectively inhibits the JNK-c-Jun interaction, 
thus influencing some of the transcriptional effects of JNKs (Holzberg et al., 2003). 
 
JBD 
JNK  
JIP 
JBD P 
S 
No access of JNK to scaffold or substrate
JNK peptide inhibitor JNK peptide inhibitor added 
Basal condition 
Addition of JNK peptide inhibitor
JIP 
S 
S 
Figure 1..6. Overview of the JNK peptide inhibitor process 
(i)   Basal condition: Substrate with JBD interacts with activated JIP signal complex 
causing phophorylation of substrates. 
 (ii) Addition of JNK peptide inhibitor: JNK inhibitor enters the cells and competes 
with JNK preventing JNK to bind to JIP scaffold, thus inhibiting activation of JNK 
signalling pathway. Simultaneously JNK inhibitor binds to JBD of substrates or 
upstream kinase preventing phosphorylation of substrates by JNK. Abbreviations: 
JNK, c-Jun terminal kinase; S, substrate (e.g. c-Jun); P, phosphate; JBD, JNK binding 
(delta) domain; JIP, JNK-interacting protein (Adapted from (Borsello et al., 2003; 
Waetzig and Herdegen, 2005) 
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Extracellular stimuli such as growth factors and cytokines activate JNK, which induces the 
phosphorylation of transcription factors and cellular substrates involved in cell survival 
and proliferation, insulin receptor signalling and mRNA stabilization. JNKs bind to and are 
activated in signal complexes such as JNK-interacting protein (JIP) and subsequently 
phosphorylate their substrates using the JNK binding domain of the substrate (Figure 1.6). 
When the cell-permeable JNK peptide inhibitor is added, the binding of JNKs to both their 
substrates and their scaffolds is blocked. Activation of JNK and the phosphorylation of 
substrates by JNK are impaired. 
 
1.6. ENDOTHELIAL PROGENITOR CELLS 
 
1.6.1. INTRODUCTION 
 
The successful isolation of endothelial progenitor cells (EPCs) in 1997 by Asahara et al.  
(Asahara et al., 1997) has led to many studies documenting how EPCs derived from the 
bone marrow (BM) and peripheral blood (PB) contribute to tissue repair in various 
pathological conditions via the formation of new blood vessels i.e. vasculogenesis. EPCs 
are believed to originate from the BM and are often mobilized into the circulation in 
response to growth factors and cytokines released following a variety of stimuli that 
include vascular trauma (Gill et al., 2001), ischaemia (Garcia-Barros et al., 2003; 
Takahashi et al., 1999), wounding and cancer (Lyden et al., 2001). EPCs home to and 
incorporate into sites of damage and mediate repair by inducing neovascularization. In 
addition to the BM and PB, EPCs can also be isolated from umbilical cord blood 
(Murohara et al., 2000), foetal liver (Peichev et al., 2000) and skeletal muscle (Majka et 
al., 2003). Traditionally, EPCs were thought to only contribute to neovascularization 
during embryonic development but recent observations show that EPCs are also involved 
in postnatal neovascularization through two mechanisms: vasculogenesis, the recruitment 
of BM-derived EPCs which migrate and differentiate in response to signals to form 
entirely new blood vessels and angiogenesis, the sprouting of pre-existing capillaries 
(Taniguchi et al., 2006). EPCs exist in very small numbers especially in circulating blood 
in adults where they only account for 0.01% of all cells, probably due to a very low 
endothelial cell turnover rate (Zammaretti and Zisch, 2005). 
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1.6.2. EPC ORIGIN 
 
EPCs are derived from haemangioblasts, the same precursor cells of haematopoietic stem 
cells (HSC). During embryogenesis, the differentiation of the vascular endothelium is 
closely associated with the appearance of HSCs (reviewed in Rumpold et al., 2004). 
Additionally, HSCs and EPCs share common markers (CD31, CD34, VE-Cad, Tie-2; 
Table 1.2). In 1997, Asahara isolated EPCs from human peripheral blood using CD34 and 
other endothelial cell markers (Asahara et al., 1997), suggesting that haemangioblasts are 
present in blood.  
 
Haemangioblasts differentiate into angioblasts (in blood islands in the yolk sac during 
embryogenesis) or EPCs (in the adult BM) and haematopoietic precursors. In postnatal 
neovascularization, EPCs derived from BM can be mobilized into the blood circulation in 
response to appropriate stimuli. EPCs circulate in the blood (at this stage, known as 
cEPCs) and either contribute to new blood vessels within pre-existing but expanding 
capillary networks, or are directed to form entirely new blood vessels that eventually 
connect to the extant capillary system. 
 
1.6.3. EPC PHENOTYPE 
 
Debate ensues as to the true phenotype of adult EPCs, which is often clouded by the 
overlap of the phenotype of EPCs with HSCs and endothelial cells, and thus, a universally-
accepted EPC phenotype remains to be achieved (Table 1.2).  EPCs express Flk-1, von 
Willebrand factor (vWF), vascular endothelial cadherin (VE-Cadherin), CD31, Tie-2/TEK 
(angiopoietin-1 receptor precursor or tunica intima EC kinase), Tie-1, c-Kit, CD34, 
CD133, Sca-1 and Flt-1 (Asahara et al., 1997; Drake and Fleming, 2000; Grant et al., 
2002; Hess et al., 2003; Jackson et al., 2001; Loomans et al., 2006; Peichev et al., 2000; 
Sato et al., 1993; Sato et al., 1995; Wu et al., 2005). EPCs overlap in phenotype with a 
variety of vascular cell stages extending from primitive haemangioblasts to fully 
differentiated endothelial cells.  
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Haematopoietic stem cells (HSCs) Mature endothelial cells 
VEGFR-2, Flk-1 (H,M) (Haruta et al., 
2001; Ziegler et al., 1999) 
VEGFR-2, Flk-1 (M,H) (McCloskey et al., 
2006; Nguyen et al., 2008) 
CD34 (M) (Baldwin et al., 1994) CD34  (H) (Peichev et al., 2000) 
CD45 (M) (Shaw et al., 2004) CD45 (H) (Rogers et al., 2007) 
Tie-1 (M)  (Puri and Bernstein, 2003) Tie-1 (M,H) (Nguyen et al., 2008; Sato et al., 
1993) 
Tie-2 (M) (Hsu et al., 2000) Tie-2 (M,H) (Nguyen et al., 2008; Sato et al., 
1995) 
vWF (H) (Hill et al., 2003; Peichev et al., 
2000))  
vWF (S, H) (Kaushal et al., 2001; Quirici et al., 
2001) 
AC133/CD133 (H) (Gallacher et al., 
2000; Yin et al., 1997) 
AC133/ CD133 (S, H) (Kaushal et al., 2001; 
Quirici et al., 2001) 
c-kit (M) (Simmons et al., 1994) VE-Cadherin (H) (Peichev et al., 2000) 
Sca-1 (M) (Grant et al., 2002; Spangrude 
and Scollay, 1990) 
Sialomucin CD146 (H)(S-endo, 
P1H12Ag)(Kaplan et al., 2005)  
Flt-1/VEGFR-1 (M) (Solovey et al., 
2001) 
CD31/PECAM-1(S, H) (Kaushal et al., 2001; 
Quirici et al., 2001) 
Endothelial progenitor cells (EPCs) 
VEGFR-2, Flk-1 (M, H)  (Balasubramaniam et al., 2007; Peichev et al., 
2000) 
Tie-1 (M)  (Sato et al., 1993; Sharpe et al., 2006) 
CD34 (H, M) (Asahara et al., 1997; Nguyen et al., 2008) 
VE-Cadherin  (M)  (Drake and Fleming, 2000; Sharpe et al., 2006) 
CD133  (H, M)  (Asahara et al., 1997; Canizo et al., 2007) 
c-kit (M) (Loomans et al., 2006) 
Sca-1 (M)  (Balasubramaniam et al., 2007) 
VEGFR-1 (M, H) (Loomans et al., 2006)  
CD31/PECAM-1 (M, H) (Hess et al., 2003; Ye et al., 2007) 
vWF (M) (Wang et al., 2008) 
Tie-2  (M,H)  (Sato et al., 1993; Sharpe et al., 2006) 
CD45 (M, H) (Balasubramaniam et al., 2007; Case et al., 
2007) 
 
 
 
Table 1.3. Cell surface markers of mature endothelial cells, HSCs and EPCs 
(Abbreviations: H, human; M, mouse; S, sheep; HSCs, Haematopoietic stem cells; 
EPCs, Endothelial progenitor cells) 
 
EPCs have also been characterised by their ability to form colonies (colony-forming units) 
in endothelial specific medium, endocytose acetylated low-density lipoprotein (acLDL), 
bind Ulex Europaeus-1 (UEA-1) lectin, form tubules and migrate in cell culture (Hill et al., 
2003; Kalka et al., 2000; Mukai et al., 2008; Peichev et al., 2000). Another approach 
commonly used to isolate EPCs in culture is by initial enrichment of cells for a progenitor 
stem cell marker such as CD133, which is not expressed by mature endothelial cells 
(Mizrak et al., 2008).  
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Some studies isolate EPCs based on the outgrowth derived from human PB in culture, 
known as early and late EPCs (Hur et al., 2004; Lin et al., 2000). These two populations of 
EPCs share the same endothelial phenotype (CD31, vWF and VEGFR-2) but have a 
different morphology, growth pattern and survival rate. The early EPCs are spindle-shaped 
and can be seen after 5-7 days culture whereas late EPCs adopt a cobblestone morphology 
after 12-21 days in culture (Hur et al., 2004). Mukai et al. tested the tubule forming 
potential of early EPCs from human PB-MNCs and late EPCs from umbilical cord blood-
MNCs using an ear vessel occlusion model; the late EPCs were able to form new blood 
vessels after transplantation into occlusion tissue whereas early EPCs could not, suggesting 
that late EPCs are more suitable for use in EPC transplantation to promote 
neovasculogenesis (Mukai et al., 2008). 
 
EPCs can be characterized based on their size and antigen expression  (Yamamoto et al., 
2008). Using 2D-dot plots and fluorescent activated cell sorting (FACS) of MNCs 
differentiating towards the endothelial lineage, two populations were defined as small and 
large EPCs; small EPCs were seen after 1 day of culture and were CD34+CD14- whereas 
large EPCs were only noted between 3-7 days of culture with a CD34-CD14+ phenotype. 
Unfortunately in this study, the ability of the two populations to contribute towards 
neovascularization was not tested. 
 
To date, the lack of defined techniques to characterise human and mouse EPCs has led to 
confusion as to the true EPC phenotype and the isolation of functionally suboptimal EPC 
populations, most likely attributable to differing culture conditions, characterization 
techniques and sources (Bischoff et al., 1997; Kraling et al., 1996; Nishiwaki et al., 2007). 
It is therefore vital to set a ‘gold standard’ to universally define EPCs in order to utilise 
them for the advancement of future clinical therapies.  
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1.6.4. EPC MOBILIZATION 
 
EPCs are mobilized by various stimuli such as tissue injury, ischaemia and hypoxia. These 
conditions can lead to tissue necrosis in which the dying cells release stimulatory factors 
such as FGF-2 to promote blood-vessel growth. Apart from contributing to 
neovascularization, it is highly likely that BM-derived EPCs contribute to the regeneration 
of the damaged tissue by releasing factors that act in a paracrine manner, reducing 
inflammation and promoting cell survival and proliferation of tissue-residing progenitor 
cells (Hess et al., 2003; Ye et al., 2007).  
 
Upon tissue injury, an ischaemic environment is created. The ischaemic tissue upregulates 
hypoxia inducible factor-1α, which in turn stimulates the production of VEGF and SDF-1, 
important EPC chemoattractants (Asahara et al., 1999; Heissig et al., 2002; Takahashi et 
al., 1999). These growth factors act synergistically to mobilize EPCs into the circulation by 
first activating matrix metalloproteinase (MMP)-9 in the BM (Figure 1.7) (Heissig et al., 
2002; Rafii et al., 2002). Activated MMP-9 cleaves membrane-bound Kit ligand on c-Kit+ 
cells and releases soluble kit ligand. c-Kit+ progenitor stem cells move from the quiescent 
to the proliferative niche (Aicher et al., 2005).  
 
At the site of injury, recruited macrophages and fibroblasts release VEGF, which induces 
phosphorylation and activation of endothelial nitric oxide synthase (eNOS), expressed by 
osteoblasts and endothelial cells (Aicher et al., 2003). eNOS is important in the BM 
microenvironment, especially in the maintenance and regulation of EPC mobilization in 
response to signals such as VEGF. eNOS elevates nitric oxide (NO) levels in the BM 
(Brem and Tomic-Canic, 2007), facilitating the release of EPCs from BM into the 
bloodstream (Figure 1.7). Once in the circulation, EPCs are recruited to the site of injury in 
response to injury-induced chemokines, such as SDF-1, released from the damaged organ 
(Kucia et al., 2004). In diabetes, this compensatory response of increased EPC 
mobilization is inadequate and fails to promote therapeutic EPC-mediated 
neovascularization. Hyperoxia via hyperbaric oxygen therapy (HBO) can reverse this EPC 
mobilization defect by increasing BM nitric oxide levels (Gallagher et al., 2007). The 
combination of exogenous administration of an EPC mobilization factor such as SDF-1α 
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and HBO therapy in streptozotocin (STZ)-induced diabetic mice synergistically increased 
EPC number, and promoted homing into the wounded area (Gallagher et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. EPC mobilization and recruitment during wounding. Wounding attracts 
fibroblasts, neutrophils and macrophages and causes inflammation. Hypoxic signals in 
the wound upregulate mobilizing growth factors. These growth factors activate eNOS, 
increasing NO levels which in turn regulate the release of EPCs into the circulation. 
Mobilized EPCs home to the wound site. In the wound site, EPCs differentiate to 
endothelial cells in response to signals and can form entirely new blood vessels as well 
as contributing to sprouting capillaries (angiogenesis). In addition, EPCs may contribute 
to the regeneration of the wound by secreting factors that act in a paracrine manner, 
reducing inflammation and promoting cell survival and proliferation. EC: Endothelial 
cell; eNOS: Endothelial nitric oxide synthase; EPC: Endothelial progenitor cell; G-CSF: 
Granulocyte colony-stimulating factor; GM-CSF: Granulocyte macrophage colony-
stimulating factor; HIF: Hypoxia-inducible factor; MMP: Matrix metalloproteinase; NO: 
Nitric oxide; SDF: Stromal cell-derived factor (Picture from Khoo CP et al., 2008). 
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1.6.5. EPC TRANSPLANTATION 
 
EPCs can be mobilized through exposure to a variety of growth factors, including VEGF, 
granulocyte macrophage colony-stimulating factor (GM-CSF), SDF-1, PLGF and 
erythropoietin (Epo). Epo, a factor known to promote mature endothelial cell proliferation 
and migration, has been used to stimulate HSC proliferation and enhance mobilization of 
EPCs from the BM of ischaemic limb mice (Heeschen et al., 2003). Numbers of cEPCs 
were increased after Epo treatment and were mainly early outgrowth EPCs. Owing to their 
potential to promote mobilization in vivo, growth factors such as PLGF and HGF have 
been administered concurrently with the transplantation of BM- or PB-derived EPCs to 
augment neovascularization in models of emphysema and hindlimb ischaemia (Table 1.3) 
(Ishizawa et al., 2004; Tamarat et al., 2004). 
 
BM- and PB-derived EPCs have the potential to augment neovascularization when 
transplanted into disease models (Table 1.3). EPCs differentiate into endothelial cells and 
incorporate into growing vessels (angiogenesis) and can create new vessels 
(vasculogenesis). There is an ongoing debate as to whether EPCs can actually create new 
blood vessels on their own, as there is evidence of cooperation between endothelial cells 
and perivascular cells in during vascular development (Darland and D'Amore, 1999). 
Recently Au et al. (Au et al., 2008) and Melero- Martin et al. (Melero-Martin et al., 2008) 
noted that co-implantation of perivascular cells and cultured EPCs resulted in robust 
vascular networks in vivo (Au et al., 2008; Melero-Martin et al., 2008). When EPCs were 
transplanted alone, both adult PB and CB-derived EPCs were still capable of 
vasculogenesis, but the process was less pronounced and the vessels rapidly regressed.  
 
Therapeutic neovasculogenesis represents a new approach to treat patients with vascular 
disease. Many studies have demonstrated successful EPC-derived cell engraftment and a 
contribution to neovasculogenesis in adult tissues, a process enhanced by increasing the 
regenerative demand within a diseased or damaged tissue (Table 1.3).  
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Treatment strategy Animal /Model used Result Reference 
Cell mobilization in vivo 
HMG-CoA inhibitor (simvastatin) Corneal injury after BM 
transplantation (M) 
Augmented corneal neovascularization. (Llevadot et al., 2001) 
Transplantation of ex vivo cultured EPCs 
CD31+ CD105 + CD45 - (CB, H) Flap ischaemia  model (M) Increased neovasculogenesis and tissue repair. (Nagano et al., 2007) 
7 day cultured MNCs (spleen, M) Carotid artery injury model (M) Re-endothelialization of denuded carotid artery 
inhibition of neointimal hyperplasia. 
(Zhao et al., 2007) 
10 day cultured MNCs (BM, R) Dimethylnitrosamine-induced liver 
fibrosis model (R) 
Hepatic fibrogenesis was suppressed. Normal liver 
function regained and increased proliferation of 
hepatocytes.  
(Ueno et al., 2006) 
10 day cultured MNCs (PB, H & M) Carbon tetrachloride-induced acute 
liver injury (M) 
Improved survival of mice following liver injury. 
Greater proliferation of hepatocytes. 
(Taniguchi et al., 2006) 
Transplantation of ex vivo cultured EPCs supplemented with growth factor 
Fresh MNCs  with placental growth 
factor (BM, M) 
Hindlimb ischaemic model (using  
diabetic mice, streptozotocin-
induced) (M) 
Improved postischaemic neovascularization  (Tamarat et al., 2004) 
Transplantation of ex vivo cultured EPCs pre-treated with growth factor 
Sca-1+ Flk-1+ c-Kit+ cells (BM, M) 
treated with G-CSF 
Emphysema (M) Significant reduction in emphysema. Augmented 
number of BM-derived EPCs in regenerated alveoli 
(Ishizawa et al., 2004) 
Freshly isolated CD34+ MNCs (PB, H) 
pre-treated with G-CSF 
Myocardial ischaemia (R) Decreased apoptosis of hypertrophied myocytes in 
the peri-infarct region. Long-term salvage and 
survival of viable myocardium. 
(Kocher et al., 2001) 
Transplantation of gene-modified EPCs 
EPC transduced with VEGF (PB, H) Hindlimb ischaemic model (M) Increased neovascularization & blood flow recovery (Iwaguro et al., 2002) 
EPC transduced with eNOS (PB, Ra) Neointimal hyperplasia (Ra) Augmented endothelialization & reduced neointima 
size 
(Kong et al., 2004) 
EPC transduced with human telomerase 
reverse transcriptase (PB,H) 
Hindlimb ischaemic model (M) Augmented neovascularization in terms of limb 
salvage and increase capillary density.  
 (Murasawa et al., 2002) 
Table 1.4. Examples of endothelial progenitor-derived cells to vascular lineages in various models of disease. (Abbreviations: MNCs, mononuclear 
cells; EPCs, endothelial progenitor cells; BM, bone marrow; M, mouse; R, rat; Ra, rabbit; PB, peripheral blood; H, human). 
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The relative scarcity of EPCs in the peripheral circulation has led to the ex vivo expansion 
of PB-EPCs prior to their transplantation. The common method to isolate EPCs is by 
seeding mononuclear cells on fibronectin-coated plates and to be grown in endothelial-
specific media for several days (Fadini et al., 2008). These cells then undergo FACS 
analysis and immunostaining to confirm phenotype. The administration of ex vivo 
expanded EPCs in rodent models of hindlimb and myocardial ischaemia was shown to 
augment capillary density as well as successfully revascularize the ischaemic target region 
(Kocher et al., 2001; Tamarat et al., 2004). In addition to the transplantation of ex vivo 
EPCs to potentiate neovascularization, GM-CSF has been used to induce angiogenesis in 
vivo in a rabbit ischaemic hindlimb model (Takahashi et al., 1999). 
 
Myocardial gene transfer of VEGF has been used for patients with symptomatic 
myocardial ischaemia with reduction of ischaemia evidenced by perfusion imaging and 
angina symptoms (Losordo et al., 1998). Although many favourable outcomes have been 
reported after transplantation of EPCs into humans and animal models, there is a 
possibility that some undesirable side effects may occur, such as uncontrolled 
neovascularization favouring the development of cancer (Rafii and Lyden, 2008) and 
atherosclerotic plaque destabilization (Moreno et al., 2004). 
 
As native EPCs from patients with diabetes (Tepper et al., 2002), arteriosclerosis 
(Landmesser and Drexler, 2005) or Alzheimer’s disease (Vagnucci and Li, 2003) have 
endothelial dysfunction, it becomes important to use either healthy EPCs or genetically 
modified EPCs for successful therapy. One gene commonly used for genetic modification 
of EPCs is VEGF, the protein having an important role as an endothelial motogen 
(Iwaguro et al., 2002; Schratzberger et al., 2001). Another gene transfected has been SDF-
1, SDF-1 being important in EPC mobilization into the peripheral circulation as shown in a 
mouse hindlimb ischaemia model, where there was augmented recovery of blood perfusion 
to the ischaemic limb and increased capillary density (Hiasa et al., 2004). Genes encoding 
HMG-CoA reductase inhibitors, in particular simvastin, increase numbers of cEPCs and 
improve neovascularization in a murine model of corneal injury (Llevadot et al., 2001), 
while eNOS inhibited neointimal hyperplasia in rabbits, augmenting endothelialization and 
reducing neointima size with no incidence of thrombosis (Kong et al., 2004). Fully 
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differentiated endothelial cells have also been used to deliver a therapeutic gene, for 
example, healthy liver sinusoidal endothelial cells were transplanted to correct factor VIII 
deficiency in haemophilia A mice (Follenzi et al., 2008).  
 
To date, no EPC cell line has been generated, as most studies use fresh isolated BM-or PB-
derived EPCs, although Qiu et al. have successfully immortalized EPCs from human CB 
by transfecting with the SV40 large T antigen (Qiu et al., 2006); the transplanted 
immortalized EPCs improved neovascularization and augmented blood flow in a model of 
ischaemic lung injury.  
 
In the context of tissue engineering, EPCs can also be used to improve the biocompatibility 
of vascular grafts. When autologous CD34+ cells (containing EPCs) were seeded onto 
artificial vascular grafts (Dacron grafts) and implanted into the canine thoracic aorta, both 
improved surface endothelialization and vascularization were noted (Bhattacharya et al., 
2000). In a similar study, CD34+ cells were seeded onto the graft with addition of 
granulocyte CSF (G-CSF), resulting in increased mobilization of leukocytes (including 
CD34+ cells), thus enhancing vascularization of the vascular graft (Kaushal et al., 2001). 
This strategy may be useful in islet transplantations where, during harvest from the donor 
pancreas, islets lose their vascular connections. The augmentation of neovascularization 
might thus increase the success rate of islet transplantations. Common treatment strategies 
for EPC transplantation are summarized in Table 1.3.  
 
1.6.6. EPCs and diseases 
1.6.6.1. Myocardial infarction 
 
Preclinical studies have shown that transplantation of human PB-derived EPCs can reduce 
left ventricular (LV) remodelling in a nude rat model of myocardial infarction (Losordo et 
al., 1998). This strategy not only promoted neovascularization, but also decreased 
apoptosis of hypertrophied myocytes in the periinfarct region, resulting in an improvement 
in cardiac function; EPCs are probably acting in a paracrine manner, releasing anti-
inflammatory and prosurvival factors into the infarct region, as they do in the regenerating 
pancreatic islet (Mathews et al., 2004). With respect to future clinical therapy, Kawamato 
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et al. were the first group to investigate the potential of autologous EPC (CD31+ MNCs) 
transplantation using the swine chronic myocardial ischaemia model (Kawamoto et al., 
2002). Adopting a novel model of real-time ischaemia mapping to directly deliver cells to 
the ischaemic site, they successfully reduced the size of the ischaemic area as well as 
improving swine LV function. Clinical trials of autologous transplantation, such as the 
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial 
Infarction (TOPCARE-AMI), involve the intracoronary infusion of EPCs into patients with 
acute myocardial infarction. Preliminary results suggest a significant improvement of 
myocardial function after 4 months of treatment (Assmus et al., 2002; Schachinger et al., 
2006). Other trials have adopted a therapeutic strategy of infusing cultured EPCs with the 
mobilization factor GM-CSF into patients with acute myocardial infarction (Ellis et al., 
2006; Zohlnhofer et al., 2007). Despite notable successes in animal studies, there was no 
significant improvement in myocardial function in these clinical trials, although there was 
an increased number of cEPCs.  
 
1.6.6.2. Pulmonary arterial hypertension 
 
Pulmonary arterial hypertension (PAH) is a vascular disease characterized by severe 
endothelial dysfunction. These patients produce insufficient NO, a vasodilator important in 
vessel growth in the pulmonary vasculature. Initial studies of transplantation of autologous 
EPCs into the lung resulted in attenuation of monocrotaline (MCT)-induced PAH in dogs 
(Takahashi et al., 2004). Nagaya et al. used human CB-derived EPCs transduced with 
adrenomedullin, a potent vasodilator peptide and transplanted them into MCT-treated rats 
(Nagaya et al., 2003; Takahashi et al., 2004). PAH was markedly ameliorated in these rats, 
causing a 39% decrease in pulmonary vascular resistance compared with 16% in rats 
receiving unaltered EPCs. Similar results were reported by Zhao et al. using human cord 
blood-derived EPCs transfected with eNOS, the enzyme involved in the production of NO 
(Zhao et al., 2005). These encouraging results using genetically modified EPCs led to the 
initiation of an early Phase IIa clinical trial, the Pulmonary Hypertension Assessment of 
Cell Therapy (PHACeT), in 2006, which was the world’s first human gene therapy trial for 
fatal lung disease, pioneered by scientists at Northern Therapeutics Inc., (Toronto, 
Canada), combining both cell and gene therapy (St. Michael’s Hospital, 2006). This 
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innovative approach involved the injection of eNOS-transduced EPCs derived from the 
patient’s own blood into the lung circulation, with the aim of restoring lung vascular 
function in severe PAH; results are awaited. 
 
1.6.6.3. Liver regeneration & repair 
 
Fujii et al. investigated the contribution of BM cells to liver regeneration after partial 
hepatectomy (Fujii et al., 2002) of mice transplanted with GFP+ BM. After liver injury, 
increased numbers of GFP+ cells were observed, with the majority of these cells 
coexpressing CD31, suggesting they were sinusoidal endothelial cells. In the carbon 
tetrachloride and dimethylnitrosamine- induced models of liver injury, fresh EPCs from 
BM and PB were used, respectively (Taniguchi et al., 2006; Ueno et al., 2006). Both 
studies observed a suppression of liver fibrosis and an increased survival rate; EPCs may 
have contributed to liver regeneration by engraftment into hepatic sinusoids, promoting 
hepatocyte proliferation through increased levels of growth factors such as EGF, HGF, 
TGF-α and VEGF in the regenerating liver. The contribution of BM-progenitor cells to 
neovascularization may depend on the type of injury. Using models of partial hepatectomy 
(PH) and allyl alcohol (AA)-induced injury, Kienstra et al. found LacZ-labeled HSCs 
engrafted within the vascular endothelium of the AA-damaged liver, with the majority 
present in highly injured areas (Kienstra et al., 2008). AA injury induces ischaemia and 
causes damage to periportal areas where local endogenous stem and progenitor cells reside 
(Alison et al., 2007). Ablated stem cells may provide space for donor HSCs (which will 
contain EPCs) to engraft, resulting in the expansion of microvessels and larger vessels. By 
contrast, transplanted cells were not found in the vasculature of regenerated liver following 
PH; here, existing endothelial cells may simply expand in numbers. In a clinical setting, 
Yannaki et al. performed three mobilization courses of G-CSF into two patients with end-
stage cirrhotic liver disease to increase the number of circulating stem cells such as cEPCs 
(Yannaki et al., 2006). Increased numbers of CD34+ cells and raised serum VEGF levels 
were noted in the two patients, suggesting again the possible contribution of EPCs to liver 
repair; the increased mobilization of stem cells and their homing to the damaged region 
resulted in lasting amelioration during 30 months of follow-up.  
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1.6.6.4.   Inflammatory bowel disease 
 
There is little evidence for a contribution of BM cells to the direct regeneration of the 
mucosa in inflammatory bowel disease. In a trinitrobenzene sulfonic acid-induced colitis 
model, BM cells engraft not only as myofibroblasts, but also as endothelial cells, vascular 
smooth muscle cells and pericytes in regions of inflammation (Brittan et al., 2005). A 
similar fate of BM-progenitor cells may underlie the beneficial effects of autologous BM 
therapy in patients with refractory Crohn’s disease (Oyama et al., 2005). 
 
1.6.6.5.  Diabetes 
 
Diabetic patients have reduced cEPCs and deregulated EPC function (reviewed in 
(Loomans et al., 2006)). Islet transplantations have been carried out since the publication 
of the Edmonton Protocol (Shapiro et al., 2000), however a shortage of cadaveric 
pancreata and a return to insulin dependence in the majority of recipients within 5 years 
means alternative treatments are required. Several studies have suggested that BM 
transplanted after STZ-induced diabetes in mice may contribute to islet neovasculature and 
promote islet β-cell regeneration. Hess et al. intravenously transplanted GFP+ BM cells 
into Streptozotocin (STZ)-induced diabetic mice 5 days after the last STZ administration 
(Hess et al., 2003). Blood glucose levels were reduced, with serum insulin levels restored 
to almost normal levels within 7 days. Contribution to vasculature was noted, with 9.2% of 
the engrafted donor cells at ductal and islet regions being endothelial cells (GFP+ PECAM-
1+) suggestive of the contribution of EPCs to the engraftment. Two other murine studies 
obtained similar results following host BM ablation and subsequent BM transplantation 
into STZ-diabetic mice (Hasegawa et al., 2007; Mathews et al., 2004). These studies 
suggested that BM, presumably containing EPCs, differentiated into endothelial cells and 
contributed to neovasculature in the injured islet, possibly also aiding islet regeneration. In 
addition, it should be remembered that BM may contain other cells that aid in the 
neovascular response. In this scenario, vascular basement membrane proteins, such as 
laminin and collagen IV, can act as endothelial signals, promoting β-cell differentiation 
and influencing their function (Nikolova et al., 2006). 
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1.6.6.6. Prognostic implications 
 
Patients with cardiovascular risk states such as arteriosclerosis (Vagnucci and Li, 2003), 
diabetes (Hill et al., 2003; Hink et al., 2001) and Alzheimer’s disease (Shintani et al., 
2001; Vagnucci and Li, 2003) have endothelial dysfunction. EPC numbers are reduced, 
and are also impeded in function, with a reduced ability to migrate and form tubules in 
these patients - this correlates with poor clinical prognosis.  For example, BM-derived 
EPCs are mobilized by eNOS activation in the BM; a process that might be impaired in 
diabetics, thus preventing these cells from reaching the damaged islets in significant 
numbers (Brem and Tomic-Canic, 2007; Schmidt-Lucke et al., 2005).  
 
EPCs from non-diabetic patients cultured under hyperglycaemic conditions show 
diminished proliferative capacity. These differences in proliferation are inversely 
correlated with glycaemic control, there is a 48% decrease in cEPCs (dual-stained cells for 
acLDL and lectin) in T2D patients compared with non-diabetic control subjects (Tepper et 
al., 2002). Likewise a 44% reduction in cEPCs in T1D pateints (Loomans et al., 2006) was 
noted. Linear regression analysis revealed that EPC numbers in both studies were inversely 
correlated with haemoglobin A1c levels (Loomans et al., 2006; Tepper et al., 2002). As 
T2D patients have reduced cEPC numbers and have a three- to four-fold increase in 
cardiovascular risk (Garber, 1998; Haffner et al., 1998), cEPC numbers in diabetes can be 
used as a barometer of cardiovascular risk (Fadini et al., 2006).  
 
The number of EPC-CFUs derived from the PB can predict multivessel coronary artery 
disease (CAD), independent of traditional risk factors such as hypertension, family history 
and hyperlipidaemia (Kunz et al., 2006). Patients with multivessel CAD had significantly 
lower EPC counts and also had a lower CFU count. This may relate to a general failure of 
the body’s EPC-driven repair mechanisms owing to either failure of EPC release from the 
BM or overall depletion of EPC numbers caused by the overwhelming demand for repair. 
Levels of cEPCs can thus be used to identify patients having a high risk of vascular 
accidents such as myocardial infarction and stroke (Werner et al., 2005). Patients with 
lower numbers of cEPCs have a higher Framingham risk score (Hink et al., 2001). Other 
pathological conditions associated with a decrease in cEPCs include chronic renal failure, 
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which contributes to accelerated atherosclerosis and impaired angiogenesis (Choi et al., 
2004), and hypercholesterolemia (Chen et al., 2004), promoting atherosclerosis and CAD. 
Thus the measurement of cEPCs as a predictive clinical parameter is useful for evaluating 
disease risk and prognosis, as well as response to treatment.  
 
1.6.7. EPCs and neoplasia 
 
EPCs contribute to angiogenesis in various tumours, including hepatocellular carcinoma 
(Spring et al., 2005) and non-small-cell lung cancer (NSCLC)(Dome et al., 2006; Hilbe et 
al., 2004). Tumours secrete growth factors such as VEGF that promote mobilization of 
EPCs to sites of vasculogenesis. The number of EPCs that home to perivascular sites 
increases to compensate for the increasing demands for oxygen and nutrients to support 
tumour growth. The early stage of tumour neovascularization is characterized by vessel 
dilation, followed by extensive vessel sprouting into a tumour, which is temporally 
mediated by the release of VEGF by the tumour and mobilization of EPCs (Hoeben et al., 
2004; Natori et al., 2002; Spring et al., 2005). 
 
It has been suggested that more advanced tumours have a higher propensity to recruit BM 
cells to the developing vasculature as shown in a study of murine liver and pancreatic 
tumours (Hammerling and Ganss, 2006). Some studies of BM-EPCs in supporting tumour 
vasculature have reported that less than 1% of blood vessels have BM-derived endothelial 
cells in a B6RV2 lymphoma model (Larrivee et al., 2005) or even a nonexistent 
contribution to vessels in a Lewis lung carcinoma model (Shinde Patil et al., 2005). Both 
studies, however, allowed only 10–14 days for tumour development before animal 
sacrifice. In a similar vein, BM-derived endothelial cells were only found in approximately 
1% of vessels in mice engineered to develop mammary tumours (Dwenger et al., 2004).  
 
In a tumour-resistant mouse with an angiogenic defect (impaired VEGF mobilization), the 
Id knockout mouse (Id1+/-Id3-/-), tumour angiogenesis and growth were restored with the 
transplantation of β-galactosidase marked wild-type (WT) BM (Lyden et al., 2001). When 
BM cells from Id mutant mice were transplanted into WT mice followed by inoculation of 
B6RV2 lymphoma, tumour growth retardation was seen. Gao et al. has developed a 
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lentiviral-based Id synthetic microRNA (miR-30)-based short hairpin RNA lentivirus 
whose activity can be induced by doxycycline to target Id expression in vivo, allowing the 
selective suppression of Id during metastasis progression without compromising the 
contribution of BM-derived endothelial cells to the growth of the primary tumour (Gao et 
al., 2008). The blocking of the transcription factor Id expression in the mammary tumour-
bearing mice significantly inhibited angiogenesis and reduced numbers of cEPCs (c-Kit+ 
VEGFR-2+ CD11b-), importantly impairing formation of lethal lung macrometastases and 
increasing mice survival. This study illustrated that EPCs are important mediators of the 
angiogenic switch, aiding the progression of metastatic lesions. 
 
Not all studies concur that PB-EPCs and cEPCs play a significant role in tumour 
development (Purhonen et al., 2008), failing to find GFP-tagged endothelial cells in WT 
mice that had received a GFP+ BM transplant and subsequent inoculation of syngenic B16 
melanoma. Moreover, no GFP+ endothelial cells were found in intestinal adenomas when 
GFP+ mice were parabiotically paired with young ApcMin/+ mice. These studies provoked a 
vehement response from advocates of the importance of EPCs to tumour 
neovascularization and an equally strident rebuttal from the authors of the negative paper 
(Kerbel et al., 2008).  
 
Unlike mouse studies, there are very few studies that have investigated the contribution of 
BM-derived EPCs to human tumour neovascularization. In a clinical setting, Peters et al. 
analyzed several tumour types from six individuals who developed cancer after receiving a 
sex-mis-matched BM transplant, finding that BM-derived cells contributed to the tumour 
endothelium, albeit at a low level averaging only 4.9% (Peters et al., 2005). In addition, 
they eliminated the possibility of cell fusion between BM-derived cells and existing 
endothelial cells in the tumour by using FISH probes for X and Y chromosome detection.  
 
1.6.7.1. Prognostic implications 
A prerequisite for cancer progression is the formation of new blood vessels either from 
pre-existing blood vessels or via the recruitment of EPCs from the BM to form entirely 
new blood vessels. Thus, levels of cEPCs, potentially recruitable to the growing vascular 
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infrastructure, may serve as a marker for disease prognosis and predict the risk of cancer 
relapse after dormancy.  
 
In patients with NSCLC, a high level of cEPCs (>1000/ml) in the PB is associated with 
poor prognosis (Dome et al., 2006). Post-treatment levels of cEPCs were significantly 
lower in patients who had achieved a partial/complete remission compared with patients 
with stable or progressive disease, therefore suggesting that EPC levels correlate with 
tumour burden. EPCs have been grown from the PB of patients with hepatocellular 
carcinoma and compared with healthy patients and patients with liver cirrhosis (Ho et al., 
2006); higher levels of cEPCs (defined by CFU counts) were found in patients with liver 
cancer compared with the other patient groups. In addition, higher levels of cEPCs were 
noted in patients with unresectable and recurrent cancer compared with respectable and 
disease-free patients enrolled a year before. The levels of CD133 mRNA (cEPC numbers) 
in the PB of colorectal cancer patients has been advocated as a useful screen for recurrence 
(Lin et al., 2007); cEPC numbers may also be useful in the prediction of the patient’s 
response to chemotherapy (Bertolini et al., 2003). These studies show that cEPCs could 
represent a class of biomarkers to gauge the response to anti-angiogenic treatment or 
chemotherapy. In rectal cancer patients, a decrease in viable PB-EPCs was observed after 
receiving a single infusion of bevacizumab (a VEGF-specific antibody) (Willett et al., 
2004). This strategy had a direct anti-vascular effect in the patients and resulted in 
decreased tumour perfusion, vascular volume, microvascular density and interstitial fluid. 
Similar results were seen following infusion of VEGFR-2-targeted anti-angiogenic agents 
into murine models of lung and breast cancer (Shaked et al., 2005). In late-stage breast 
cancer patients receiving chemotherapy, a 28% decrease in the number of EPCs suggested 
this measurement could be a useful biomarker or even a therapeutic target (Naik et al., 
2008). 
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1.7. AIMS OF PROJECT 
 
Endothelial progenitor cells (EPCs) in the bone marrow (BM) and peripheral blood (PB) 
contribute to tissue repair in various pathological conditions via the formation of new 
blood vessels, and thus have a degree of stem cell potential. Previous studies indicate that 
diabetic patients have reduced EPC number and deregulated EPC function, although the 
regenerative properties of EPCs in diabetes are unknown. I wish to characterise and 
compare EPCs from pre-diabetic and diabetic non-obese diabetic (NOD) mice, a model of 
T1D, in order to delineate the role of these cells in the pathogenesis of autoimmune 
diabetes. As EPC numbers are low in number from BM and blood, I aim to isolate these 
EPCs from BM, expand and characterize them. The purified EPCs will be transplanted into 
diabetic NOD mice in the hope of promoting the restoration of pancreatic function 
following the onset of autoimmune diabetes, possibly by contributing to tissue regeneration 
via the mechanism of neovasculogenesis. 
 
In addition to promoting endogenous β-cell regeneration using EPCs, I intend to 
investigate the potential of a protease peptide XG-102 developed by Xigen, to block β-cell 
death via apoptosis. It was previously shown that XG-102, has efficiently protected 
neurons against cell death in animal models of stroke. Since apoptosis of β-cells is one of 
the putative mechanisms involved in the cascade of events leading to T1D, I aim to test 
XG-102 for β-cell protection and prevention of β-cell loss in the NOD mouse. 
 
In general both experimental strategies will be evaluated for their ability to prevent or 
delay diabetes in the NOD mouse.  
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CHAPTER 2: METHODS  
 
2.1. INTRODUCTION 
 
Two strains of mice were used in this study. The first strain, NOD mice came from the 
NOD/Ba colony established in 1987 at St. Bartholomew’s Medical College, London, UK, 
originally derived from Dr E. Leiter’s laboratory (Bar Harbor, ME, USA). There is a stable 
cumulative incidence of diabetes of approximately 60% in female and 15% in male mice at 
30 weeks of age (Mansfield et al., 1992). The colony is housed in a purpose-built area and 
maintained strictly according to international (N.I.H., 1985) and UK HMSO (Her 
Majesty’s Stationary Office), 1986 guidelines for animal care.  
 
The diabetic status of the mice was initially diagnosed by monitoring urinary glucose 
levels (Diabur Test 5000, Mannheim, Germany) and then confirmed by measuring blood 
glucose levels (≥11.5 mmol/l) using Accu-chek AVIVA Blood Monitor (Roche 
Diagnostics GmbH, Mannheim, Germany). Balb/c mice were obtained from Charles River 
Laboratories (Charles River Laboratories, Maine, USA). Both strains of mice are 
maintained at the biological animal unit of Queen Mary, University of London. Overall 
health of mice enrolled is checked every day and urinary glucose level checked once every 
week at a fixed time. Mice that were unhealthy during the duration of study were sacrificed 
by cervical dislocation. Blood glucose levels of mice were taken before culling. All mice 
were sacrificed by cervical dislocation. 
2.2. BONE MARROW AND ORGAN COLLECTION 
After cervical dislocation, the femurs, tibias and iliac crests were dissected out using a 
disposable scalpel (Swann-Morton, Sheffield, UK), cleaned and collected in Bijou tubes 
containing sterile x 1 phosphate buffer saline (PBS). 
Pancreata from these groups of mice were also acquired and divided, where half were fixed 
in 10% neutral buffered formalin (BDH Laboratory Supplies Inc., Hertfordshire, UK) for 
24 hours before storing in 70% alcohol and the remaining pancreata snap frozen in liquid 
nitrogen and kept at -80 0C. The pancreata were then processed and paraffin-embedded for 
immunohistochemical studies.  
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2.3. ISOLATION OF WHOLE BONE MARROW CELLS  
Bones (femurs, tibias and iliac crests) from a single mouse were immersed in sterile PBS 
and kept on ice until use for experiments. The bones were cleaned with sterile vernaid 
dressing towel (Vernon-Carus Limited, Lancashire, UK) and the ends of these bones 
trimmed with a pair of sterile scissors. BM cells were collected by flushing the bones with 
Iscove’s Modified Dulbecco's Medium (Iscove's MDM) with 2% Foetal Bovine Serum 
(FBS)(Stem Cell Technologies, Vancouver, Canada) using a 23G needle (Neolus Terumo 
Corporation, Madrid, Spain). After each flushing of a part of the bone, the cells were 
collected in a 5ml Falcon polystyrene tube and were mixed using a 21G needle (BD 
Microlance 3, Becton-Dickinson) several times to prevent coagulation. Next the cells were 
filtered with a 70 μm cell strainer (Becton-Dickinson) into another 5ml Falcon polystyrene 
tube and centrifuged (Hettich Zenrifugen Microcentrifuge, Jensons-Pls, Bedfordshire, UK) 
at 1500 rpm for 6 mins at 40C. The resulting pellet was resuspended in 1ml of cold 1% 
FBS PBS and kept on ice. Cells (10 µl) were counted using a haemocytometer and diluted 
with x 1 PBS to obtain 1 x 106 cells. 
2.4. IN  VIVO ANIMAL EXPERIMENTS 
2.4.1. Gender mis-matched cell transplantation 
In order to investigate the contribution of BM cells to adult cell lineages in the pancreas, 
sex-mis-matched, male to female, BM transplants were performed where the donor cells 
and their differentiated progeny could be identified by the presence of the Y chromosome 
in the female recipient tissues. Breeding and isolation of BM were carried out under UK 
Home Office procedural and ethical guidelines (Home Office Project License NO. 
70/5962) at Biological Services Unit, Charterhouse Square. Administration of BM and 
stem cells and maintenance of chimaeric mice were carried out in the Biological Resource 
Unit, Cancer Research UK, London Research Institute. BM cells were collected from 
femurs, tibiae and iliac crest of donor male Balb/c and female NOD mice aged 10 weeks of 
age on the day of transplantation. 
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2.4.2. Preparation of cell transplant 
Cells for transplant were resuspended in 200 µl sterile 2% PBS FBS for intravenous (i.v.) 
tail vein injection into the recipient female mice on the same day. The number of nucleated 
cells was counted using a haemocytometer by the dye exclusion test using trypan blue 
(Stem Cell Technologies). Cells were stored on ice for no more than 1 hour before 
administration. Following administration, the mice were housed in sterile conditions and 
specific protocols were performed in accordance to each defined study. 
 
2.4.3. Monitoring diabetes development 
 
During the duration of transplantation, blood glucose levels will be evaluated once every 7 
days using an Accu-chek AVIVA Blood Monitor (Roche). To monitor diabetes 
development, mice were classified diabetic if blood glucose was confirmed as ≥ 11.5 
mmol/l. At the end point, all mice were killed by cervical ‘dislocation’ and/or CO2 
inhalation dependent on the type of tissue collected. Pancreas, spleen, kidney and liver 
were fixed in 10% neutral buffered formalin (BDH Laboratory Supplies Inc.) for 24 hours 
at room temperature (RT) before being embedded in paraffin wax. Mice transplanted with 
BM or EPCs were monitored for 14 weeks and 3-4 weeks respectively. The number of 
animals used for each treatment group is detailed in Table 2.1. 
 
Cell fraction Number of 
animals 
Animal model Number of cells 
transplanted 
Whole BM 
cells 
 20 Lethally irradiated pre-diabetic 
mice (12week) 
2 x 106 cells 
EPCs 13 Early diabetic mice (0-3 days 
diabetic) 
5 x 104 cells 
 
 
Table 2.1. Details of cell transplantation.  
Experimental details for BM and EPC transplant into prediabetic and early diabetic 
mice (Abbreviations: EPCs, endothelial progenitor cells; BM, bone marrow) 
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2.5. HISTOCHEMISTRY 
2.5.1. Tissue fixation, embedding and tissue sectioning 
All mice were killed by ‘dislocation’ and/or CO2 inhalation, dependent on type of tissue 
collected. Half of the organs (pancreas, spleen, kidney and liver) were fixed in 10% v/v 
neutral buffered formalin (BDH Laboratory Supplies Inc.) for 24 hours at RT and the 
remaining snap frozen in liquid nitrogen. Formalin-fixed tissues were transferred to 70% 
v/v ethanol and then embedded in paraffin wax. Paraffin embedded tissues were sectioned 
at a thickness of 5 µm and placed on ThermoShandon plus slides (Thermo Fisher Scientific 
Inc.,Waltham, USA) and allowed to dry in an incubator for 40 0C overnight. Slides were 
then stored at RT until required. Pancreata snap frozen in liquid nitrogen were serially 
sectioned at 7µm and kept at -80 0C. 
2.5.2. Dewaxing, blocking endogenous peroxidase and rehydration  
Paraffin embedded slides first were deparaffinized with xylene for 5 mins twice and then 
rehydrated for 1 min each through a descending series of ethanol (100, 95 and 70% v/v 
ethanol) and then blocked with 0.3% v/v hydrogen peroxidase in methanol 
(DakoCytomation) for 10 mins to block endogenous peroxidase activity when using 
peroxidase-dependent immunostains.  
2.5.3. Heat-mediated antigen retrieval 
Heat-mediated antigen retrieval was used in some of our immunohistochemistry protocols 
to restore the immunoreactivity of the antigen. After dewaxing, blocking of endogenous 
peroxidase and rehydration steps, slides were subjected to antigen retrieval by treatment in 
pre-heated 10mM sodium citrate buffer (pH 6.0) in a microwave (100-V, 800-W 
microwave) for between 5-20 mins depending on the type of antibody used. 
2.5.4. Haematoxylin and eosin (H&E) staining 
H&E staining is used to examine the morphological structure of the tissue section. Paraffin 
embedded sections first were deparaffinized with xylene as outlined in method section 
2.5.2. Next, sections were stained with haematoxylin for 2 mins before washing the excess 
Chapter 2                                                                                         Materials and Methods 
 
 
 
Cheen Khoo                                                                                                                           52             
 
in tap water for 1 min. Sections were then dipped in acid water before counterstaining with 
eosin. After counterstaining, sections were dehydrated for 2 mins in 70%, 90% and 100% 
v/v ethanol for 5 mins followed by clearing in xylene twice for 1 min before mounting with 
DEPEX (BDH Laboratory Supplies Inc.) and coverslipping. 
2.5.5. General immunohistochemistry protocol 
For specific immunostaining, the following antibodies were used at a dilution as specified. 
Paraffin embedded slides were first deparaffinized with xylene, blocked with 0.3%  v/v 
hydrogen peroxidase in methanol for 10 mins and then rehydrated in a descending series of 
ethanol (100, 95 and 70% v/v ethanol). After washing in distilled water for 1 min, slides 
were subjected to heat-mediated antigen retrieval for between 5-20 mins depending on the 
type of antibody used. To block non-specific binding, slides were next incubated with 
serum from the same species from which the secondary antibody was raised in at a dilution 
of 1:25 for 15 mins at RT. Primary antibody was next added to the sections for 35 mins at 
RT. Sections were then washed in PBS for 5 mins twice, and next incubated with the 
biotinylated secondary antibody for 35 minutes at RT. The sections were then washed in 
PBS and incubated with streptavidin: horseradish peroxidase (Dako) for 35 mins at RT. 
After washing in PBS, DAB (3, 3’-diaminobenzidine) chromogen (1:4)(Immpact DAB 
diluent, Vector Laboratories) was applied to sections and the substrate-reaction allowed to 
take place for 1-3 mins. This reaction (brown colour) was stopped by washing in distilled 
water for 1 min and followed by counterstaining in haematoxylin for 1 min, rinsing in tap 
water, acid water, lithium carbonate, tap water, 70%, 90% and 100% v/v alcohol, xylene, 
and finally mounted with DEPEX and coverslipped.  
2.5.6. CD31 microvessel staining 
To evaluate blood vessel density, an anti-CD31 antibody was used to stain for endothelial 
cells lining blood vessels. Both primary and secondary antibodies were diluted in blocking 
buffer, made up of goat serum (Dako) diluted in PBS (1:25). Frozen pancreata (half) were 
serial sectioned at 7 µm thickness and three sections from positions 500 µm apart for each 
block were used for microvessel staining.  The sections were then brought to temperature 
before fixation in ice cold acetone (BDH) for 2 mins. Next, sections were air dried for 1 
hour and rehydrated in PBS for 10 mins. Sections were blocked with blocking buffer for 30 
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mins before adding rat anti-mouse CD31 (BD Pharmigen) (1:100) for 1 hour. After 3 
washes in PBS for 5 mins, goat anti-rat Alexa 488 (Dako) (1:600) and DAPI (Invitrogen) 
(1:2000) was added to the sections for 1 hour. Sections were washed with PBS three times 
before coverslipping with vectashield mounting medium (Vector Laboratories). For 
scoring of blood vessel density, see section 2.6.2. 
 
2.5.7. Combined endomucin immunohistochemistry and Y chromosome detection 
Immunohistochemistry for various antigens was used to establish cell phenotype. In tissues 
of female recipient mice that received a male BM transplant, in situ hybridisation for the Y 
chromosome was used to distinguish the transplanted cells. Therefore combined 
immunohistochemistry and in situ hybridisation permitted both lineage tracing and 
phenotypical analyses. For all immunohistochemical and in situ hybridisation protocols, 
appropriate positive and negative controls were used. Prior to use of any newly acquired 
antiserum, a serial dilution was tested on positive control sections of fixed tissue in order to 
establish the optimal dilution of each antibody. 
To differentiate between the host- and donor-derived endothelial cells, in situ hybridisation 
for the Y chromosome was combined with immunohistochemical characterisation of 
endomucin, an endothelial marker. Paraffin sections were dewaxed, blocked with 0.3% v/v 
hydrogen peroxidase in methanol and rehydrated through a descending series of alcohol in 
PBS (100%, 95% and 70% v/v ethanol ), before incubation in 20% v/v acetic 
acid/methanol for 10 mins. After incubation, slides were rinsed with PBS before addition 
of rabbit serum (Dako) for 30 mins. Rat monoclonal anti-mouse Endomucin (V.7C7) 
(Santa Cruz). Antibody was added (1:250) for 40 mins and subsequently washed twice 
with PBS for 5 mins. Secondary antibody, rabbit biotinylated anti-rat IgG (1:100) (Vector 
Laboratories) was added to sections and incubated for 35 mins. Sections were washed 
twice for 5 mins before addition of alkaline phosphatase streptavidin (1:50) (Vector 
Laboratories) for 25 mins. After washing sections twice for 5 mins, sections were 
developed according to manufacturer’s instructions using alkaline phosphatase substrate 
kit 1 (Vector Laboratories). Sections were washed in PBS twice for 5 mins. 
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Subsequently sections were incubated in 1 mol/l sodium thiocyanate for 10 mins at 80 °C, 
washed in PBS, and then digested in 1.2% w/v pepsin in 0.1 mol/L HCl at 37 °C for 
varying times, depending on the pre-treatment used for immunohistochemistry. The 
protease was quenched in 0.2% v/v glycine in double-concentration PBS and the sections 
were then rinsed in PBS, post fixed in 4% w/v paraformaldehyde in PBS for 2 mins, 
dehydrated through graded alcohols, and air dried. A fluorescein isothiocyanate-labelled Y 
chromosome paint (Cambio Ltd) was added to the sections, sealed under a glass coverslip, 
heated to 80 °C for 10 mins, and incubated overnight at 37 °C. The next day, slides were 
washed with SSC to remove unbound DNA sequences. Slides were mounted with hardset 
mounting 4’6-diamidino-2-phenylindole (DAPI) medium (Vector Laboratories). A Leica 
microscope, with x 40 objective lens, was used to detect the signal and BM engraftment 
was calculated by counting the number of Y-chromosome+ nuclei (donor origin) and total 
number of DAPI-stained nuclei in 10 random fields and was expressed as a percentage +/- 
SEM. 
 
2.5.8. Combined Ki-67 and insulin immunohistochemistry  
To quantify β-cell proliferation and regeneration in the pancreata after BM transplantation, 
pancreatic sections were stained with anti-insulin and anti-Ki-67 antibodies. For insulin/ 
Ki-67 double labelling, alkaline phosphatase staining with a guinea pig anti-insulin 
antibody (Dako) was followed by a rabbit anti-Ki-67 antibody (NCL-Ki-67-P, 
Novocastra), which was developed with immunoperoxidase staining. 
Two paraffin embedded sections from positions 100 µm apart (5 µm thick) were used for 
double immunostaining using Ki-67 and insulin antibodies. The sections were routinely 
dewaxed and blocked. For development of alkaline phosphatase, sections were then 
incubated with ice cold 20% v/v acetic acid in methanol for 5 mins. Antigen retrieval was 
performed by microwaving sections (700W) in 0.01M citrate buffer at pH 6 for 10-20 
mins. After cooling sections for 5 mins in PBS, sections were pre-incubated with goat 
serum (Dako) at a dilution of 1:25 for 15 mins to reduce non-specific background staining. 
The sections were then incubated with a guinea pig anti-insulin antibody (1:400) for 35 
mins. Following two washes in PBS, sections were incubated with a biotinylated goat anti-
guinea pig antibody at 1:200 (Dako) for 35 mins. For the third layer following PBS 
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washing, alkaline phosphatase (Vector Laboratories) at a 1:50 dilution was applied to 
sections for 35 mins. Slides were developed using alkaline phosphatase substrate kit 
according to the manufacturer’s instructions (Vector Laboratories) for 10 mins. Sections 
were next washed in PBS before staining for Ki-67. Sections were now blocked with goat 
serum (Dako) at a dilution of 1:25 for 15 mins followed by incubation with a rabbit anti- 
Ki-67 polyclonal antibody at a 1:200 dilution for 35 mins. For the second layer following 
PBS washing (twice for 5 mins each), sections were incubated with a biotinylated swine 
anti-rabbit antibody (Dako) at a 1:500 dilution for 35 mins. Following PBS washing, goat 
anti-rabbit (Invitrogen) at a 1:150 dilution were applied to the sections for 35 mins. After 
PBS washing, slides were mounted using Vectashield (Vector Laboratories). 
The stained sections were examined at 400 x magnification. For the relative proportion of 
Ki-67+-β-cells, total numbers of β-cells indicated by positive insulin staining with Ki-67+ 
nuclei were counted and expressed as a percentage (see section 2.6.3). 
2.6. TISSUE ANALYSIS 
2.6.1. Scoring of insulitis 
In order to investigate the effect of  XG-102 or BM-derived cells on the homing of antigen 
driven T-cells in the endocrine pancreas, insulitis was evaluated by H&E staining of islets 
from two pancreatic sections (200 µm difference) of each group after XG-102 or PBS 
injections. Sections were examined in a “blinded fashion” and islet infiltration was scored 
as follows: no infiltration (grade 0); peri-insulitis (grade I), where about 10% of the islet 
area is infiltrated by a peripheral ring of lymphocytes; moderate (grade II), where 25% to 
50% of the islet shows mononuclear infiltration and severe (grade III), where over 50% of 
the islet area was infiltrated by lymphocytes. 
2.6.2. Microvessel density calculation  
CD31-positive vessels were used for assessment of vascular density. Islets were identified 
and viewed at 200 x magnification using a Nikon Eclipse TE2000-S microscope (Nikon 
Instruments Europe B.V., Amstelveen, The Netherlands) with the observer blinded to 
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pathology data. Images were taken using single channel colours and merged using Adobe 
Photoshop CS2.  
 
To calculate the volume fraction of stained regions, a picture was taken of the islet and 
surrounding tissue. Each positive endothelial cell or group of cells in contact with a spot 
was counted as an individual vessel. Endothelial staining in large vessels with tunica 
media, and non-specific staining of non-endothelial structures, was disregarded in vessel 
counts. Measure of vessel density was estimated by the number of blood vessels in the islet 
in the total field of view. Vessel density was quantified in all islets from 3 stained sections 
(obtained at 500 µm apart). Blood vessel density in each of these sections was then 
averaged to give a final measurement for each pancreatic block.  
2.6.3. Ki-67/Insulin  calculation  
Cells double stained for Ki-67 and insulin  antibody were used for assessment of islet 
regeneration. Islets were identified and viewed at 400 x magnification using a Nikon 
Eclipse TE2000-S microscope (Nikon Instruments Europe B.V., Amstelveen, The 
Netherlands) with the observer blinded to pathology data.  
To calculate the % of insulin-positive cells that were also Ki-67 positive, a picture was 
taken of the islet at 400 x magnification. Ki-67+ Insulin+ cells were quantified in all islets 
from two stained sections (obtained 100 µm apart) and was then averaged to give a final 
percentage for each pancreatic block. 
2.7. STATISTICS 
Results are expressed as means ± SEM. Statistical significance of differences was assessed 
using Student’s unpaired t-tests.  
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2.8. BUFFERS AND SOLUTIONS 
Medium Medium 
constituents 
Company 
EPC medium EGM-2 bullet kit Lonza 
 20% FBS PAA 
 Pen/Strep Invitrogen 
MACS buffer 2mM EDTA Sigma 
 PBS PAA 
 0.5% BSA Sigma 
4% Paraformaldehyde   
Paraformaldehyde 20 g Sigma 
PBS 500 ml PAA 
20 X SSC (pH 7.5)  CRUK 
NaCl 175.5 g Sigma 
Na citrate 88 g Sigma 
Distilled water made to 1L total 
volume 
  
Sodium citrate buffer (pH 6.0)  CRUK 
NaCl 175.5 g Sigma 
Na citrate 88 g Sigma 
Distilled water made to 1L total 
volume 
  
                                                                                                                                                 
 
Table 2.2. Buffers and solutions used in experiments. 
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2.9. SUPPLIERS AND DISTRIBUTORS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BDH Laboratory Supplies Inc. Hertfordshire, UK. 
BD Biosciences New Jersey, USA. 
BD Pharmingen San Diego, USA. 
Becton-Dickinson Bedford, USA. 
Cambio Ltd. Cambridge, UK. 
Cedarlane Ltd. East Sussex, UK. 
Charles River Laboratories Maine, USA 
Dako Cambridge, UK. 
Diabur Mannheim, Germany. 
Gibco Paisley, UK. 
Invitrogen Paisley, UK. 
Jensons-Pls Bedfordshire, UK. 
Lonza Wokingham, UK. 
Millipore Watford, UK. 
Molecular Probes Leiden, Netherlands. 
Neolus Terumo Corporation Madrid, Spain. 
Nikon Instruments Europe B.V. Amstelveen, Netherlands. 
Novocastra Newcastle, UK. 
Roche Diagnostics GmbH Mannheim, Germany. 
Santa Cruz Biotechnology Santa Cruz , USA. 
Sarstedt Numbrecht, Germany. 
Scientific Laboratory Supplies Ltd Nottingham, UK. 
Sigma Chemical Co. Oxford, UK. 
Stem Cell Technologies Vancouver, Canada. 
Swann-Morton Sheffield, UK. 
Thermo Fisher Scientific Inc.  Waltham, USA. 
Weldtite Products Ltd. Barton-on-Humber, UK. 
Vector Laboratories Inc. Burlingame, USA. 
Vernon-Carus Ltd. Lancashire, UK. 
Zymed Laboratories, Inc. San Francisco, USA. 
 Table 2.3. List of suppliers and distributors. 
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CHAPTER 3: STUDIES ON BLOOD AND BONE MARROW 
EPC-LIKE CELLS  
 
3.1. INTRODUCTION 
 
The successful isolation of EPCs in 1997 by Asahara et al. (Asahara et al., 1997) has led to 
many studies of EPCs to date, and it is now well known that EPCs derived from the BM 
and PB contribute to tissue repair in various pathological conditions via the formation of 
new blood vessels, i.e. neovasculogenesis. EPCs are believed to originate from the BM and 
are often mobilized into the circulation in response to growth factors and cytokines 
released following a variety of stimuli which include vascular trauma (Gill et al., 2001), 
ischaemia, wounding or cancer (Takahashi et al., 1999). EPCs home-to and incorporate 
into sites of damage and mediate repair by inducing neovascularization. 
  
Recent studies on angiogenesis have revealed a significant impairment of angiogenesis in 
diabetic patients (Caballero et al., 2007; Loomans et al., 2004). Additionally, these patients 
have a reduced number of PB EPCs (Fadini et al., 2005; Loomans et al., 2004). Loomans 
et al. showed that this endothelial dysfunction does not occur due to increased apoptosis 
but perhaps is associated with alterations in BM mobilization and hyperglycaemic stress 
(Loomans et al., 2004). Parallel studies have been carried out in ischaemic (Emanueli et 
al., 2007) and induced diabetic animal models (Caballero et al., 2007; Thum et al., 2007a), 
but has yet to be carried on the most valuable spontaneous model of T1D such as the NOD 
mouse. 
 
Accordingly, the aim of this study was to characterize and compare BM and PB EPCs from 
pre-diabetic and diabetic NOD mice, in order to delineate their fate in the natural history of 
autoimmune diabetes. 
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3.2. METHODS 
 
3.2.1. Mice 
 
Three groups of mice were used in this study, pre-diabetic NOD, diabetic NOD and wild 
type (Balb/c) mice. These mice were maintained in the animal unit at Charterhouse Square. 
Diabetes status of the mice was monitored and confirmed by measuring blood glucose 
levels (≥11.5 mmol/l) using an Accu-chek AVIVA Blood Monitor as outlined in Method 
2.1. 
3.2.2. Blood collection 
A single blood aliquot was collected by cardiac puncture from the ventricle under terminal 
isoflurane anaesthesia using appropriate size needles and collected into heparin coated 
tubes (Sarstedt, Numbrecht, Germany). Fresh blood collected in heparin coated tubes was 
mixed thoroughly to prevent coagulation and spun down briefly. Blood was stored on ice 
and used within two hours of collection.  
3.2.3. Bone marrow collection and isolation 
Outlined in Method 2.2 and 2.3. 
3.2.4. Isolation of peripheral blood 
Fresh blood collected in heparin coated tubes was mixed thoroughly and spun down 
briefly. A volume of 100 μl of blood was aliquoted into separate 15 ml Falcon tubes 
(Scientific Laboratory Supplies Ltd, Nottingham, UK). Next, 2 ml of FACS lysing solution 
(Becton-Dickinson, Bedford, USA) were added into each tube, vortexed and left to 
incubate for 15 mins in the dark. After incubation, 2 ml of x 1 PBS were added into each 
tube to dilute the FACS lysing solution and spun down at 2200 rpm for 7 mins. The 
resultant supernatant was removed and pellet resuspended in 2 ml of x 1 PBS. The mixture 
was centrifuged at 2500 rpm for 5 mins and resuspended in x 1 PBS for FACS analysis. 
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3.2.5. Direct staining of cells for fluorescence-activated cell sorting (FACS) analysis  
FACS analysis was carried out to quantify the numbers of EPC and cEPCs from BM and 
PB respectively. 
3.2.5.1. Staining: Whole bone marrow cells 
Cells that do not stain with CD23 (platelets, natural killer cells), CD45 (leukocytes), 
CD11b (monocytes, macrophages) and TER119 (erythrocytes) antibodies were defined as 
lin-. EPCs were defined by positive staining for c-Kit (BD Pharmingen, San Diego, USA), 
stem cell antigen 1 (Sca-1; BD Pharmingen) and CD31 (BD Pharmingen). Appropriate 
fluorochrome-conjugated isotype controls were used for each staining procedure.  
3.2.5.2. Staining: Whole blood 
A volume of 100 µl PB was incubated for 15 mins in the dark with an FITC-conjugated 
monoclonal antibody against mouse CD45 (lin-) (BD Pharmingen) in combination with an 
APC-conjugated antibody against mouse c-Kit (BD Pharmingen), PE-Cy7-conjugated 
antibody against mouse stem cell antigen 1 (Sca-1; BD Pharmingen) and PE-conjugated 
antibody against CD31 (BD Pharmingen). Isotype-identical antibodies served as controls 
(BD Pharmingen). After incubation, erythrocytes in the PB were lysed and washed with 
PBS before analysis. Each analysis included approximately 10,000 events. 
3.2.6. FACS analysis 
3.2.6.1. Analysis gating strategies: Whole bone marrow cells 
Characterization of EPCs from whole BM cells (approximately 1 x 106 cells) was analyzed 
with the fluorescence-activated cell sorter (FACS) Aria (Becton Dickinson). Single colour 
and negative selection antibodies with isotype controls were analysed first (Table. 3.1). 
This was followed by the analysis of cells labelled with lineage positive antibodies (c-Kit+ 
CD31+ Sca1+) but not antibodies: TER119, CD23, CD11b, CD45, i.e. lin-. Compensation 
and gating strategies were performed by Dr. Gary Warnes (blind manner). c-Kit+ lin- cells 
were first isolated. These cells are then gated to include only CD31+ Sca1+ cells. Only  
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single cells of c-Kit+ CD31+ Sca1+ lin- were obtained and located in the mononuclear 
region of a FSC vs. SSC graph. 
3.2.6.2. Analysis gating strategies: Whole blood  
Characterization of EPCs (c-Kit+ CD31+ Sca1+ lin-) from lysed blood was performed 
(approximately 0.5 x106 cells) as carried out previously using bone marrow cells. Cells 
were analysed on BD LSR II (Becton Dickinson). Single colour, negative selection 
antibody with isotype controls followed by combination of positive (c-Kit+ CD31+ Sca1+) 
and a negative selection antibody, CD45 i.e. lin- were analysed. Gating strategies was 
performed similar to the gating strategies to obtain BM-EPCs, as explained previously in 
which c-Kit+ lin- cells were first obtained and further gated to obtain CD31+ Sca1+ cells. 
Doublet discrimination was performed to obtain an EPC niche consisting c-Kit+ CD31+ 
Sca1+lin- cells. 
 
Antibodies Isotype Fluorochrome  
CD45 (Ly-5) Rat (LOU/Ws1/M) IgG2b, κ FITC 
TER-119 (Ly-76) Rat (WI) IgG2b, κ FITC 
CD23 Rat (LOU/M) IgG2a, κ FITC 
CD11b Rat (DA) IgG2b, κ FITC 
Lineage negative Abs 
Antibodies    
CD31 (PECAM-1) Rat (LEW/Cr1BR) IgG2a, κ R-PE 
c-Kit (CD117) Rat (Wistar) IgG2b, κ APC 
Sca-1 (Ly-6A/E) Rat (LEW) IgG2a, κ PE-Cy7 
Lineage positive Abs 
 
 
Table 3.1. Details of FACS antibodies used. All antibodies were purchased from BD 
Pharmigen, San Diego, USA. (Abbreviations: FITC, Fluorescein Isothiocyanate; R-
PE, R-Phycoerythrin; APC, Allophycocyanin)  
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3.3 RESULTS 
3.3.1. Information on batches of bone marrow and blood used in the experiments 
 
 
Matching BM and blood samples from 3 groups of mice were used in this study: Wild type 
(Balb/c) mice; pre-diabetic NOD mice and diabetic NOD mice (> 11.5mmol/l glucose). 
 
 
3.3.2. Characterization and numbers of EPCs in peripheral blood and bone marrow of 
NOD mice 
 
Debate ensues as to the true phenotype of adult EPCs, which is often clouded by the 
overlap of the phenotype of EPCs with HSCs and endothelial cells, and thus, a universally-
accepted EPC phenotype remains to be achieved. Based on recent EPC studies in mice, we 
used flow cytometry and determined the numbers of c-Kit+ CD31+, Sca-1+ lin- cells in the 
PB and BM. 
 
FACS analysis was first carried out on BM and PB of wild type (Balb/c) and non-diabetic 
NOD mice (Figure 3.1). To obtain a single cell population of EPCs, c-Kit+ lin- cells were 
first gated and subsequently gated for CD31+ and Sca-1+ cells. FACS analyses revealed 
that there was no significant difference in EPC number (%) (n=5) (c-Kit+ CD31+ Sca-1+ lin- 
cells) in BM and blood from non-diabetic NOD mice compared to WT (Balb/c) mice 
(Figure 3.1). In the following experiments, BM and blood from non-diabetic NOD mice 
served as controls and the same gating strategies were used. 
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 Figure 3.1. EPC numbers (%) comparison (bone marrow and blood) 
between non-diabetic NOD and WT (Balb/c) mice. EPCs (c-Kit+ 
CD31+ Sca1+ lin−) were obtained using flow cytometry. All experimental 
data are expressed as means ± SEM of respective number of experiments, 
using two types of mice (n = 5) (non-diabetic NOD mice versus Balb/c 
mice). 
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Using the same gating strategies, FACS analyses were carried out to compare the number 
of BM and PB EPCs in the diabetic and non-diabetic NOD mice. Figure 3.2 and Figure 3.3 
show the representative FACS gating strategies to obtain BM and blood EPCs (c-Kit+ 
CD31+ Sca-1+ lin-) respectively. 
 
 
 
 
 
 
 
 
 
 
 
A B C D 
A B C D 
Figure 3.2. Characterization of EPCs (c-Kit+ CD31+ Sca-1+ Lin-) from whole bone 
marrow cells (1.0 x 106 cells). Cells were analysed on a BD FACSAria cell sorter. 
Single colour and negative selection antibodies with isotype controls were also 
analysed. (A) Compensation and gating strategies were performed by firstly gating c-
Kit+ lin- (APC +ve and FITC −ve cells presented as histogram, figure not shown), (B) 
CD31+ Sca1+ cells (PE and PE-Cy7+ve cells) were then gated from c-Kit+ lin- cells, (C) 
A band of uniform expressing APC +ve cells were then gated against forward side 
scatter (FSC) and doublet discrimination achieved by use of side scatter width (SSC-W) 
parameter against FSC, (D) These events were then back-gated against FSC versus SSC 
to obtain single cells of c-Kit+ CD31+ Sca1+ lin- which are located in the mononuclear 
region of the FSC versus SSC graph. 
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A B C D 
A B C D 
Figure 3.3. Characterization of EPCs (c-Kit+ CD31+ Sca-1+ Lin-) from peripheral 
blood cells (< 0.5 x 106 cells). Heparinized and lysed PB cells were analysed on a BD 
LSRII cell sorter. Single colour and negative selection antibodies with isotype controls 
were also analysed. (A) Compensation and gating strategies were performed by firstly 
gating c-Kit+ lin- (APC +ve and FITC −ve cells presented as histogram, figure not 
shown), (B) CD31+ Sca1+ cells (PE and PE-Cy7 +ve cells) were then gated from c-Kit+ 
lin- cells, (C) A band of uniformly expressing APC +ve cells were then gated against 
FSC and doublet discrimination achieved by use of SSC-W parameter against FSC, (D) 
These events were then back-gated against FSC versus SSC to obtain single cells of c-
Kit+ CD31+ Sca1+ lin- which are located in the mononuclear region of the FSC versus 
SSC graph. 
The results demonstrated a significant decrease in EPC number (CD31+ c-Kit+ Sca-1+ lin-) 
in BM from diabetic compared to non-diabetic NOD mice (P=0.021) (Figure 3.4.). 
Conversely, EPC number (%) was significantly increased in PB from diabetic (compared to 
non-diabetic NOD mice (P=0.015)).  
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Figure 3.4. EPC numbers (%) are plotted based on the average EPC% 
obtained from FACS analyses from five non-diabetic and five diabetic mice. All 
experimental data are expressed as means ± SEM of respective number of 
experiments, using two types of mice (diabetic versus non-diabetic mice). Statistical 
significance was tested by Student’s unpaired t-test, * = significant.   
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As demonstrated in many studies, EPCs are present in very low numbers in the BM and 
circulating blood, in accordance with the above results, we demonstrated using FACS 
sorted BM, EPCs are reduced in diabetic mice compared to non-diabetic mice (Figure 3.5). 
The FACS sorting was carried out using pooled BM from two mice and we obtained 
approximately 1217 viable (DAPI+) EPCs from non-diabetic mice, more so than in diabetic 
female mice (~ 140 cells). 
 
10 week non diabetic female mice (n=2 pooled data) ( Total sorted cells = 134,580)
20 week diabetic female mice (n=2 pooled data) (Total sorted cells = 96,820)
1217 cells
0.009%
139 cells
0.0014%
A B C D E
A B C D E
 
 
 
 
 
Figure 3.5. Characterization and sorting of viable bone marrow-derived EPCs 
from non-diabetic and diabetic NOD mice (n=2) respectively. (A) Double 
discrimination, (B) Selection of viable cells using DAPI, (C) Gating for mononuclear 
cells, (D) Gating for c-Kit+ Lin- cells (APC +ve and FITC −ve cells presented as 
histogram, figure not shown, (E) Further gating for CD31+ Sca-1+ cells to get obtain c-
kit+ CD31+ Sca-1+ cells. 
 
3.4. DISCUSSION  
 
In the present study, we have characterized and isolated EPCs from the BM and PB of 
Balb/c and NOD mice. To characterize EPCs from the BM and blood, c-Kit, CD31 and 
Sca-1 markers were used. c-Kit is a primordial stem marker and is important in EPC 
mobilization (Jackson et al., 2001). Sca-1 (stem cell antigen-1) is a well known progenitor 
stem cell marker and is important in the regulation of c-Kit. The third marker used in this 
study was CD31/PECAM-1, suggested to be a marker for early angiogenesis (Rongish et 
al., 1996) as well as the earliest marker of endothelial cell differentiation (Baldwin et al., 
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1994). To isolate a purified population of EPC cells, lineage antibodies (CD23, CD11b, 
TER119 and CD45) were used to eliminate platelets, natural killer cells, macrophages and 
leukocytes. In our study, fresh cells were isolated from BM and PB. In contrast to other 
studies that used enriched mononuclear fractions (Loomans et al., 2004; Zhang et al., 
2006), we have demonstrated that EPC or EPC-like cells can be isolated from freshly 
prepared whole BM and PB, although EPC populations are small. A low number of 
circulating EPCs was similarly observed by Thum et al. where they reported the number of 
circulating EPCs (CD133+ VEGFR2+) in human is in the range of 0.003%-0.009% (Thum 
et al., 2007b). When cells are pooled, analysed and sorted using flow cytometry, a six-fold 
difference between diabetic and non-diabetic BM EPCs (Figure 3.5) was noted, which is in 
line with our FACS analysis data in which we demonstrated a reduction of BM EPCs in the 
diabetic mice and an increase of circulating EPCs in the blood (Figure 3.4). 
 
Based on these data, BM-derived EPCs may have been stimulated to enter the systemic 
circulation in response to signals from the pancreas, although this hypothesis requires more 
evidence. Further studies need to be carried out to investigate whether EPCs can home to 
the damaged pancreas and contribute to β-cell regeneration. Mathews et al., have 
demonstrated that BM-derived EPCs could be stimulated to enter the systemic circulation 
in response to signals from the pancreas (Mathews et al., 2004). This latter observation is 
supported by several studies of BM-derived stem cell engraftment and contribution to 
neovasculogenesis in adult tissues (Brittan et al., 2005; Fujii et al., 2002; Hatzopoulos et 
al., 1998; Ishizawa et al., 2004; Kocher et al., 2001; Taniguchi et al., 2006), which is 
enhanced by increasing regenerative demand within a diseased or damaged tissue. The 
exact signaling pathways and molecular mechanism for this EPC recruitment are as yet 
unknown.  
 
Human studies have demonstrated a reduction of EPCs in the PB of diabetics (Loomans et 
al., 2004). However we observed that there is an increase of circulating EPCs in diabetic 
mice compared to non-diabetic NOD mice. This could be attributed to the extent of 
pancreatic damage of this disease model in which the mice used in the study have been 
diabetic for two weeks. Besides their ability to migrate and differentiate into endothelial 
cells when recruited, there is existing evidence suggesting that EPCs have paracrine effects 
in which EPCs release cytokines or growth factors to contribute to tissue regeneration at a 
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damaged site. There is a possibility that the EPCs were recruited to the injury site during 
the pre-diabetic stages and successfully engraft with the help of the cytokines released to 
aid regeneration of the pancreas. However as shown in humans, the EPCs in diabetic mice 
may be dysfunctional, and thus, they would be unable to completely vascularize or 
regenerate the damaged site.  
 
The progression of autoimmune T1D in mouse and humans is characterized by infiltration 
of inflammatory cells and increasing blood glucose levels. Cytokines such as IL-1β can be 
released during the inflammation process in the islets. Amano et al., have shown that IL-1β 
can increase vascular cell adhesion molecule (VCAM-1) expression on endothelial cells 
(Amano et al., 2004), and thus may play a role in mobilization and recruitment and homing 
of EPCs in response to the signals from the pancreas. Further studies are thus warranted to 
investigate the relationship between insulitis and EPC recruitment. 
 
Various methods have been used to characterize and isolate EPCs from blood or BM which 
includes their ability to proliferate, adhere, form tubules and migrate in cell culture. 
However, debate still ensues as to the true phenotype of adult EPCs, which is often 
clouded by the overlap of the phenotype of EPC cells with haematopoietic stem cells and 
endothelial cells, and thus, a universally-accepted EPC phenotype remains to be achieved. 
These approaches are further hampered by the fact that only a small number of cells can be 
isolated from blood or BM (Lin et al., 2000). 
 
In conclusion, our data have illustrated that in the most appropriate model of autoimmune 
diabetes, the decrease in EPC of the BM and the increase in circulatory EPC’s may reflect 
increased mobilization of BM cells. The role of these cells in β-cell regeneration therapy 
should be investigated in the future.  
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CHAPTER 4: XG-102 STUDIES ON DELAYING β-CELL 
DEATH USING THE NOD MOUSE  
 
4.1. INTRODUCTION 
 
In type 1 and type 2 diabetes, JNK (c-Jun N-terminal protein kinase), a member of the 
mitogen-activated protein kinase (MAPK) family plays an important role in apoptosis. 
Extracellular stimuli such as growth factors, cytokines and radiation activates the JNK 
pathway (Tawadros et al., 2005). JNK activity is controlled by IB-1, a scaffold protein 
which interacts with upstream signalling components such as cell surface receptors, 
receptor-like proteins and upstream G proteins that can activate kinase substrates such as 
JNK. Activated JNK can phosphorylate transcription factors such as c-Jun that play a 
critical part in controlling expression of genes involved in apoptosis.  The JNK protein 
kinase is a member of the MAPK group that is activated in response to dual 
phosphorylation on threonine and tyrosine. Ten JNK isoforms were identified in human 
brain by molecular cloning. These protein kinases correspond to alternatively spliced 
isoforms derived from the JNK1, JNK2 and JNK3 genes. 
 
JNK signalling is important in normal development and pathogenesis of several diseases, 
thus JNK represents a valuable target in development of therapies. In recent years, JNK 
inhibitors were developed and found to have a therapeutic effect in models of rheumatoid 
arthritis (Gaillard et al., 2005), cardiac ischaemia (Ferrandi et al., 2004) and diabetes 
(Bonny et al., 2000). To date, two main strategies to study the biological function of JNK 
are by using JNK knockout models and using JNK peptide inhibitors. Ten JNK isoforms 
have since been identified, where each JNK protein kinase corresponds to alternatively 
spliced isoforms derived from JNK1, JNK2 and JNK3 genes. The loss of a single isoform 
in the JNK1 knockout mouse was shown to alter T-cell differentiation, where they 
differentiated preferentially into T helper cells and exhibited reduced activation-induced 
cell death in T-cells, in which activation through the T-cell receptor results in apoptosis 
(Dong et al., 1998).  
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IB-1 is highly expressed in pancreatic β-cells and is important in the regulation of JNK 
activity (Haefliger et al., 2003). Cytokines such as IL-1β and TNF-α activate the JNK 
pathway, contributing to cell signalling towards apoptosis. Dickens et al., used JNK 
binding domain (JBD) of IB-1/JIP-1 to block JNK activation, successfully preventing 
apoptosis >90% (Dickens et al., 1997).The importance of IB-1 in JNK signalling is further 
highlighted in a study where IB-1 was overexpressed in a mouse insulin-secreting cell line 
βTC-3. JNK mediated activation of transcription factors, c-Jun, ATF2 and Elk-1 was 
prevented with IL-1β mediated apoptosis decreased by 80% (Bonny et al., 2000). A similar 
study used adenovirus-mediated gene transfer of IB1 to increase IB-1 content in primary 
pancreatic islets and INS-1 cells; they showed a decrease in JNK activity and cells were 
protected from cytokine-induced apoptosis (Haefliger et al., 2003). 
 
As with pancreatic β-cell death, JNK signalling has been shown to have a part in neuronal 
death (Borsello and Forloni, 2007; Wu et al., 2000). To investigate the role of this kinase 
in cell death, a protease-resistant peptide derivative of IB-1 was developed, D-JNK11 
(trade name XG-102) and administered in rat models of cerebral ischaemia (Borsello et al., 
2003; Hirt et al., 2004). XG-102 is made up exclusively of D-amino acids, in which this D-
retroinverso form renders them protease resistant and additionally expand its half-life in 
vivo (Borsello et al., 2003). Borsello et al., first showed a significant reduction in brain 
lesion volume in rat models of middle cerebral artery occlusion (transient) and permanent 
occlusion after 6-12 hours of ischaemia (Borsello et al., 2003). Hirt et al., observed a 
neuronal protective effect as little as 48 hours after drug administration and demonstrated a 
significant reduction in infarct volume 3 hours after the onset of ischaemia, in severe 
cerebral ischaemia mouse model (Hirt et al., 2004). This compound has thus shown 
striking efficacy in protecting neurons against cell death in both studies by selectively 
blocking the access of JNK to c-Jun and other substrates by a competitive mechanism. XG-
102 competitively blocks the propagation of the pro-apoptotic events by blocking protein-
protein interaction between IB1 and its partner JNK.  
 
Members of JNK family, JNK2 and JNK1 have often been implicated in T1D and T2D 
progression respectively (Hirosumi et al., 2002; Jaeschke et al., 2005). The role of JNK1 in 
T1D however is not known. Since apoptosis of β-cells is one of the putative mechanisms 
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involved in the cascade of events leading to T1D, we intend to test XG-102 that might be 
useful for β-cell protection and prevention of β-cell loss in the NOD mouse. Our study 
using the NOD mouse is the first of its kind to investigate the potential role of JNK1 in 
T1D progression. 
4.2. METHODS 
 
4.2.1. Mice 
 
Early diabetic female NOD mice were used in this study and maintained in animal unit of 
Charterhouse Square. Diabetes status of the mice was monitored and confirmed by 
measuring blood glucose levels (≥11.5 mmol/l) using an Accu-chek AVIVA Blood 
Monitor as outlined in Method 2.1. 
 
4.2.2. XG-102 administration into diabetic NOD mice  
4.2.2.1 Pilot study 
 
NOD mice enrolled for this study (0-7 days diabetic and having blood glucose in the range 
of 11.5 mmol/l to 30 mmol/l) were divided into 3 groups (Figure 4.1): 
 
 a) Group A:  5 female animals (15 to 25 weeks old) have been injected intraperitoneally 
(i.p.) with XG-102 (0.1 mg/kg) once a week for 4 weeks. Mice that were unhealthy during 
the study were sacrificed (around week 3, 4, 5).  
b) Group B: 6 female animals (15 to 25 weeks old) have been injected i.p. with XG-102 
(0.1 mg/kg) once a week for 4 weeks with intended follow-up for 4 weeks, before re-
administration with the same dose at the end of the 4th week. Following the 2nd treatment, 
mice to be followed-up until week 13; mice that were unhealthy during the study were 
sacrificed (around week 3, 4, 5 and onwards).  
c) Group C: 5 female animals (15 to 25 weeks old) as control (PBS i.p. weekly for 4 
weeks) mice that were unhealthy during the study were sacrificed (around week 3, 4, 5). 
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4.2.2.2 Second study 
Figure 4.1. Initial experimental strategy.  
Group A and B mice were injected i.p. with XG-102 (0.1 mg/kg) once a week for 4 
weeks. Mice that survived past 4 weeks were to be re-administered with the same 
dose at the end of the 4th week of follow-up to further inhibit apoptosis (Group B). 
Group C, control mice were injected i.p. with PBS once a week for 4 weeks 
(Abbreviations: PBS, phosphate buffer saline; i.p., intraperitoneal)  
Mice enrolled in this study (0-3 days diabetic with blood glucose in the range of 11.5 
mmol/l to 25 mmol/l) were divided into 2 groups (Figure 4.2): a) Group A:  6 female 
animals (15 to 25 weeks old) were injected intraperitoneally (i.p.) with XG-102 (0.1 
mg/kg) once a week for 4 weeks. Group B: 6 female animals (15 to 25 weeks old) acted as 
control (PBS i.p. weekly for 4 weeks). All mice that were unhealthy during the study were 
sacrificed by cervical dislocation (approximately at week 3, 4, 5). 
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4.2.3. Insulin and glucagon immunohistochemistry  
Paraffin embedded sections previously fixed in 10% v/v neutral buffered formalin were 
used (Method 2.2). For specific immunostaining the following antibodies were used at a 
dilution as specified. Guinea-pig anti-insulin (DakoCytomation, Carpinteria, USA) was 
used at a dilution 1:100 to identify β-cells. Rabbit anti-glucagon (Zymed Laboratories, Inc, 
San Francisco, USA) was used at a dilution 1:50 to visualise α-cells. 
Sections were incubated with CAS Block (Zymed Laboratories) to block non-specific 
binding for 10 mins at RT after dewaxing and blocked with 0.3% v/v hydrogen peroxidase. 
Primary antibody was next added to the sections for 1 hour at RT. Sections were washed in 
PBS for 5 mins thrice and next incubated with the secondary antibody using LSAB+ 
System-HRP system (DakoCytomation) (at the dilution supplied by the vendor) for 30 
mins at RT. Sections were then washed in PBS and incubated with Streptavidin peroxidase 
complex (DakoCytomation), for 30 mins at RT. After washing in PBS, DAB (3, 3’-
diaminobenzidine) chromogen (Vector Laboratories) was applied to sections and the  
 
PBS 1     2     3     4    5     6     7      8     9
CULLED; 
EAS FIXEDPANCR
Group C
weeks
XG-102 
Dose:  (0.1 mg/kg)  
PBS 
1     2     3     4    5     6     7      8     9 weeks 
CULLED; 
PANCREAS 
FIXED
Group A - TREATED 
roup B - CONTROL CULLED; 
PANCREAS 
FIXED
1     2     3     4    5     6     7      8     9 weeks 
Figure 4.2. Chosen experimental strategy. Group A mice were injected i.p. with XG-
102 (0.1 mg/kg) once a week for 4 weeks. Group B, control mice were injected i.p. with 
PBS once a week for 4 weeks (Abbreviation: PBS, phosphate buffer saline; i.p., 
intraperitoneal)  
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substrate-reaction allowed to take place for 1-3 mins. This reaction (brown colour) was 
stopped by washing in distilled water for 1 min and followed by counterstaining in 
haematoxylin for 1 min, rinsed in tap water, 70%, 95% and 100% v/v alcohol, xylene, 
before mounting with hardset mounting medium (Vector Laboratories) and coverslipped. 
Controls were performed to exclude non-specific staining. As positive control for insulin 
and glucagon, murine pancreas sections were stained. 
4.2.4. TUNEL staining for detecting apoptotic β-cells 
The presence of apoptosis in the pancreas was confirmed by staining tissue sections using 
the terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end 
labelling method (TUNEL), which allows the identification of apoptotic cells in situ by 
using terminal deoxynucleotidyl transferase (TdT) to transfer biotin-dNTP to the DNA 
strand breaks caused by internucleosomal cleavage. The TUNEL method was performed 
using the ApopTag® Plus Peroxidase In Situ Apoptosis Detection Kit (Oncor, 
Gaithersburg, USA) according to the manufacturer's instructions. Briefly, the sections were 
deparaffinized in xylene and then rehydrated in a descending series of ethanol (100, 95 and 
70% v/v ethanol) before incubating in proteinase K solution (20 μg/ml, Dako) for 15 mins. 
Sections were next washed in two changes of distilled water for 2 mins each and next 
blocked with 0.3% v/v hydrogen peroxidase in methanol for 10 mins. After two changes in 
PBS for 5 mins each, sections were incubated with a mixture of terminal deoxynucleotidyl 
transferase and reaction buffer containing digoxigenin-dUTP (Oncor) in a humidified 
chamber for 1 hour at 37°C, washed in wash buffer (Oncor) for 10 mins and washed in 
PBS thrice for 5 mins each. Sections were incubated in anti-digoxigenin-peroxidase 
(Oncor) for 1 hour at RT, washed in PBS for 5 mins twice before developing in DAB for 
1-3 mins. This reaction was stopped by washing in distilled water for 1 min and followed 
by counterstaining in haematoxylin for 1 min, rinsing in tap water, acid water, lithium 
carbonate, tap water, 70%, 90% and 100% v/v alcohol, xylene, and finally mounted with 
DEPEX and coverslipped. Controls were performed to exclude non-specific staining. 
Intestinal villus sections were used as a positive control for TUNEL. 
4.2.5. Scoring of insulitis  
Insulitis was evaluated using stained H&E sections as outlined in Method 2.6.1. 
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4.2.6. Quantification of apoptosis  
As apoptosis is a major mechanism for β-cell death, we aimed to investigate whether 
treatment with XG-102 reduces the rate of programmed cell death by calculating the 
number of apoptotic cells in the islets of each group of treated and control mice. Apoptosis 
was evaluated by first staining with H&E. Apoptotic cells are detected by the presence of 
morphological characteristics such as condensed nuclei, membrane blebbing and cellular 
fragmentation.  
 
The presence of apoptosis in the pancreas was confirmed by staining tissue sections using 
the TUNEL method, which allows the identification of apoptotic cells in situ by using 
terminal deoxynucleotidyl transferase (TdT) to transfer biotin-dNTP to the DNA strand 
breaks caused by internucleosomal cleavage (Figure 4.3). The cleavage site can be detected 
with the reaction of horseradish peroxidase (HRP) conjugated streptavidin and DAB 
chromogen, giving a brown colour. 
Apoptosis results in the degradation of 
DNA, forming nucleosome sized DNA 
fragments
TdT enzyme from kit transfer biotin-dNTP
to bind to tail of the DNA fragment forming 
an oligomer composed of digoxigenin-
conjugated nucleotide and unlabeled 
nucleotide in a random sequence
Biotin-labeled cleavage sites are then 
detected by reaction with HRP conjugated 
streptavidin and visualised by DAB (brown 
colour)
Anti-digoxignenin (conjugated to 
peroxidase reporter molecule) binds to 
DNA fragment labelled with the 
digoxigenin-nucleotide
 
 
Figure 4.3. TUNEL ApopTag® method. Diagram showing the 
detection principle of the TUNEL method (Abbrevations: TdT, 
terminal deoxynucleotidyl transferase; HRP, hydrogen peroxidase; 
DAB, 3,3’-diaminobenzidine)(Modified from ApopTag® Plus, Oncor)  
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TUNEL-positive cells were viewed under a 40 x objective (total magnification = x 400) in 
all islets present in the pancreas to provide an index of apoptotic β-cell death. The field of 
view where islets reside were taken using Nikon Eclipse TE2000-S microscope (Nikon 
Instruments Europe B.V., Amstelveen, The Netherlands) with the observer blinded to the 
origin of data. Islet area was calibrated and measured using ImageJ version 1.38x software 
(http://rsbweb.nih.gov/ij/). Cells showing typical features such as condensed nuclei, 
absence of cytoplasmic staining and cellular fragmentation were counted as TUNEL-
positive cells. Necrotic cells with weak diffuse cytoplasmic staining without nuclear 
condensation were not included. Index of β-cell death was expressed as the number of islet 
TUNEL-positive cells/mm2 islet area. 
4.3 RESULTS 
4.3.1. Information on batches of mice used in experiments 
 
Mice enrolled for this study were pre-diabetic mice confirmed by measuring blood glucose 
levels. Mice enrolled in Study 1 (Initial study) had blood glucose levels in the range from 
11.5 mmol/l to 30 mmol/l and were 0-7 days diabetic prior to diagnosis whereas mice from 
Study 2 (Modified study) had blood glucose levels in the range from 11.5mmol/l to 25 
mmol/l and were 0-3 days diabetic. 
 
4.3.2. Initial study 
 
A pilot study was first carried out to estimate the possible survival rate of these diabetic 
mice with treatment of XG-102 and PBS. During the course of the study, mice started to 
become sick after 3 weeks on XG-102 and PBS. Some mice from Group A survived past 5 
weeks after drug administration (Figure 4.4). Group B mice also received XG-102 
once/week for 4 weeks. The majority of Group B mice did not survive long enough to 
receive the 2nd administration of XG-102 at the 7th week, so they are grouped together to 
calculate their survival rate. At approximately 4 weeks after the 1st treatment, the treated 
mice (i.e. Group A & B) mice had an average survival rate of 55% compared to 20% 
survival rate for non-treated mice (Group C) (Figure 4.4). One mouse from Group B 
managed to survive past the 7th week, received a 2nd dose of XG-102 and survived until 
week 13. 
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Figure 4.4. Survival rate of mice (%) after 1st administration of XG-102 and PBS 
Group A & B; mice treated with XG-102. Group C; mice treated with PBS  
The survival rate of Group A & B mice; treated with XG-102 and Group C mice; treated 
with PBS was plotted (n=16).  
4.3.3. Modified study 
 
The pilot data as outlined above was used as a basis for a modified study to limit factors 
that may affect the outcome of the study. Mice enrolled in the modified study were 0-3 
days diabetic; separated into two groups, had narrower blood glucose levels ranging of 
11.5 mmol/l to 25 mmol/l and kept for a set period of time (3-4 weeks). 
 
The successful incorporation of XG-102 by i.p. injection was confirmed by staining of 
anti-XG-102 (performed by Xigen partners) in several pancreatic sections of treated 
animals (Figure 4.5A.). Rat kidney section (treated via i.v. with 11 mg of XG-102/kg/day) 
was used as a control for XG-102 (Figure 4.5B.). XG-102 was not observed in the 
untreated mice (not shown). 
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Figure 4.5. Pancreas immunoreactivity to anti XG-102 antibody staining in 
treated animal (A) XG-102 peptide is present in the islet after administration 
for 4 weeks (brown colour staining). This is evident because XG-102 is cell-
permeable (B) Postive control: Rat kidney section (treated i.v. with 11 mg of 
XG-102/kg/day) was used as a control for the XG-102 antibody (C) Negative 
control: Mouse pancreas section (CD-1 mouse) (no XG-102 treatment) was used 
as a control for the XG-102 antibody (x 400 magnification). (D) Mouse pancreas 
section (treated i.p. with PBS) was used as a control for the XG-102 antibody (x 
200 magnification). 
 
 
 
 
 
 
4.3.4. Reduced destructive insulitis in treated mice 
 
Insulitis was gauged using H&E stained sections and carried out by an observer blinded to 
the treatment group. The following grading standard was used (Fig. 4.6).  
To study the effect of XG-102 on lymphocyte homing into islets, insulitis were scored in 
pancreatic sections from 6 mice each in both group A and group B (Figure 4.6). Insulitis 
was quantified in all islets present in two H&E-stained sections from each animal, each 
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section being separated from the next by at least 200 µm. These mice had been on XG-102 
or PBS for the same duration of time of 4 weeks.  
 
 
 
 
 
 
 
Figure 4.6. Standard insulitis grading  
(A) Grade 0, normal islet without any infiltration ; (B) Grade I, peri-insulitis, where 
10% of islet area is infiltrated by a peripheral ring of lymphocytes; (C) Grade II, 
moderate insulitis, where 25% to 50% of the islet shows mononuclear infiltration; (D) 
Grade III, severe insulitis, where over 50% of the islet area was infiltrated by 
lymphocytes. 
 
After 4 weeks of injection with XG-102, insulitis in group A mice was less prevalent 
compared to the control mice. The majority (36 %) of islets from Group A mice showed 
little infiltration and destruction of pancreatic β-cells (grade 0 insulitis) whereas only 7 % 
of islets from Group B mice had no insulitis with the majority of islets heavily infiltrated 
(*P-value: 0.04) (Figure 4.7).  
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Figure 4.7. Grades of insulitis observed in Group A and Group B early diabetic 
NOD mice. Grade 0, normal islet ; Grade 1, peri-insulitis ; Grade 2, moderate insulitis; 
Grade 3, severe insulitis. The data are the sum of islets from six mice for each group. 
On average, 5 islets commonly located at the “tail” part of the pancreas, were scored 
from each mouse. (Abbreviation: n= number of islets scored) 
4.3.5. Significant change in blood glucose level before and after XG-102 
 
After 3-4 weeks of XG-102 administration, Group A had an average blood glucose level 
increase of 7% compared to the significant increase of 73% in Group B mice (*P-value: 
0.04) (Figure 4.8). These data suggest that Group A mice have a better control of blood 
glucose level compared to control mice (Group B). The significant increase in blood 
glucose levels is expected as they did not receive any XG-102 drug. 
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Figure 4.8. Average blood glucose levels (random, non-fasting blood glucose levels) 
in Group A (n=6) and Group B (n=6) diabetic NOD mice before and after 
treatment. Statistical significance was tested by Student’s t-test (Abbreviation: n= 
number of mice) 
4.3.6. Analysis of cell death 
 
Following H&E staining, the apoptotic index for islets cells in each group was determined 
by TUNEL staining (Figure 4.9). TUNEL-positive cells matched the H&E stained cells 
showing characteristics of condensation of nuclear chromatin, membrane blebbing and 
presence of apoptotic bodies. Since TUNEL is a measure of apoptotic cell death, apoptotic 
cell death was observed in insulin-negative area, mainly in the intra-islet infiltrate. 
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Figure 4.9. Representative islets stained using TUNEL method. 
The brown staining represents TUNEL+ve cells; mainly localized at the periphery of the 
islet (x 400 magnification) (arrows) (A) treated mice; (B) control mice. 
Although, there are very few TUNEL+ cells observed in the islets, there is a higher 
frequency of islets containing TUNEL-positive cells in control mice than treated mice  
(Figure 4.10)  
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Figure 4.10. Number of islets which contained more than one TUNEL-positive cell. 
Statistical significance was tested by Student’s t-test (Abbreviation: n= number of mice)  
  
4.3.7. β-cell function 
 
To investigate whether the treatment could have affected insulin production in β-cells, 
insulin staining was carried out (Figure 4.11A). Very few insulin-positive cells were 
present in the islets and thus we were unable to carry out a quantitative analysis. However, 
the majority of cells remaining in the islets were alpha cells as confirmed by glucagon 
staining (Figure 4.11C). 
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Figure 4.11. Insulin and Glucagon immunohistochemistry. (A)  Representative 
insulin staining on pancreatic section from treated animal (B) Wild type pancreatic 
section was used as a control for the insulin antibody.The brown staining represents 
insulin immunoreactivity; all positive staining was localized within the islets (x 400 
magnification) (C) Representative glucagon staining on pancreatic section from 
treated animal (D) Wild type pancreatic section was used as a control for the glucagon 
antibody. The brown staining represents glucagon immunoreactivity; all positive 
staining was localized within the islets (x 200 magnification). 
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4.4. DISCUSSION  
 
In the present study, we have administered a JNK inhibitor, XG-102 to female diabetic 
NOD mice to test whether it reduces the rate of programmed β-cell death. Female mice 
were chosen for this study as a higher incidence of diabetes is reported, 60% compared to 
15% in males. Before administration of XG-102 or PBS, blood glucose levels of mice were 
determined to confirm chosen mice were diabetic. This method of blood glucose 
measurement however may be suboptimal owing to the fact that mice may have just eaten 
before blood glucose measurement. To account for non-fasting glucose measurement, mice 
were subjected to weekly measurements during the duration of the study.  
 
The blood glucose range used in this study was 11.5 mmol/l to 30 mmol/l Thus, the 
severity of the diabetes in the mice used maybe underestimated and this may explain their 
low survival rate even with the presence of XG-102. In the first experimental study, we 
observed that mice treated with XG-102 (Group A and B) survived longer than non-treated 
mice (Group C). One mouse from Group B however managed to survive past 10 weeks and 
was finally culled at week 13. The blood glucose level of that particular mouse increased 
marginally from 12 mmol/l (start of dosing) to 14.83 mmol/l (after 13 weeks). There is a 
possibility therefore that the mouse treated with XG-102 was protected from extensive β-
cell destruction and thus extending its survival. More mice were enrolled in the 2nd study 
to further investigate the role of XG-102 in β-cell death. 
 
T1D is an autoimmune disease, commonly characterized by insulitis and subsequent 
destruction of the insulin-secreting β-cells of the pancreas. To investigate the influence of 
JNK inhibition on the infiltration of mononuclear cells in the endocrine pancreas, we 
graded the incidence of insulitis based on severity. We observed less severe insulitis in 
treated mice compared to non-treated mice.  
 
Immunohistochemical staining of pancreatic specimens from diabetic NOD mice 4 weeks 
after treatment with XG-102 showed very few insulin-positive cells. These β-cells may 
have become undifferentiated or discharged their insulin content in order to normalise 
blood glucose levels in the animal. The majority of islet cells were positive for glucagon, 
indicating the selective destruction of β-cells. This suggests that in the absence of β-cells 
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that normally make up the large, inner part of the islet, other pancreatic cells, notably alpha 
cells form small dense conglomerates (Zorina et al., 2003). 
 
It is well established now that JNK plays a major role in apoptosis, the main mode of death 
in β-cells. Jaeschke et al., showed the importance of JNK2 in T1D where the disruption of 
the gene encoding JNK2 in NOD mice decreased destructive insulitis and reduced disease 
progression (Jaeschke et al., 2005). Additionally, they have demonstrated that JNK2 
deficient NOD mice have lower numbers of CD4 and CD8 T cells which correlates with 
the reduced production of the pro-inflammatory cytokine IFN-γ (secreted by Th1 cells). 
JNK2 therefore may have a role in regulating T-cell differentiation to T helper cells (Th1), 
implicated in immune responses. Thus, when JNK signalling is inhibited such as in our 
study, regulation of T-cell differentiation as well as autoimmunity may be affected. 
 
As apoptosis is a major mechanism for β-cell death, we aimed to measure the number of 
apoptotic cells in the islets of each group of treated mice. In mice treated with XG-102, we 
observed fewer numbers of islets containing apoptotic cells compared to control mice 
although the difference was not statistically significant. Staining also showed that apoptotic 
cells were found only in islets infiltrated by mononuclear cells, as similarly observed by 
Augstein et al. in the NOD mouse (Augstein et al., 1998). These immuno-inflammatory 
cells may therefore be the major source of apoptotic events.  
 
In some conditions, apoptosis could cause autoimmunity. Apoptosis has traditionally been 
thought to be a non-inflammatory process. However it has been demonstrated that 
apoptosis can initiate β-cell directed autoimmunity following the discovery that a neonatal 
wave of β-cell apoptotic cells can provide auto-antigens by allowing apoptotic cells to 
display autoreactive antigens in their surface blebs (Trudeau et al., 2000). Apoptotic cells 
can also activate dendritic cells and induce formation of auto-antibodies after exposure of 
apoptotic thymocytes in a mouse model of systemic lupus erythematosus (SLE), triggering 
autoimmunity (Mevorach et al., 1998). Based on our study, β-cell destruction by apoptosis 
may have been delayed which consequently affects autoimmune islet destruction. 
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Our data imply that XG-102 may be acting by reducing lymphocyte homing into the islets, 
which could explain the reduction in blood glucose levels, however the competitive 
blocking of JNK1 induced by XG-102 had little effect on β-cell apoptosis. These data 
support our assumption that when the process of β-cell destruction is well advanced and 
with few residual β-cells left, it is difficult to reverse the disease. Attempts should be made 
to intervene earlier in the natural history of β-cell destruction when more β-cells are 
present.  
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CHAPTER 5: EPC EXPANSION & CHARACTERIZATION 
5.1. INTRODUCTION 
 
EPCs are derived from the BM and PB, contributing to tissue repair in various pathological 
conditions via the formation of new blood vessels, that is, neovascularization. In 1997, 
Asahara et al. successfully isolated EPCs from human PB and demonstrated the ability of 
these cells to differentiate into mature endothelial cells (Asahara et al., 1997). These cells 
were thought to be only involved in vasculogenesis during embryogenesis, but are now 
recognized to have a significant bearing upon disease outcome through their contribution 
to neovascularization in a variety of pathological states in adulthood. Additionally, there is 
existing evidence suggesting that EPCs have a paracrine role in tissue regeneration (Di 
Santo et al., 2009). 
 
Presently, the two main techniques to obtain EPCs are flow cytometry and/or cell culture. 
Flow cytometry is useful to enumerate EPCs from fresh PB or BM and quantifying cells 
expressing a number of markers (Fadini et al., 2008). Additionally, the analysis by FACS 
can be variable owing to technical factors such as washing and centrifugation steps, 
number of cells, buffers, antibodies and gating technique used (Ozdogu et al., 2007).  
 
EPCs exist in very small numbers, especially in circulating blood in adults where they only 
account for 0.01% of all cells. Owing to the low frequency of these cells, cell culture is 
often used to expand them. Generally, the mononuclear fraction of BM or blood is isolated 
by centrifugation, seeded on fibronectin coated plates and cultured in endothelial growth 
medium. Cell culture using this technique results in two distinct EPC populations, which 
are early outgrowth cells and late outgrowth cells. These populations differ in timing of 
their emergence during culture, tubule formation and paracrine properties (Table 5.1) (Hur 
et al., 2004; Shantsila et al., 2008; Yoder et al., 2007). EPCs have also been characterized 
by their ability to form colonies known as colony-forming units (CFUs) which involves the 
pre-plating of non-adherent cells after 2 days of plating MNCs (Hill et al., 2003). These 
CFU colonies have been shown to be haematopoietic in origin, the majority possessing 
myeloid progenitor cell activity (Yoder et al., 2007). Although isolation of EPCs via 
culture is useful to expand their numbers, these early progenitor cells compared to 
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circulating cells may lose their angiogeneic and phenotypic properties as they mature in 
culture (Timmermans et al., 2008). 
 
Early EPCs  Late EPCs 
Appear after 3-5 days of culture Appear after 7-14 days of culture 
Round to spindle shaped appearance Typical cobblestone morphology 
Express endothelial markers Express endothelial markers 
Express haematopoietic markers Does not express haematopoietic markers – 
CD133, CD14 or CD45 
Bind UEA-1 lectin and uptake Dil-ac-LDL Bind UEA-1 lectin and uptake Dil-ac-LDL 
Some proliferative potential Robust proliferative potential 
Do not form vascular tubes in vitro/in vivo 
in matrigel 
Form vascular tubes in vitro/in vivo in 
matrigel 
Augment vascular network in a paracrine 
fashion/ secrete angiogenic cytokines 
Does not exert paracrine angiogenic effects 
Improve neovascularization in vivo Improve neovascularization in vivo 
 
 
 
 
Table 5.1. Comparison of properties between early and late EPCs (adapted from 
Timmermans et al., 2008) (Abbreviations: UEA-1 lectin, Ulex europaeus agglutinin-1; 
Dil-ac-LDL, Dil-labelled acetylated low density lipoprotein)   
In addition to phenotyping EPCs using FACS or immunocytochemistry, it is important to 
test the functional properties of these newly derived cells. The most common in vitro 
assays are the uptake of Dil-labelled acetylated low-density lipoprotein (Dil-ac-LDL), 
binding of the ulex lectin, and chemokine and tubule formation assays. Many studies have 
also tested the angiogenic properties of these cells in in vivo models such as flap ischaemia 
and induced liver fibrosis model (Nagano et al., 2007; Ueno et al., 2006).  
 
Due to different morphologies and biological properties used in earlier studies, the 
phenotypical and functional properties of newly derived EPCs should be carefully re-
examined and taken into consideration when future studies are performed. Additionally, 
the continual maturation of these cells needs to be taken into account as it results in an 
antigenic marker shift, and thus markers used for initial isolation of cells using FACS may 
not be suitable to isolate cultured EPCs (Shantsila et al., 2008).  
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This study aimed to characterize and isolate BM-derived EPCs using two methods – (i) 
using selective media and (ii) magnetic cell sorting for c-Kit+ cells. The EPC population 
that demonstrates both phenotypic and functional properties of endothelial cells will then 
be transplanted into NOD mice, to test their ability to form new blood vessels or contribute 
to pancreatic regeneration via release of paracrine factors. 
 
5.2. METHODS 
 
5.2.1. Foetal bovine serum batch testing  
To ensure optimal EPC growth conditions, six batches of defined-FBS from Sigma, PAA 
and Lonza were tested (Sigma Lot# 036K3395, 076K3395, #085K3395 and 105K3396; 
PAA Lot# A15207-1979 and Lonza Lot# 75B0018). An equal number of whole BM cells 
(approximately 1 x 107 cells) (n=3) were plated onto human fibronectin-coated (Sigma, St. 
Louis, USA) 6-well culture plates at a density of 1-2 x 106 cells/well with endothelial 
growth media and the respective batch of FBS (Table 5.2). Cells were cultured in the 6 
constituted medium in parallel for 12 days, in triplicate wells and the number of colonies 
was counted on day 6 and day 12 of culture. Overall growth was also evaluated by 
morphological evaluation for a set period of 2 weeks to define the optimal EPC growth. 
FBS Name Catalogue No Lot No Company n of colonies 
(Day 6) 
n of colonies 
(Day 12) 
FBS A F7524 #036K3395 Sigma 1 1 
FBS B F7524 #076K3395 Sigma 1 1 
FBS C F0804 #105K3396 Sigma 3 5 
FBS D A11-152 #A15207-1979 PAA 1 5 
FBS E F9665 #085K3395 Sigma 1 14 
FBS F DE14-870C #76B0018 Lonza 0 6 
 
 
 
Table 5.2. Foetal bovine serum batch details and number of colonies obtained after 
day 6 and day 12 of culture (Abbreviation: FBS, foetal bovine serum) 
5.2.2. Protocol 1: Isolation of EPCs using selective media  
 
Whole BM cells from non-diabetic NOD mice (control) were first isolated as previously 
described. Density gradient centrifugation (Cederlane) was performed on the BM cells to 
obtain mononuclear cells (MNCs). Whole BM and MNCs were suspended in 2% FBS 
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IMDM medium (Stem cell technologies) supplemented with 18% FBS (Autogen Bioclear), 
murine VEGF (Peprotech EC Ltd, London, U.K.), murine bFGF (Peprotech), murine IGF-
1 (Peprotech) and Pen/Strep (Gibco) and plated onto separate human fibronectin-coated 
(Sigma, St. Louis, USA)  6-well culture plates, incubated in a 5% CO2 incubator at 37 0C. 
First media change was performed 3 days after plating and maintained for 12 days. Each 
cluster or colony was followed-up every day (Figure 5.1). 
Whole bone marrow (1.5 x 108 cells/2 mice)
Cultured on fibronectin for 3-4 weeks
Protocol : 1 Protocol : 2
Total starting volume: 1 X 108 cells
Separation of lineage negative cells using 
MACS
Separation of c-Kit + cells using MACS
Average cells per well of 24 well plate 
= 2 X 105 cells
Medium change every 3rd day
Appearance of spindle-like cells after 10-14 
days
Cells cultured in EGM-2 Bulletkit (hEGF, 
hydrocortisone, GA-1000, VEGF, hFGF-B, 
R3 -IGF-1, ascorbic acid and heparin with 
20% FBS.
Isolation of mononuclear cells by density 
gradient centrifugation
Average cells per well of 6 well plate 
= 1 X 106 cells
Cells cultured in 2% FBS IMDM medium 
supplemented with 18% FBS, murine
VEGF, murine bFGF, murine IGF-1 and 
Pen/Strep.
Cultured on fibronectin for 1 week
First medium change 3 days after plating
Appearance of spindle-like cells after 4 days
 
 
 
 
Figure 5.1. Flow chart of EPC culture protocols. Whole BM used in optimization of 
protocol was from 10 -12 week old non-diabetic female mice (Abbreviations: MACS, 
magnetic cell separation; FBS, foetal bovine serum;  IMDM, Iscove's Modified 
Dulbecco's Medium; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast 
growth factor; IGF-1, insulin like growth factor-1; hEGF, human epidermal growth 
factor; GA-1000, Gentamicin; Amphotericin-B;  hFGF-B; human fibroblast growth 
factor-basic).    
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5.2.3. Protocol 2: Isolation of EPCs using magnetic cell separation system (MACS)  
 
5.2.3.1. Magnetic labelling with lineage negative microbeads  
 
 
Whole BM cells were isolated as previously described and washed in cold EPC medium. 
Cells were passed through a 30 µm filter (Miltenyi Biotec Ltd.,Surrey, U.K.) and then 
centrifuged at 1500 rpm for 5 mins at 4 0C. Supernatant was removed and cells 
resuspended in 1 ml of MACS buffer. A fraction of 100 million cells was aliquoted into a 
new 5ml Falcon polystyrene tube and incubated with the lineage negative cocktail 
according to the manufacturer’s instructions (Mouse Lineage Cell Depletion Kit, Miltenyi 
Biotec, Bergisch-Gladbach, Germany). Briefly, cells were resuspended in 400 µl MACS 
buffer. Next, 100 µl biotin antibody cocktail was added, mixed well and incubated for 10 
mins in the fridge. After incubation, a further 300 µl MACS buffer was added and 
incubated with 200 µl anti biotin cocktail for 15 mins in the fridge. Cells were 
subsequently washed with 1ml MACS buffer and centrifuged at 300 x g (1300 rpm) for 10 
mins at 40C. Pelleted cells were resuspended in 500 µl MACS buffer and kept on ice ready 
for cell separation. 
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A
B
C
D
 
Figure 5.2. Isolation for enriched c-Kit+lin- EPCs 
using MACS cell separation system. (A) 1st 
magnetic labelling: Washed whole bone marrow 
cells were magnetically labelled with biotinylated 
lineage negative antibody cocktail and subsequently, 
anti-Biotin MicroBeads (B) 1st magnetic separation: 
Undesired cells such as natural killer cells and 
erythrocytes are retained in a MACS® Column 
placed in a MACS Separator while the unlabeled 
cells (lineage negative cells, lin-) pass through (C) 
2nd magnetic labelling: Lin- were then magnetically 
labelled with c-Kit+ MicroBeads (D) 2nd magnetic 
separation: Cells were then passed through another 
prepared column and c-Kit+lin- cells were retained in 
the column while unlabelled cells pass through. 
After the column is removed from the separator, the 
target cells are eluted as the enriched, positively 
selected c-Kit+ cell fraction (adapted from Miltenyi 
Biotec, http://www.miltenyibiotec.com). 
5.2.3.2. Magnetic separation  
 
LS columns (Miltenyi Biotec Ltd.) were used to magnetically separate labelled positive 
lineage cells from the lineage negative cells. LS column was placed on a MidiMACS 
separator unit (Miltenyi Biotec Ltd.). Column was rinsed with 1000 µl MACS buffer (3 
times). Cell suspension was then applied onto the column into a 5ml Falcon polystyrene 
tube. This was followed by washing of the column with 1000 µl MACS buffer (3 times) 
into the same tube which collects all unlabelled cells (i.e. negative fraction of cells). To  
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obtain the positive fraction of cells, 1000 µl MACS buffer was added onto the column and 
subsequently flushed out into a new 5 ml polystyrene tube using the supplied plunger. 
Positive labeled cells collected were spun at 300 x g for 10mins at 4 0C, resuspended in 
appropriate volume and kept on ice. 
 
5.2.3.3. Positive selection of c-Kit+ cells by magnetic cell sorting  
 
Lineage negative cells (Lin-) were enriched for c-Kit+ cells using a c-Kit Isolation Kit 
(Miltenyi Biotec) according to manufacturer’s instructions. Briefly, lineage negative cells 
collected were spun down at 300 x g for 10 mins at 4 0C and resuspended in 800 µl MACS 
buffer. Next, 100 µl CD117 microbeads (Miltenyi Biotec Ltd.) were added and incubated 
for 15 mins in the fridge. Cells were subsequently washed with an additional 1ml MACS 
buffer and spun down at 300 x g for 10 mins at 4 0C. Pelleted cells were resuspended in 
500µl MACS buffer and loaded onto a pre-washed column to obtain c-Kit+ Lin- cells. 
 
5.2.3.4. Analysis of c-Kit+ purity using flow cytometry  
 
An aliquot of the c-Kit+ cell fraction was analyzed to assess purity. The purity of c-Kit+ 
selected cells was determined after isolation. Isotype-matched mouse immunoglobulin 
served as controls. All incubations were performed at RT. After each incubation, cells were 
washed in PBS containing 2% FBS. Cells were incubated with a c-Kit antibody for 15 
mins. Each analysis included at least 5000 events. The percentage of c-Kit+ cells was 
assessed after correction for the percentage of cells reactive with an isotype control.  
 
5.2.3.5. c-Kit+ Lin- cell  culture  
 
Freshly isolated c-Kit+ Lin- cells were spun down at 300 x g for 10 mins at 40C. Cells 
obtained were resuspended in 300µl MACS separation buffer and manually counted by 
using a haemocytometer.  c-Kit+ Lin- cells were cultured at a density of 2 x 105 – 3x 105 
cells in 24-well plates coated with fibronectin (Sigma) and maintained using EPC medium 
EGM-2 Bulletkit (Lonza Wokingham Ltd, London, U.K.) which includes EGM basal 
media and growth factor supplements containing hEGF, hydrocortisone, GA-1000 
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(Gentamicin, Amphotericin-B), VEGF, hFGF-B, R3-IGF-1, ascorbic acid and heparin 
(Lonza Wokingham Ltd.) and additionally supplemented with 20% FBS (PAA 
Laboratories Ltd, Yeovil Somerset, U.K.) and Pen/Strep (Invitrogen Ltd, Renfrew, U.K.), 
at 37 °C in a 5% CO2 atmosphere. For immunostaining, c-Kit+ Lin- cells were plated at a 
density of 8 x 104 – 12x 104 cells in 8-well chamber slides (BD) coated with fibronectin. 
Half media change was performed every two days and maintained for 3-4 weeks. 
 
5.2.4. Characterization of EPCs  
 
5.2.4.1. FACS analysis of bone marrow-EPCs  
 
For analysis of cultured EPCs, cells were washed with PBS twice before adding 0.25% 
trypsin EDTA (Invitrogen). After 5 mins, cells were neutralised with 2% v/v PBS FBS and 
spun down at 1500 rpm for 5 mins. Resuspended cells were then incubated with c-Kit 
antibody (APC, BD Biosciences) (1:100 dilution) and analysed using BD FACSAria (BD 
Biosciences). Analysis was performed with isotype-matched IgG controls. 
 
5.2.4.2. Immunocytochemistry of EPCs 
 
Cells cultured on 8-well chamber slides for 3-4 weeks were washed twice with PBS and 
fixed for 15 mins with 4% w/v paraformaldehyde. Specimens were then incubated for 45 
mins with a primary antibody. The following primary antibodies were used: anti-CD31 
(BD), anti-CD34 (eBioscience, San Diego, USA), anti-von Willebrand factor (Dako), anti-
CD133 (Abcam) and anti-VEGFR-2 (BD) (Table 5.3). In brief, we used a fluorescent 
direct immunostaining method and this was performed as follows: fixed cells were washed 
twice with PBS, then permeabilised with 0.2% v/v Triton-100 for 10 mins, and washed 
twice with PBS. After blocking with 2% v/v goat serum for 30mins, cells were incubated 
with primary antibody at RT for 45 mins. Then, cells were washed with PBS, incubated 
with appropriate fluorescent label (with the addition of DAPI, Molecular Probes) for 45 
mins, and washed with PBS before mounting with Vectashield (Vector Laboratories Ltd). 
Negative controls were performed by omitting the primary antibodies. Fluorescent images 
were taken using a florescence microscope (Nikon, Japan). 
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Primary 
antibodies 
Dilution Vendor Secondary 
antibodies 
Dilution Vendor 
Rat anti-
CD31 
1:100 BD Biosciences Goat anti rat-488 1:500 Molecular 
Probe 
Rabbit anti- 
vWF 
1:50 Dako Goat anti rabbit-
488 
1:1000 Molecular 
Probe 
Rabbit anti- 
CD133  
1:100 Abcam Goat anti rabbit-
488 
1:1000 Molecular 
Probe 
Rat anti-
CD34  
1:100 eBioscience Goat anti rat-488 1:500 Molecular 
Probe 
Rat anti-
VEGFR-2 
1:30 BD Biosciences Goat anti rat-488 1:500 Molecular 
Probe 
 
 
 
Table 5.3. Details of primary and secondary antibodies used for immunostaining of 
cultured cells 
5.2.4.3. Dil-acLDL uptake assay and lectin staining of cultured EPCs  
 
The phenotype of culture BM-EPCs was examined by uptake of Dil-labelled acetylated 
LDL (Dil-acLDL) and staining for lectin. Briefly, attached cells (after 5 days of culture) 
were incubated with Texas-Red Dil-ac-LDL (Invitrogen). After one hour incubation, cells 
were fixed with 4% w/v paraformaldehyde for 10 mins. Cells were then stained with FITC-
UEA-1-lectin (Sigma) and viewed under the fluorescent microscope. Cells double positive 
for Dil-ac-LDL and UEA-1 lectin were deemed EPCs and quantified by examining random 
microscopic fields (Figure 5.3). Human carcinoma cell line (Caco2) cells were used as 
negative control for Dil-ac-LDL and UEA-1 lectin to confirm that only EPCs are stained 
positive.  
 
5.2.4.4.  Tubule formation assay  
 
Cells were starved with 1% v/v FBS EPC medium overnight. Growth factor reduced 
matrigel (BD) was coated on 96 well culture plates and allowed to polymerize for 1 hr at 
37 0C. Approximately 3 x 104 cells were seeded on the matrigel in 0.5% w/v BSA RPMI 
medium supplemented with and without 50ng/VEGF and incubated for 5 hr. Images were 
captured at x 200 magnification in 5 random fields of view. Number of cell clusters and 
branching were counted, and expressed as mean folds of branching compared to control 
group.  
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5.2.4.5. Migration assay 
 
 
Migration assays were performed in Transwell tissue culture wells containing 8 μm pore 
size inserts (Nunc). Cells were starved with 1% FBS EPC medium overnight. Gelatin 
(Sigma) was coated on 24 well culture plates and allowed to set overnight at 4 0C. 
Approximately 1 x 103 cells were seeded on the gelatin in 0.5% BSA RPMI medium 
supplemented with and without 50ng/VEGF (Peprotech) and incubated for 4 hrs. After 
incubation period, filter was removed from the respective wells and non-migrated cells on 
the upper side of the filter were scraped-off gently with cotton bud. Next, insert were fixed 
in 4% PFA at RT for 15 mins and stained with crystal violet. Filters were washed with PBS 
several times before viewing under the microscope. Numbers of cells migrating through 
the membrane were counted and image captured at 200× magnification in 8 high power 
fields on the underside of each insert membrane. 
 
5.3 RESULTS 
 
5.3.1. Foetal bovine serum batch testing 
 
Overall, EPCs grew well in all different batches of FBS. However, PAA serum was chosen 
as the FBS of choice, as it favours the formation of cell colonies. Additionally, the cells 
were morphologically similar each time new cells were plated using the same FBS 
supplement. PAA FBS was therefore used in further EPC expansion cultures.  
 
5.3.2. Isolation of EPCs using selective media 
 
Whole BM cells and MNC cells were isolated and grown in selective media as used by 
Zhang et al. (Zhang et al., 2006).  Briefly, BM cells and MNC cells were isolated and 
seeded onto fibronectin-coated tissue plates in media, which contained 20% FBS, VEGF, 
b-FGF, IGF and IMDM basal media to promote EPC outgrowth. Cells changed from round 
shaped (Figure 5.3.A) to thin and flat (Figure 5.3. B&C), then pebble-like shaped and 
arranged in a linear manner after 12 days of culture (Figure 5.3.D). Both BM and MNCs 
differentiated in the same manner and morphology in culture during the duration of 12 
days. 
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Figure 5.3. Morphological changes in murine bone marrow cells cultured in 
selective media. (A) day 1 (x 100 magnification), (B) day 3, (C) day 5 and (D) day 12 
of culture (x 200 magnification) 
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5.3.3. Isolation of EPCs using MACS 
 
The isolation of EPCs by enriching for c-Kit+ lin- cells was performed as previously 
described by Zhang et al. with some modifications (Zhang et al., 2006).  c-Kit was chosen 
as the initial isolation marker as it is an early stem cell progenitor marker and receptor for 
the cytokine, stem cell factor. Briefly, isolated BM cells were first incubated with lineage 
negative antibodies to remove non-target cells such as natural killer cells, macrophages and 
then positively selecting c-Kit+ cells using sequential sorting developed by MACS. Total 
number of whole BM cells used per isolation was 1 x 108 cells and approximately 561,829 
± 93,744 (n=7) c-Kit+ cells were obtained, aliquoted into separate wells and grown for 3-5 
weeks. 
 
The purity of MACS-isolated c-Kit+ cells was analyzed using flow cytometry. 
Approximately 60-70% of cells were positively stained for c-Kit (Figure 5.4). 
7.8% 75.2%
A B
 Figure 5.4. Representative FACS analysis of c-Kit+ cells isolated after MACS.  
(A ) Cells incubated with isotype antibody (B) Cells expressing c-Kit marker. 
 
Freshly isolated c-Kit+ cells were plated within 1-2 hours of culture. Once cells began to 
adhere, cells formed a monolayer, consisting predominantly of small-sized cells. Single, 
large cells with endothelial morphology were also observed. No significant proliferation 
was noted between 1- 7 days of culture. From day 7 onwards, a proliferating population of 
round cells occurred. Morphological analysis of the adherent cells around 10 days in 
culture revealed a heterogeneous cell population, comprising small-sized round cells, 
large-sized round cells with cytoplasmic granules, and large flat cells with an endothelial 
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morphology in some areas of the coated plates (Figure 5.5A). At 14 days of culture, round 
and spindle shaped cells formed circular structures (Figure 5.5B) which eventually 
expanded into colonies of cells (Figure 5.5C). The majority of cells were capable of 
forming cords in culture (Figure 5.5D). 
 
 
Figure 5.5. Representative phase contrast pictures of cells cultured from c-
Kit+ cells isolated from MACS (A) A mixture of round and spindle shape cells 
appears after 10 days of culture (x 400 magnification) (B) Spindle shaped cells 
start to form circular colonies around 14 days of culture (x 200 magnification) (C) 
Two typical extended EPC colonies after 2-3 weeks (x 100 magnification) (D) 
Formation of cord-like structures (arrows) in culture after 3 weeks culture on 
fibronectin coated plate (x 200 magnification)  
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5.3.4. Characterization of EPCs  
 
EPC-derived cells from method 1 and 2 incorporated Dil-ac-LDL and bind with UEA-1, 
which are functional phenotypes of endothelial cells (Figure 5.6). 
 
 
 
 
Figure 5.6. c-Kit+ EPCs binding and uptake of Dil-ac-LDL. (A-C) Phase contrast 
and binding of UEA-1 lectin and uptake of Dil-ac-LDL in cells isolated using 
selective media. (D-F) Phase contrast and binding of UEA-1 lectin and uptake of Dil-
ac-LDL in cells isolated using the MACS method (x 200 magnification). 
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EPC-derived cells using method 1 and 2 expressed numerous cell surface antigens 
including CD31, CD34, vWF, CD133, VEGFR-2 (Figure 5.7).  
 
 
 
 
Figure 5.7. Fluorescence microscopic demonstration of markers of bone marrow-
derived EPCs. The antibodies were labelled with FITC (x 400 magnification)  
 
Similar results were observed in 3 independent experiments. Antigen staining was 
corroborated by FACS analysis where c-Kit+ lin- cells isolated using method 2 highly 
express CD31, VEGFR-2, CD34 and vWF which are characteristic of late EPCs (Table 
5.4). BM-derived EPCs grown in selective endothelial growth media only highly expressed 
VEGFR-2 and vWF. 
 
Antigen Method 1 Method 2 
CD31 7.1 ± 3.8 16.5± 2.7 
VEGFR-2 27.7 ± 3.5 16.2± 2.0 
CD34 0.55 ±0.27 19.5± 3.2 
CD133 4.87 ±3.34 2.7± 0.5 
vWF 36.5 ± 10.3 22.9± 1.6 
 
 
 
Table 5.4. Cell surface antigen expression using FACS analysis of EPCs isolated 
using Methods 1 and 2. 
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In addition to FACS analysis and immunocytochemistry, tubule formation assays and 
migration studies were carried out to confirm the functional endothelial properties of the 
BM-derived EPCs. BM-derived EPCs using method 1 were able to form tubules in 
matrigel and also able to migrate towards 50ng/ml VEGF growth factor (25 ± 2 cells) 
compared to basal conditions (3 ± 2 cells) (Figure 5.8 A&B). c-Kit+ EPCs cultured for 28 
days were also able to form tubules and migrate, but due to lack of cell numbers isolated, 
we were unable to perform a statistical analysis.  
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Figure 5.8. In vitro assays 
testing endothelial function  
(A) Tubule formation of BM-
derived cells (c-Kit+ EPCs) on 
reduced growth factor matrigel 
after 18 hours incubation (x 400 
magnification)  
(B&C) Migration assay tests the 
ability of BM-derived EPC using 
selective media to migrate 
towards a stimulus (50ng/ml 
VEGF) (Picture C) compared to 
basal condition (Picture B). Cells 
were fixed with 4% PFA, stained 
with crystal violet (purple) and 
image captured at x 200 
magnification. 
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5.5. DISCUSSION 
 
EPCs have received a lot of attention over the past few years due to their ability to form 
new postnatal blood vessels, as demonstrated in many injury models. The phenotypic 
properties of these cells however are debatable, with many studies using various 
combinations of cell surface markers to identify EPCs.  
 
Human EPCs are commonly isolated from peripheral blood and normally characterised by 
the expression of CD133+ CD34+ (Asahara et al., 1999; Nguyen et al., 2008). In the 
present study, whole BM cells were used to obtain c-Kit+ cells using magnetic cell sorting 
and grown in endothelial growth medium. In contrast to other studies, we used whole BM 
instead of an enriched mononuclear fraction to avoid the loss of cells from centrifugation 
and vigorous cell-washing procedures (Ozdogu et al., 2007). Total BM cells were then 
incubated with lineage negative antibodies to remove platelets, natural killer cells, 
macrophages and leukocytes and subsequently selected for c-Kit+ cells. BM cells were 
enriched for c-Kit as c-Kit is reported to be an early mouse stem cell progenitor marker and 
these cells can differentiate towards the endothelial lineage (Zhang et al., 2006). 
Additionally, Li et al., demonstrated that c-Kit+ cells can contribute to neovascularization 
when transplanted into ischaemic mice (Li et al., 2003).   
 
Various methods to isolate and culture EPCs have been used to date. Some studies have 
used peripheral blood mononuclear cells as their starting cells, and re-plate non-adherent 
cells after 24 hours in culture (Hill et al., 2003). In our study, we use whole BM cells and 
did not re-plate the cells, but instead non-adherent cells such as monocytes, macrophages, 
and any circulating mature endothelial cells were removed to prevent contamination. We 
compared two methods of isolation of BM-derived EPCs: (i) method 1, the culture of BM 
cells in selective endothelial growth media and (ii) method 2, the culture of enriched c-Kit+ 
cells in commercial endothelial growth medium.  Based on previous studies, we have 
generated early EPCs using method 1 as they start to produce colonies at 4-7 days of 
culture.  These cells also bind to UEA-1 lectin and demonstrate uptake of Dil-ac-LDL, 
form vascular tubes in matrigel and have some proliferative potential in culture, 
characteristics reported by many studies (Hur et al., 2004; Lin et al., 2000). EPCs grown 
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for more than 21 days using method 2, demonstrated similar characteristics as cells isolated 
from method 1, but have very limited proliferative potential. This could be due to the low 
density of c-Kit+lin- cells (5x 105 cells/well) initially plated compared to number of cells 
plated for method 1 (2x 106 cells/well).  
 
To date, there is no defined panel of markers to identify mouse EPCs. Based on several 
papers, we have identified six markers of importance, namely VEGFR-2. CD34. CD133, 
CD31 and vWF for quantification using FACS analysis (Balasubramaniam et al., 2007; 
Matsumoto et al., 2008; Nguyen et al., 2008; Wang et al., 2008; Ye et al., 2007). FACS 
analysis shows that cells isolated from method 1, highly express vWF and VEGFR-2, but 
have low expression of CD34 and CD133. c-Kit+lin- cultured cells show similar expression 
of CD31, VEGFR-2, CD34 and vWF. Based on FACS and immunocytochemistry data, our 
c-Kit+lin- cultured cells express the same markers as late EPCs, i.e. CD133-, vWF+, CD34+, 
VEGFR-2+, CD31+ (reviewed by Hristov et al., 2004). We therefore have demonstrated the 
potential of c-Kit+lin- cells, of being functional EPCs in culture as shown by the ability of 
these cells to express a combination of endothelial and early progenitor markers, as well as 
the ability to form tubules and migrate towards a stimulus.  
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CHAPTER 6: BONE MARROW TRANSPLANTATION INTO 
NOD MICE 
 
6.1. INTRODUCTION 
 
Islet transplantations have been carried out since the publication of the Edmonton Protocol 
(Shapiro et al., 2000) as a treatment for T1D. However, a shortage of cadaveric pancreata 
and a return to insulin dependence in the majority of recipients within 5 years means 
alternative treatments are required.  
 
Some studies have reported improvement of hyperglycaemia when whole BM was 
transplanted into diabetic animal models such as streptozocin (STZ)- induced diabetic mice 
(Ianus et al., 2003), E2f1/E2f2 mutant mice (Li et al., 2003) and NOD mice (Lee et al., 
2006). This is not the case for some studies where they fail to show normalization of blood 
glucose levels as well as low rates of haematopoietic chimaerism (Lechner et al., 2004; 
Mathews et al., 2004). These discrepancies could be due to several factors such as non 
efficient irradiation, different mouse strains, extent of diabetic injury and lineage tracing 
methods. 
 
Several studies have suggested that BM transplanted after STZ-induced diabetes in mice 
may contribute to islet neovasculature and promote islet β-cell regeneration (Hasegawa et 
al., 2007; Hess et al., 2003; Mathews et al., 2004). In particular, Hess et al. intravenously 
transplanted GFP+ BM cells into STZ-induced diabetic mice 5 days after the last STZ 
administration (Hess et al., 2003). They reported reduction in blood glucose levels and 
serum insulin levels within 7 days after transplantation of GFP+ BM cells. Additionally, 
the authors observed that 9.2% of engrafted cells were endothelial cells (GFP+PECAM-1+) 
suggesting that BM, presumably containing EPCs, may have differentiated into endothelial 
cells and contributed to neovasculature in the injured islet, possibly also aiding islet 
regeneration.  
 
BM contains a number of stem cell populations including mesenchymal stem cells (MSCs) 
and HSCs, which have the ability to differentiate into other cell types. Ianus et al. 
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suggested BM cells transplanted into diabetic animal can transdifferentiate into β-cells in 
an attempt to regenerate the pancreas (Ianus et al., 2003). Other studies followed 
attempting to reproduce the results, but no donor-derived insulin-expressing cells were 
found (Choi et al., 2003; Lechner et al., 2004; Taneera et al., 2006). It is clear that BM 
cells may play a role in β-cell regeneration by other mechanisms rather than repopulating 
the islets with transdifferentiated β-cells. Some suggest that β-cell regeneration could be 
due to replication of existing β-cells (Dor et al., 2004; Gao et al., 2008) and β-cell 
neogenesis from pancreatic ducts (Bonner-Weir et al., 2004). Other mechanisms which 
may occur at a lesser extent include cell fusion and dedifferentiation (Herzog et al., 2003; 
Terada et al., 2002). 
 
As diabetes is an autoimmune disease, some studies used purified MSCs and HSCs derived 
from the bone marrow as immunomodulators, in an attempt to arrest the autoimmune 
reaction against β-cell auto-antigens in the pancreas. Administration of purified HSCs into 
diabetic NOD mice has been shown to restore glucose homeostasis by altering thymic and 
peripheral T-cell responses against auto- and allo-antigens, thus augmenting regeneration 
of remaining endogenous β-cells (Beilhack et al., 2003).  
 
Accordingly, the aim of this study was to investigate the potential of whole BM from wild 
type (Balb/c) and NOD mice in delaying diabetes using non diabetic NOD mice. 
Additionally, I studied the effect of whole BM cells on blood glucose levels, insulitis and 
β-cell replication. 
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6.2. METHODS 
6.2.1. Mice 
 
Two groups of mice were used in this study, pre-diabetic NOD and wild type (Balb/c) 
mice. Wild type mice were purchased from Charles River Laboratories and housed in the 
animal facility at Charterhouse Square. NOD mice were bred and housed in the same 
facility. At 10-11 weeks of age, NOD mice were transferred to Biological Resource Unit, 
Cancer Research UK, London Research Institute to receive BM transplantation. 
 
6.2.2. Bone marrow transplantation into pre-diabetic and early diabetic NOD mice  
6.2.2.1. First study 
 
Recipient NOD mice were 10-11 weeks old non diabetic female NOD mice with a blood 
glucose level in the range of 5 mmol/l to 6 mmol/l (Figure 6.1):  
 
a) Group A:  10 female animals were irradiated with a split dose (2 x 500 cGy, 2-3 hours 
apart) of total body irradiation (TBI) and were reconstituted within 3 hours via intravenous 
(i.v.) injection of freshly isolated male WT BM (2 x 106 cells). Mice were kept for 14 
weeks unless unwell due to diabetes.  
b) Group B: 10 female animals were irradiated with a split dose (2 x 500 cGy, 2-3 hours 
apart) of TBI and were reconstituted within 3 hours via i.v. injection of freshly isolated 
female non diabetic NOD BM (2 x 106 cells). Mice were kept for 14 weeks unless unwell 
due to diabetes.  
c) Group C: 6 female non diabetic NOD mice served as a control. These mice did not 
receive any irradiation nor BM transplantation, and were kept together with Group A and 
B mice. 
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 Figure 6.1. Initial experimental strategy.  
Group A and B mice (10-11 weeks old) were injected i.v. with 2 million freshly 
isolated BM cells after 2 doses of irradiation (1000 cGy). Group C, control mice did 
not receive a lethal dose of irradiation nor BMT (Abbreviations: BMT, bone marrow 
transplantation; Gy, gray; i.v., intravenous, P, pancreas; S, spleen; K, kidney; L, 
liver
 
 
 
)  
 
6.2.2.2. Second study  
 
This second study was carried out to investigate whether BM cells can engraft after 
transplantation of 2 million BM cells into early diabetic and non-diabetic NOD mice, 
measured at 14 days after transplantation. Mice enrolled in this study were either diabetic 
(0-4 days diabetic with blood glucose in the range of 11.5 mmol/l to 25 mmol/l) or non 
diabetic (<11.5 mmol/l):  
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a) Group A:  3 female animals (early diabetic NOD, 20-24 weeks old) were irradiated with 
a split dose (2x 500cGy, 2-3 hours apart) of TBI and were reconstituted within 3 hour via 
i.v. injection of freshly isolated male NOD BM (2 x 106 cells). Mice were kept for 2 
weeks.  
b) Group B: 3 female animals (non diabetic NOD, 10 weeks old) were irradiated with a 
split dose (2x 500cGy, 2-3 hours apart) of TBI and were reconstituted within 3 hour via i.v. 
injection of freshly isolated male NOD BM (2 x 106 cells). Mice were kept for 2 weeks. 
 
6.2.3. Gender mis-matched bone marrow transplantation into NOD mice  
 
Breeding and isolation of BM were carried out under UK Home Office procedural and 
ethical guidelines (Home Office Project License NO. 70/5962) at the Biological Services 
Unit, Charterhouse Square. Administration of BM and maintenance of chimaeric mice 
were carried out in the Biological Resource Unit, Cancer Research UK, London Research 
Institute (refer to Method 2.4.1 for more details). 
 
6.2.4. Preparation of bone marrow transplant  
 
Bone marrow transplantation procedures were carried out in sterile conditions. Female pre-
diabetic NOD recipient mice (10-11 weeks of age) underwent whole body, lethal gamma 
irradiation with 1000 cGy in a divided dose, 2-3 hours apart, to ablate their BM using an 
IBL 637 gamma irradiator equipped with a caesium 137 source (Cis-Bio International). 
This was followed by a tail vein injection with whole bone marrow from the donor at a 
dose of 2 x 106 cells per female recipient.  
 
The cells for bone marrow transplantation were obtained on the same day from 10 weeks 
old wild type (Balb/c) and NOD male mice. Femur, tibia and iliac crest from the male 
donors were removed and bone marrow was flushed with 2% v/v FBS PBS using a 5 ml 
needle syringe. Cells were filtered through a 70-micron filter and centrifuged at 1500 rpm 
for 5 mins to separate the supernatant from the cells. The pellet was then resuspended in 
200 µl sterile PBS for i.v. tail vein injection into the recipient female mice on the same day 
(refer to Method 2.4.2. for more details).  
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6.2.5. Monitoring of diabetes development  
 
During the duration after transplantation, blood glucose levels were evaluated once every 7 
days using an Accu-chek AVIVA Blood Monitor (Roche). To monitor diabetes, mice were 
classified diabetic if blood glucose was confirmed as ≥ 11.5 mmol/l. At the end point, all 
mice were killed by cervical ‘dislocation’ and/or CO2 inhalation, dependent on the type of 
tissue collected. Pancreas, spleen, kidney and liver were fixed in neutral buffered formalin 
for 24 hours at room temperature before being embedded in paraffin wax. Mice 
transplanted with BM were monitored for 14 weeks (First study). 
 
6.3 RESULTS 
6.3.1. Mice that received a bone marrow transplant prior to onset of hyperglycaemia 
 
In order to study the possible contribution of BM in delaying hyperglycaemia, sex-mis-
matched BM from wild type (Group A) and non-diabetic NOD mice (Group B) were 
transplanted prior to the onset of diabetes (First study). Of the 10 female mice transplanted 
with WT BM cells at 10-11 weeks of age prior to the onset of diabetes, 9 mice survived 
and 1 mouse died 6 days post transplant of unknown cause (Group A). The survival rate of 
Group B mice were the same with Group A with 8 out of 9 mice surviving. In control 
group mice, 5 mice out of 6 survived, but 1 mouse became very sick due to diabetes and 
was culled before the end-point.  
 
6.3.2. Little evidence of bone marrow contribution in pre-diabetic recipient NOD mice 
 
To characterise BM engraftment, Y-Fluorescent In Situ Hybridization (Y-FISH) analysis 
was performed on paraffin embedded sections containing pancreata, kidney, liver and 
spleen. Y-FISH was performed as previously described by our group (Brittan et al., 2005). 
All staining on test sections were carried out in parallel with male control sections (Figure 
6.2.A).  The success of detecting Y-chromosome in these sections required vigorous 
optimization of parameters such as duration and concentration of pepsin digestion and the 
denaturing temperature. To rule out the over digestion of tissue by pepsin, pancentromeric 
hybridization was performed using the same conditions. DNA of the cells was intact and 
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not completely digested (Figure 6.2.B).  After repeated experiments, only a few donor-
derived Y chromosome-positive cells were observed in the spleen, islets and in the 
exocrine pancreas (Figure 6.2.C). 
 
Figure 6.2. Y-Fluorescent In 
Situ Hybridization (Y-FISH) 
analysis  
(A) Y chromosomes present in 
pancreas of male control (x 200 
magnification)  
(B) Pancentromeric hybridization 
on female mouse pancreas 
transplanted with NOD BM (x 
200 magnification)  
(C) Female mouse pancreas that 
received WT BM demonstrating 
FITC-labelled Y-chromosome 
probe (Y-chromosomes – white 
arrows) (x 400 magnification) 
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Due to a low number of Y- chromosomes present in pancreata, double staining for 
endomucin (endothelial marker) was not performed, and thus I was unable to confirm that 
donor cells were of the endothelial lineage. 
 
6.3.3. Proof of principle: Bone marrow engraftment in diabetic recipient NOD mice 
 
Due to low number of Y-chromosomes observed in recipient mice from the first BM study, 
another batch of mice were enrolled to investigate whether BM cells can engraft after 
transplantation of 2 million BM cells into early diabetic and non-diabetic NOD mice.  All 
staining on test sections were carried out in parallel with male control sections and 
parameters optimized for each section such as duration and concentration of pepsin 
digestion and the denaturing temperature. After repeated experiments, Y-chromosomes 
were present in all early diabetic mice and mainly present in the spleen, islets (Figure 6.3) 
and in the exocrine pancreas.  
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Figure 6.3. Y-chromosomes present in the pancreas of female diabetic recipient 
transplanted with NOD BM cells (A) Image of an islet stained with endomucin 
antibody (red) (x 200 magnification) (B) Close up image of Y-chromosomes (arrows).  
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6.3.4. Large number of Grade 0 islets in bone marrow transplanted animals 
 
Insulitis was gauged using H&E stained sections and carried out by an observer blinded to 
the treatment group.  
 
To study the effect of whole BM transplantation on lymphocyte homing into islets, insulitis 
was scored in pancreatic sections from 8-9 mice each in both group A and group B (using 
grading standard shown on Figure 4.6). Insulitis was quantified in all islets present in two 
H&E-stained sections from each animal, each section being separated from the next by at 
least 100µm. These mice have been irradiated and transplanted with BM either from WT 
or NOD for the same duration of time of 14 weeks. 
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Figure 6.4. Grades of insulitis observed in Group A, B and C mice. Grade 0, normal 
islet; Grade 1, peri-insulitis; Grade 2, moderate insulitis; Grade 3, severe insulitis. The 
data are the sum of islets from nine mice for each group (Abbreviation: n= number of 
islets scored)
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The majority of islets (36-41%) of islets from Group A and B showed little infiltration and 
destruction of pancreatic β-cells (grade 0 insulitis) whereas only 10% of islets from control  
mice were free of insulitis with the majority of islets heavily infiltrated (*P-value: 0.01-
0.04) (Figure 6.4.). The % of islets with grades 1-3 insulitis were almost the same in Group 
A & B mice, thus indicating that BM effects on the NOD mice is the same regardless of 
the strain of donor mice.  
 
6.3.5. Significant change in blood glucose level before and after bone marrow 
transplantation 
 
Blood glucose levels of Group A and Group B mice were in the range of 5-6 mmol/l before 
BMT transplantation. Average blood glucose levels of control mice began rising at 8 
weeks after BMT (18-20 weeks of age) steadily increasing over the next 6 weeks, the 
blood  until end point, whereas blood glucose level of Group A and Group B mice did not 
change significantly (Figure 6.5A). At 14 weeks after BMT, Group A and B had an 
average blood glucose level increase of 1% and 43% respectively (Figure 6.5B). Control 
mice had an average increase of 84% in blood glucose levels (*P-value=0.05), which is 
expected as they did not receive any lethal irradiation and subsequent BM transplantation 
(Figure 6.5B). These data suggest that mice transplanted with BM (Group A and B) have a 
better control of blood glucose level compared to Group C mice.  
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Figure 6.5. Blood glucose levels (random, non-fasting blood glucose levels) in 
Group A, B and C mice (A) Average blood glucose levels of Group A, Group B and 
Group C (control) mice over 14 weeks since BMT (B) Average blood glucose levels of 
Group A and B mice before and after BMT. Statistical significance was tested by 
Student’s t-test (Abbreviations: n= average number of mice). 
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6.3.6. Evidence of islet regeneration by bone marrow transplantation once disease is 
established. 
 
To quantify β-cell proliferation and regeneration in the pancreata after BM transplantation, 
pancreatic sections were stained with anti-Ki-67 and anti-insulin antibodies. Wild type 
mouse gut and pancreas were used as positive control for the anti-Ki-67 and anti-insulin 
antibodies (Figure 6.6A,B).  
 
  
 
 
 
 
 
 
Figure 6.6. Insulin, Ki-67 and CD45 immunohistochemistry. (A) Wild type small 
intestine section was used as a control for the Ki-67 antibody (B) Wild type pancreas 
section was used as a control for the insulin antibody. The red staining represents insulin 
immunoreactivity; all positive staining was localized within the islets (C) 
Representative insulin and Ki-67 staining on pancreatic section from pre-diabetic WT 
BM transplanted animal. (D)  Representative CD45 and Ki-67 staining on pancreatic 
section from pre-diabetic NOD BM transplanted animal (x 400 magnification) 
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Most Ki-67+ Insulin+ cells (Figure 6.6C) surrounding the islets stained positive for the pan-
haematopoietic marker (CD45) (Figure 6.6D).  
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taining for Ki-67 and insulin revealed a higher rate of proliferation in the islets of WT 
 
 
Figure 6.7. Ki-67 labelling index of Insulin-positive cells of Group A and Group B 
mice. Statistical significance was tested by Student’s t-test (Abbreviations: n= average 
number of mice, Ins= insulin)  
 
S
BM transplanted mice compared to NOD BM transplanted mice (Figure 6.7).  
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6.3.7. Increased islet neovascularization in both groups of mice. 
o evaluate the contribution of BM-derived endothelial cells in β-cell regeneration by 
 
T
neovascularization, blood vessel density of pancreatic sections was assessed using a CD31 
antibody as a marker to stain for endothelial cells lining blood vessels (Figure 6.8A).  
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Figure 6.8. Islet blood vessel density. (A) Representative CD31 blood vessel staining 
in the pancreatic islet (x 200 magnification) (B) Blood vessel density of Group A, 
Group B and Group C mice
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Group B mice have increased blood vessel density compared to control mice (without 
.4. DISCUSSION 
he potential of BM transplantation to treat diabetes has been shown in many animal 
o reconstitute the immune system, recipient mice must receive a lethal dose of irradiation 
irradiation & BMT) (Figure 6.8B). In addition, our data demonstrated a significant 
difference in blood vessel density in Group B mice compared to Group A mice (*P-value: 
0.03). 
 
6
 
T
models. In this study we hoped to demonstrate the potential of wild type and non diabetic 
NOD BM cells to block the onset of diabetes in non-diabetic NOD mice.  
 
T
to eliminate mature autoreactive memory B and T-cell lymphocytes. Low dose irradiation 
(250/450 cGy) of STZ-induced diabetic mice followed by BMT only temporarily delayed 
the development of hyperglycaemia, as the low dose of irradiation did not kill the majority 
of T-cell lymphocytes, allowing destructive insulitis to occur (Urban et al., 2008). High 
dose irradiation is therefore required to improve the efficiency of BMT to restore 
normoglycaemia. In our study, the recipient female mice received a lethal dose of 
irradiation of 1000 cGy before the onset of diabetes, to eliminate mature autoreactive 
memory B and T-cell lymphocytes in the NOD peripheral lymphoid tissue, allowing new 
BM cells to reconstitute the NOD immune system and contribute to haematopoiesis. 
Majority of Group A and B mice that received BM transplantation did not develop diabetes 
during the time frame, with only 2/18 developing diabetes. The 3-4 week transient delay in 
the development of diabetes could be attributed to the time taken (approximately 2-3 
weeks) for the donor BM to reconstitute the immune system after lethal irradiation. As 
diabetes occurs spontaneously in the NOD mice, the best available control to measure the 
effect of donor BM is NOD mice, but without irradiation or BM transplantation. Control 
mice that did not receive any irradiation and BMT had an increase in blood glucose levels 
from 18 weeks of age. This is expected as the immune system is still intact and thus will 
have an earlier onset of diabetes compared to Group A and Group B mice.  
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It has been documented that BM transplantation can initiate β-cell regeneration in many 
hile a few studies have suggested that transplanted BM cells can normalise the blood 
arious models of diabetes have been used to date to investigate the contribution of BM to 
diabetic animal models. Mechanisms involved in β-cell regeneration by BM cells however 
are still unclear. BM transplantation into STZ-induced diabetic mice revealed that donor 
derived cells surrounding islets were CD45+ cells (Hasegawa et al., 2007). Lechner et al. 
and Taneera et al. similarly found a substantial number of donor-derived haematopoietic 
(CD45+ cells) in the pancreas of irradiated female mice with pancreatic injury transplanted 
with unfractionated male GFP and eGFP labelled BM cells (Lechner et al., 2004; Taneera 
et al., 2006). We similarly observed cells surrounding the islets in our BMT mice that were 
CD45+ cells. There is a possibility that haematopoietic cells may have expanded, mobilized 
into peripheral blood and migrated to the damaged pancreas upon receiving signals from 
the damaged pancreas to aid in pancreatic repair.  
 
W
glucose levels of diabetic animals once diabetes is established (Ianus et al., 2003; Lee et 
al., 2006; Li et al., 2003), several subsequent studies have not been able to confirm these 
findings (Akashi et al., 2008; Lechner et al., 2004; Mathews et al., 2004). In our study, we 
transplanted wild type and non-diabetic NOD BM before the onset of diabetes. The blood 
glucose range of the non-diabetic recipient mice before transplantation was 5 to 6 mmol/l. 
All female recipient mice chosen for this study were 10-11 weeks old at the point of 
transplantation and monitored until 25 weeks of age; the peak diabetes incidence is 
reportedly between 20-22 weeks of age. Our data showed that only 1/9 (Group A) and 1/8 
Group B mice started to develop diabetes between 23-24 weeks of age. Although, insulitis 
had already started to develop at this stage, there were still 36-41% of islets free from 
insulitis at 14 weeks after transplantation compared to control mice with only 10% Grade 0 
islets. Additionally, blood glucose levels of Group A and B mice were generally controlled 
in the same manner during the whole duration, suggesting that new bone marrow may have 
a role in inhibiting T-cell-mediated immune responses against newly formed β-cells. 
 
V
rescue diabetes. Chemically induced diabetic mice such as the STZ-treated mice are 
commonly used, but they have their disadvantages. When STZ is given in low doses, it can 
cause non-specific islet inflammation. Unlike STZ-treated mice, NOD mice are a clinically 
relevant model of human T1D, as they mimic spontaneous development of diabetes in 
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humans and exclude an artificial influence for induction of diabetes to recipients. When T-
cell depleted allogeneic BM cells were transplanted into NOD mice prior to the onset of 
diabetes with non lethal and lethal irradiation (700 cGy, 950cGy), reversal of destruction 
of β-cells was observed (Zorina et al., 2003). Although we did not demonstrate complete 
reversal of insulitis in the BMT mice, all mice had controlled blood glucose levels, with a 
significant number of islets without infiltration and delayed diabetes development.  
Induction of haematopoietic chimaerism via allogeneic BM transplantation had been 
M stem cells were initially thought to transdifferentiate into β-cells, causing the reversal 
shown to arrest progression of autoimmune diabetes in both pre-diabetic and diabetic NOD 
mice (Kang et al., 2005; Li et al., 1996). Zorina et al. demonstrated that chimaerism even 
at a level of 1%, can reverse insulitis in pre-diabetic NOD mice (Zorina et al., 2003). This 
could be attributed to the large number of donor cells of 25 x 106 BM cells as similarly 
found by Gao et al., where mice transplanted with 6.5 x 106 BM cells have a significant 
reduction in blood glucose level compared to STZ-induced mice transplanted with 1 x 106 
BM cells (Gao et al., 2008). Our mice were transplanted with 2 x 106 BM cells after lethal 
irradiation of 1000cGy, and we observed a very low engraftment level of BM donor cells 
(i.e. Y-chromosome positive cells) in the pancreata and spleen of our recipient female 
NODs. The number of donor BMCs could therefore be an important factor in improving 
the efficiency of BM engraftment, on the other hand a large number of donor cells could 
result in the possibility of cells getting caught in the capillary beds of the lung reducing the 
number of cells actually reaching other organs. Another factor to consider is the nature 
(intensity) of the stimulus as demonstrated in the second study, where Y-chromosomes 
were detected in all recipient early diabetic mice. 
 
B
of diabetes in STZ-induced mice (Ianus et al., 2003). Other studies however demonstrated 
the incidence of transdifferentiation is very rare and collectively suggested that BM cells 
can promote regeneration and survival of endogenous β-cells. The identity of new β-cells 
has been controversial but Dor et al. suggested that new β-cells arise primarily from 
proliferation of existing β-cells (Dor et al., 2004). Further studies concluded that all β-cells 
have equal potential for growth and maintenance (Brennand et al., 2007). It is also possible 
that β-cell regeneration could involve the transient dedifferentiation of β-cells followed by 
proliferation and re-differentiation (Ouziel-Yahalom et al., 2006), although recent lineage 
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tracing studies of cultured β-cells showed otherwise (Morton et al., 2007; Weinberg et al., 
2007). We observed significant β-cell regeneration (Ki-67+ Ins+ cells) in both groups of 
BM transplanted mice. Upon receiving signals of β-cells destruction, BM cells may have 
homed into the islet and contributed to healing by promoting the proliferation of pre-
existing β-cells or secreted cytokines and growth factors as a mode of pancreatic repair. 
Another mechanism that may have delayed diabetes development is pancreatic repair via 
neovascularization as shown by several studies (Hasegawa et al., 2007; Hess et al., 2003; 
Mathews et al., 2004). These studies suggest that BM, presumably containing EPCs, 
differentiated into endothelial cells and contributed to the repair of injured islet 
neovasculature. Although we did not show endothelial cells in the islets are donor-derived 
cells, we observed an increase of islet blood vessel density in our NOD BM transplanted 
mice compared to the control mice. Additionally, we cannot exclude the possibility of a 
small contribution of stem cells or other non β-cells to β-cell regeneration, as we observed 
some β-cells scattered throughout exocrine tissue suggesting transdifferentiation of 
exocrine cells, possibly acinar cells into β-cells. 
 
Our data imply that BM cells from either wild type or non diabetic NOD mice 
administered before the onset of diabetes may have an effect in delaying β-cell destruction 
evidenced by glycaemic control, reduced inflammation and increased number of 
proliferating Ki-67+ Ins+  cells. These data support our assumption that attempts to reverse 
the disease by promotion of β-cell regeneration need to be carried out before β-cells are 
completely destroyed. Although we did not reverse the development of diabetes in all our 
mice, we have collectively shown the potential of BM cells in aiding β-cell regeneration 
and are an encouraging proof of concept for a regenerative medicine approach to treating 
diabetes. 
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CHAPTER 7: ENDOTHELIAL PROGENITOR CELL 
TRANSPLANTATION INTO NOD MICE 
7.1. INTRODUCTION 
BM cells have been shown to aid in pancreatic repair in spontaneous or induced diabetic 
models. The exact mechanisms by which stem cells in the BM initiate repair are still 
unknown. BM cells consist of three types of stem cells; mesenchymal stem cells (MSCs), 
EPCs and HSCs. Both MSCs and EPCs were believed to have the paracrine ability to 
secrete a variety of cytokines and growth factors (Chen et al., 2008; Di Santo et al., 2009). 
Recently, Di Santo et al. demonstrated that EPCs secrete a number of growth factors 
important in stem cell mobilization and homing such as SDF-1, VEGF and HGF (Di Santo 
et al., 2009). It has also been reported that EPCs may play a role in the tissue regeneration 
via the formation of new blood vessels. New blood vessels formed via neovascularization 
can deliver essential growth factors, nutrients, inflammatory cells and oxygen to injured 
sites during the healing process. 
 
Patients having diabetes and vascular disease have reduced numbers of circulating EPCs 
and impaired function to form tubules, migrate and recruit cells for re-endothelialization 
after vascular injury (Ii et al., 2006; Loomans et al., 2005). An impairment of EPC 
function may result in an imbalance between the reparative effort of EPCs and injury by 
inflammatory leukocytes, thus explaining the reduced ability for neovascularization in 
diabetes. These alterations decrease vascular regeneration and thus may contribute to the 
pathogenesis of vascular complications in T1D and T2D. Anti-diabetic strategies such as 
treatment with thiazolidinedione pioglitazone was shown to increase numbers and 
functional capacity of EPCs in patients with T2D (Wang et al., 2006). Alternatively, 
transplantation of healthy EPCs or genetically modified EPCs may be able to improve 
vascular function in vivo. 
 
EPCs generally exist in small numbers in the circulation and therefore culture expansion is 
necessary prior to transplantation into animal models. Many studies have demonstrated the 
potential of EPCs to promote neovascularization in myocardial and hindlimb ischaemia 
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(Kocher et al., 2001; Tamarat et al., 2004), pulmonary arterial hypertension (Takahashi et 
al., 2004) and liver injury animal models (Taniguchi et al., 2006; Ueno et al., 2006). 
Recently, Jeong et al. demonstrated the intramuscular administration of ex vivo expanded 
BM-EPCs into STZ-induced diabetic mice can reverse diabetic neuropathy manifestations 
through direct modulation of nerves (Jeong et al., 2009). Paracrine factors such as VEGF-
A, FGF-2 and SDF-1α were highly upregulated in the EPC-transplanted mice. 
Additionally, blood vessel density and blood flow in nerves were increased suggesting that 
EPCs had augmented nevoascularization in the nerves. Taken together, the dual angiogenic 
and neutrophic effects of EPCs may be an attractive therapeutic option in treating other 
vascular diseases. 
 
Accordingly, we investigated whether transplantation of WT and NOD EPCs could 
attenuate or reverse T1D in the NOD mouse model by promoting neovascularization and 
providing paracrine factors.   
 
 
 
 
 
 
 
 
 
 
 
Chapter 7                                                                                             EPC transplantation 
 
 
 
Cheen Khoo                                                                                                                           130           
 
7.2. METHODS 
7.2.1. Mice 
 
Two groups of mice were used as donors in this study, pre-diabetic NOD and wild type 
(Balb/c) mice. Wild type mice were purchased from Charles River Laboratories and 
housed in the animal facility at Charterhouse Square. NOD mice were bred and housed in 
the same facility. NOD mice were initially diagnosed to be diabetic by monitoring the 
urinary glucose level (Diabur Test 5000) and were subsequently tested for diabetes by 
measuring blood glucose levels using an Accu-chek AVIVA Blood Monitor. These newly 
diabetic mice were then transferred within two days to the Biological Resource Unit, 
Cancer Research UK to receive EPC transplantation. 
 
7.2.2. EPC transplantation experimental plan  
EPCs used in this study were c-Kit+ lin- cells magnetically isolated from BM and cultured 
on fibronectin coated plates for 3-4 weeks in endothelial growth media as previously 
described in Chapter 5 (Figure 7.1.). 
 
 
 
 
Figure 7.1. General experimental strategy.  
c-Kit+ cells isolated from BM were grown on fibronectin coated plates for 3-4 weeks and 
administered into early diabetic and non diabetic NOD mice. (Abbreviations: EPC, endothelial 
progenitor cells; MACS, magnetic activated cell sorting; i.v., intravenous; FACS; fluorescence 
activated cell sorting; Dil-acLDL, Dil-labelled acetylated low-density lipoprotein). 
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NOD mice used in this study (0-3 days diabetic with a blood glucose level in the range of 
11.5 mmol/l to 25 mmol/l) were divided into 3 groups (Figure 7.2):  
 
a) Group A: 7 female animals (early diabetic NOD, 15-23 weeks old) have been injected 
i.v. with 5 x 104 BM-derived EPCs (cultured c-Kit+ cells) isolated from wild type mice. 
Mice were kept for 2-4 weeks unless unwell due to development of diabetes.  
b) Group B: 6 female animals (early diabetic NOD, 15-23 weeks old) have been injected 
i.v. with 5 x 104 BM-derived EPCs (cultured c-Kit+ cells) isolated from NOD mice. Mice 
were kept for 2-4 weeks unless unwell due to development of diabetes. 
c) Group C: 7 female animals (early diabetic NOD, 15-23 weeks old) served as a control. 
These mice did not receive any EPC transplantation and were kept together with Group A 
and B mice in the animal facility. 
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FIXED
RECIPIENT :          NOD
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Figure 7.2. Experimental strategy.  
Female early diabetic (0-3 days) Group A and B mice were injected i.v. with 5 x104 
cells cultured EPC cells. Group C, control mice did not receive any cultured EPCs 
(Abbreviations: BMT, bone marrow transplantation; i.v., intravenous; P, pancreas; 
S, spleen; K, kidney; L, liver) 
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7.2.3. Gender mis-matched EPC transplantation into NOD mice  
 
Breeding of mice and isolation of BM were carried out under UK Home Office procedural 
and ethical guidelines (Home Office Project License NO. 70/5962) at the Biological 
Services Unit, Charterhouse Square. Administration of EPCs and maintenance of 
chimaeric mice were carried out in the Biological Resource Unit, Cancer Research UK, 
London Research Institute. 
 
7.2.4. Preparation of EPCs for transplantation  
 
The cells for EPC transplantation were obtained from the BM of wild type (Balb/c) and 
NOD male mice. c-Kit+ derived EPCs were obtained by culture in endothelial growth 
media, of the enriched c-Kit+ fraction from fresh BM of age matched wild type and NOD 
male mice (approximately 10-12 weeks old) (Figure 7.1.). After 3-4 weeks, adherent cells 
were washed with PBS before addition of trypsin to remove them from the bottom of the 
24-well plate. After 5 mins incubation, cells were washed with EPC growth media at 3 
times the volume of trypsin to neutralise the effect of trypsin. Cells were centrifuged at 
1500 rpm for 5 mins to separate the supernatant from the cells. The pellet was then 
resuspended in 200 µl sterile PBS for i.v. tail vein injection into the recipient female mice 
on the same day. The number of nucleated cells was counted using a haemocytometer by 
the dye exclusion test using trypan blue (Stem Cell Technologies). Cells were stored on ice 
for no more than 1 hour before administration. Following administration, the mice were 
housed in sterile conditions and specific protocols were performed in accordance to each 
defined study.  
 
7.2.5. Monitoring of diabetes development  
 
In the period after transplantation, blood glucose levels were evaluated once every 7 days 
using Accu-chek AVIVA Blood Monitor (Roche). At the end point, all mice were killed by 
cervical ‘dislocation’ and/or CO2 inhalation dependent on the type of tissue collected. 
Pancreas, spleen, kidney and liver were fixed in neutral buffered formalin for 24 hours at 
room temperature before being embedded in paraffin wax. Mice transplanted with EPCs 
were monitored for 21-28 days. 
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7.2.6. Endomucin microvessel staining 
In this study, an anti-endomucin antibody was used to stain for endothelial cells lining 
blood vessels as endomucin is closely related to CD34, a putative mouse EPC marker. 
Both primary and secondary antibodies were diluted in blocking buffer, made up of goat 
serum (Dako) diluted in PBS (1:25). Paraffin sections were dewaxed, blocked with 0.3% 
v/v hydrogen peroxidase in methanol and rehydrated through a descending series of 
alcohol in PBS (100%, 95% and 70% v/v ethanol), before incubation in 20% v/v acetic 
acid/methanol for 10 mins. After incubation, slides were rinsed with PBS before addition 
of goat serum (Dako) for 30 mins. Rat monoclonal anti-mouse Endomucin (V.7C7) (Santa 
Cruz) antibody was added (1:250) for 40 mins and subsequently washed twice with PBS 
for 5 mins. Secondary antibody, rabbit biotinylated anti-rat IgG (1:100) (Vector 
Laboratories) was added to sections and incubated for 35 mins. Sections were washed 
twice for 5 mins before addition of alkaline phosphatase streptavidin (1:50) (Vector 
Laboratories) for 25 mins. After washing sections twice for 5 mins, sections were 
developed according to the manufacturer’s instructions using alkaline phosphatase 
substrate kit 1 (Vector Laboratories). Sections were washed in PBS twice for 5 mins. Next 
sections were stained with haematoxylin for 2 mins and washed with excess in tap water 
for 1 min. Sections were then dipped in acid water before counterstaining with eosin. After 
counterstaining, sections were dehydrated for 2 mins in 70%, 90% and 100% v/v ethanol 
for 5 mins followed by clearing in xylene twice for 1 min before mounting with DEPEX 
(BDH Laboratory Supplies Inc.) and coverslipping. 
 
For scoring of blood vessel density, see section 2.6.2.  
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7.3. RESULTS 
7.3.1. Mice that received an EPC transplant prior to onset of hyperglycaemia 
 
In order to study the possible contribution of EPCs in delaying hyperglycaemia, sex-mis-
matched EPCs from wild type (Group A) and non-diabetic NOD mice (Group B) were 
transplanted into female early diabetic mice. At approximately 14 days after EPC 
transplantation, Group A mice and control mice had an average survival rate of 60% 
compared to 100% survival rate for Group B mice (Figure 7.3). One mouse from Group B 
survived past 21 days until 28 days, which was the end point of the study. 
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Figure 7.3. Survival rate of mice (%) after administration of EPCs.  
Group A (blue), mice administered with wild type EPCs; Group B (pink), mice 
administered with NOD EPCs; Group C (yellow), control mice without 
administration of EPCs. 
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7.3.2. EPC contribution in the pancreas 
 
To characterise EPC engraftment, Y-Fluorescent In Situ Hybridization (Y-FISH) analysis 
was performed on paraffin embedded sections containing pancreata, kidney, liver and 
spleen. All staining on test sections was carried out in parallel with male (as previously 
done, Figure 6.2A) and female control sections (Figure 7.4A&B). Optimisation of 
parameters such as duration and concentration of pepsin digestion were carried out in all 
sections for all tissue samples, as certain tissue sections were more resistant to the effects 
of pepsin digestion than others.  
 
Y-chromosome-positive cells were detected in the pancreas and spleen, but not kidney or 
liver of all female recipient mice that received an EPC transplant. The majority of the Y-
chromosomes were detected inside the islets (Figure 7.4C). These observations indicate 
that injected EPCs have mobilized and engrafted in the damaged pancreas. To differentiate 
between the host- and donor-derived endothelial cells, in situ hybridisation for the Y-
chromosome was combined with immunohistochemical characterisation of endomucin, an 
endothelial marker. After repeated experiments, our results demonstrated that donor-
derived cells were very rarely of the endothelial lineage due to the absence of Y-
chromosome detection in majority of endomucin+ cells (endothelial cells) (Figure 7.4F). 
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Figure 7.4. Y-chromosomes detected in female recipient transplanted with NOD 
EPCs (A) Female control mouse pancreas demonstrating the FITC labelled Y-
chromosome probe (fluorescent green) does not label female (XX) (B) Close up image 
of female cells (C) Endothelial cells labelled with endomucin (red), nuclei (blue), Y-
chromosomes (green). Dashed lines circle an islet (x 200 magnification)
(D) Y-chromosomes are present in most of the cells in the islets. (E) Endothelial cells 
stained with endomucin antibody (asterisk) (F) Donor-derived cells present close to 
blood vessels (white arrows) and a single donor-derived endothelial cell (asterisk)(x 400 
magnification).  
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7.3.3. Larger number of Grade 0 and 1 islets in EPC transplanted animals 
 
Insulitis was gauged using H&E stained sections and carried out by an observer blinded to 
the treatment group.  
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Figure 7.5. Grades of insulitis observed in Group A, B and C mice. Grade 0, 
normal islet ; Grade 1, peri-insulitis ; Grade 2, moderate insulitis; Grade 3, severe 
insulitis. The data are the sum of islets from 6-7 mice for each group (Abbreviation: 
n= number of islets scored) 
 
To study the effect of EPC transplantation on lymphocyte homing into islets, insulitis was 
scored in pancreatic sections from 6-7 mice each in both group A and B mice (using 
grading scheme shown on Figure 4.6). Insulitis was quantified in all islets present in two 
H&E-stained sections from each animal, each section being separated from the next by at 
least 100 µm. After 21 days of receiving wild type EPCs, 16% of islets from Group A mice 
showed little infiltration and destruction of pancreatic β-cells (grade 0 insulitis) whereas 
only 3% of islets from control mice were grade 0 (*P-value: 0.05). However 29% of islets 
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in group B mice had peri-insulitis (grade 1) compared to 13% islets in the control mice 
(*P-value: 0.03) (Figure 7.5).  The percentage of islets with Grade 0, 1, 2 and 3 insulitis 
were almost the same in Group A & B mice, thus indicating that the EPC effects on 
inflammation are the same regardless of the strain of the donor mouse. 
 
7.3.4. Little change in average blood glucose levels before and after EPC transplantation 
 
Blood glucose levels of Group A and Group B mice were in the range of 15-25 mmol/l 
before EPC transplantation. Average blood glucose level of Group A, B and control mice 
at 21-28 days after EPC transplantation did not change significantly (Figure 7.6).  
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Figure 7.6.  
Average blood 
glucose levels 
(random, non-
fasting blood 
glucose levels) of 
Group A, B and C 
(control) mice over 
21 days after EPC 
transplantation 
(Abbreviation: n= 
average number of 
mice, BG= blood 
glucose) 
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7.3.5. Evidence of islet regeneration by EPC transplantation once disease is established 
 
To quantify β-cell proliferation and regeneration in the pancreata after EPC transplantation, 
pancreatic sections were stained with Ki-67 and insulin antibodies. All Ki-67 and insulin 
antibody staining on test sections was carried out in parallel with positive wild type mouse 
gut and pancreas sections respectively. Majority of islets in control mice were Grade 3 
islets, thus have none or very few Insulin+ cells (Figure 7.7C,D). There was both Ki-67+ 
Insulin+ cells (Figure 7.7A,B) and Ki-67+ Insulin- cells present in the islets of mice that 
received WT or NOD EPCs. 
 
  
 
 
 
 
 
Figure 7.7. Insulin and Ki-67 immunohistochemistry.  
(A) Insulin+  cells which are also Ki-67+  (arrows) in grade 2 islet from female recipient 
mouse that received NOD EPCs (B) Merged image of Ki-67+ Insulin+ cells stained with 
nuclear stain, DAPI (x 400 magnification)  (C) Nuclear stain in a grade 3 islet of a 
female control mice (Group C control mice). No Insulin+ cells were detected (D) 
Merged image of Ki-67+ DAPI+ cells (x 200 magnification)  
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In the absence of insulin staining, it was obvious that a number of the Ki-67+ cells present 
would most likely be proliferating inflammatory cells (Figure 7.7B). 
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Figure 7.8. Ki-67 labelling index of Ins-positive cells of Group A, B and C mice. 
Statistical significance was tested by Student’s t-test (Abbreviations: n= average number 
of mice; Ins= insulin) 
 
Staining for Ki-67 and insulin revealed a higher level of proliferation in the islets of NOD 
EPC transplanted mice (Group B mice) compared to control mice and WT EPC 
transplanted mice (Group A mice) (Figure 7.8).  
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7.3.6. Increased islet neovascularization in both groups of mice 
 
To evaluate the contribution of BM-derived EPCs to pancreatic repair by 
neovascularization, blood vessel density of pancreatic sections was assessed using 
endomucin as a marker to stain for endothelial cells lining blood vessels. Endomucin 
(clone v.7c7) was chosen in this study instead of CD31 as endomucin is closely related to 
CD34, a putative mouse EPC marker. 
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Figure 7.9. Islet blood vessel density of EPC transplanted mice (Group A, B, C 
mice)  
Group A mice (WT EPC transplanted mice) had increased blood vessel density compared 
to Group B (NOD EPC transplanted mice) and control mice (Figure 7.9). There were no 
significant differences in blood vessel density between Group B and control mice. 
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7.4. DISCUSSION  
 
EPCs isolated from BM, umbilical CB and PB have been shown to improve 
angiogenesis/vasculogenesis in disease models through two mechanisms, vasculogenesis, 
the recruitment of BM-derived EPCs that migrate and differentiate in response to signals to 
create new blood vessels, and angiogenesis, the endothelial sprouting of pre-existing 
vessels. Some new vessels can be formed by a combination of angiogenesis and 
vasculogenesis. In our study, we observed very few donor-derived endothelial cells as 
witnessed by co-localization of the Y-chromosome with the endothelial cell marker, 
endomucin in the islets of Langerhans. This suggests that donor EPCs had differentiated 
into endothelial cells, although very infrequently. We found in many occasions, the 
presence of a cluster of donor-derived cells near the blood vessels which may possibly be 
undifferentiated EPCs. Additionally, we observed an increased islet blood vessel density in 
WT EPC transplanted mice compared to control mice. These observations thus led us to 
hypothesise that this process is due to a greater contribution by angiogenesis than 
vasculogenesis as similarly observed by Jeong et al. using a diabetic neuropathy animal 
model (Jeong et al., 2009). 
 
EPCs are mobilized by various stimuli such as tissue injury, ischaemia and hypoxia. In this 
study, the NOD mouse is used as a model of T1D where β-cells in the islets are destroyed 
by inflammatory cells resulting in hyperglycaemia. Using Y-FISH analysis, we detected Y-
chromosomes in the pancreas and spleen but neither in the kidneys nor liver of recipient 
mice. This suggests that EPCs injected intravenously may have been stimulated to enter the 
systemic circulation and migrate to the damaged islets in response to signals from stressed 
β-cells. Our observations support previous findings from Hess et al. and Mathews et al. 
that BM-derived stem cells preferentially engraft damaged pancreatic tissue, further 
supporting the notion that tissue damage is necessary for the recruitment of BM-derived 
cells (Hess et al., 2003; Mathews et al., 2004). 
 
In addition to differentiating into endothelial cells to contribute to wound healing, various 
studies demonstrated that EPCs are able to produce paracrine factors including cytokines 
and growth factors. These factors released from transplanted EPCs may have important 
roles in the regulation of neovascularization, fibrosis, inflammation and endogenous repair 
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(Burchfield and Dimmeler, 2008). Our results demonstrated that NOD EPC transplantation 
can initiate and augment proliferation of the pancreatic β-cells (Ki-67+ Ins+ cells), 
compared to the lower level of proliferation detected in early diabetic mice that did not 
receive EPCs. We postulate that these EPCs release a mixture of physiologically relevant 
cytokines and growth factors, inducing a permissive environment for differentiated cells as 
well as progenitor cells of the recipient to mediate pancreatic repair. Additionally, we 
observed a higher number of Grade 0 and Grade 1 islets in WT and NOD EPC transplanted 
mice compared to control mice, indicating the potential effect of EPCs in controlling 
inflammation in diabetic mice. Ohnishi and colleagues have shown that BM-derived MSCs 
may possess anti-inflammatory properties as they reported reduced inflammation in the 
heart, in particular histiocytic infiltration (marked by CD68+ cells) in a rat model of acute 
myocarditis (Ohnishi et al., 2007). The authors concluded that the anti-inflammatory 
effects in the transplanted rat were due to paracrine factors released from the MSCs. There 
is a possibility therefore that the delayed inflammation in our BM-derived EPC 
transplanted mice could be due to the immunosuppressive factors released by these cells.  
 
The blood glucose range used in this study was 15 mmol/l to 25 mmol/l. As NOD mice 
spontaneously develop diabetes, it is difficult to enrol mice with the same diabetes 
severity, however we tried to minimise the differences by enrolling only mice that were 0-
3 days diabetic. One mouse from our control mice (Group C) without insulin or EPC 
therapy became severely diabetic after 7 days and this pattern was subsequently followed 
by other mice in the group, until the maximum time period of 21 days. The survival rate of 
Group B mice was slightly better where mice started to get severe diabetic symptoms only 
from day 14 onwards. In contrast, one mouse from the NOD EPC transplanted group 
(Group B) managed to survive past 21 days and was culled at 28 days only due to 
timeframe set for the experiment. The blood glucose level of that particular mouse before 
EPC transplant was 17.28 mmol/l and decreased to a normoglycaemia level of 9.89 mmol/l 
after 28 days. This particular mouse did not exhibit any physical signs of diabetes 
compared to the other diabetic mice. There is a possibility therefore that the mouse treated 
with NOD EPCs was protected from hyperglycaemia, thus extending its survival.  
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Early outgrowth cells or early EPCs have a limited ability to form vascular tubes in vivo 
and in vitro, but augment neovascularization by secretion of growth factors such as VEGF, 
which plays a role in revascularization of injured tissues, HGF, G-CSF and IL-8 
(Ziegelhoeffer et al., 2004). Recently Di Santo et al. discovered that culture expanded 
EPCs in hypoxic conditions release high concentrations of growth factors with angiogenic 
properties, namely bFGF and TNFα, IL-8, SDF-1, HGF, angiogenin, PDGF-BB, VEGF-A 
(Di Santo et al., 2009). When conditioned media is injected intramuscularly into rat 
hindlimb ischaemic mice, neovascularization was augmented in terms of increased blood 
flow and capillary density. Although we did not measure the levels of growth factors in the 
EPC transplanted mice, we postulate that islet blood vessel density was increased due to 
both paracrine release of pro-angiogenic factors as well as by modest differentiation into 
endothelial cells. 
 
It has been demonstrated that T1D and T2D patients with cardiovascular problems have 
reduced numbers of EPCs and are dysfunctional in ways of homing to the site of injury and 
formation of tubules, demonstrated in vitro (Loomans et al., 2005; Tepper et al., 2002). 
When  autologous (dysfunctional) progenitor cells from CAD patients was transplanted 
into patients with myocardial infarction, EPCs prove to be ineffective in improving 
neovascularization and heart function (Heeschen et al., 2004). In line with previous 
observations, our results demonstrated that NOD EPCs did not increase the blood vessel 
density of diabetic recipient mice (Group A mice). On the other hand, recipients of healthy 
EPCs (i.e. WT EPCs) had a significant increase in blood vessel density. 
 
Our data imply that EPC cells from either WT or non-diabetic NOD mice transplanted 
during the early stages of diabetes may have an effect in delaying β-cell destruction, 
evidenced by reduced inflammation. Although there were no significant changes in 
glycaemic control in the majority of the EPC transplanted mice, hyperglycaemia was 
successfully reversed in one recipient mouse transplanted with NOD EPCs. In summary, 
our study showed that exogenous EPCs transplanted into early diabetic mice can promote 
β-cell regeneration, and control hyperglycaemia possibly via neovascularization and/or 
release of paracrine factors. BM-derived EPC transplantation therefore may be a feasible 
approach in the future to improve the regeneration of other organs and tissues. 
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CHAPTER 8: GENERAL SUMMARY AND FUTURE 
DIRECTIONS 
8.1. GENERAL SUMMARY 
Pancreas and islet transplantations have so far proved to be a successful treatment for T1D, 
however due to insufficient supply of donor pancreata and islets and reported immune 
system rejection, alternative strategies such as stem cell therapy have been considered. In 
recent years, adult stem cells have emerged to have the ability to cross lineage boundaries 
and form lineages within other tissues. Studies have so far tried to replace damaged β-cells 
with newly derived insulin-secreting cells from BM and cord blood, however efforts have 
proved futile as these cells did not demonstrate appropriate characteristics of functional β-
cells and were thus unsuitable for transplantation therapy. Besides the ability to 
transdifferentiate into other cell lineages, extrapancreatic adult stem cells were believed to 
have the ability to release paracrine factors which can promote a regenerative environment 
in vivo. 
 
Through this thesis, I have investigated two strategies for enhancing pancreatic 
regeneration and produced data demonstrating their potential application in T1D therapy. 
The first strategy involves the study of the contribution of BM cells and BM-derived EPCs 
to promote β-cell regeneration in the damaged pancreas of NOD mice. 
 
Based on various reports demonstrating the ability of EPCs to promote neovascularization 
in animal models of disease, I decided to first isolate and measure the number of 
circulating EPCs using typical murine EPC markers that exist in both non-diabetic and 
diabetic NOD mice using FACS analysis (Chapter 3). Following are a number of 
observations: 
 
1) EPCs exist in very low numbers in mouse PB and BM. 
2) EPC number is markedly reduced in the BM of diabetic mice, but is conversely 
increased in the bloodstream, indicating the possibility of recruitment of BM-derived 
EPCs to mobilize into the blood circulation upon receiving signals from the damaged 
pancreas.  
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To fully understand the EPC recruitment process and contribution to the damaged 
pancreas, BM-derived EPCs were first isolated using magnetic isolation (Chapter 5) and 
next transplanted into early diabetic NOD mice (Chapter 7). Two different methods were 
used to expand BM-derived EPCs and cells were assessed based on phenotypic and 
functional endothelial properties. I could draw the following conclusions: 
 
1) BM-derived EPCs isolated using magnetic isolation of c-Kit+ cells express markers of 
murine EPCs and appears to be late EPCs. 
2) BM-derived EPCs isolated using selective media did not express the panel of EPC 
markers and have limited proliferative activity. Magnetic isolation therefore is the 
method of choice for the isolation of BM-derived EPCs. 
3) In the early diabetic NOD mouse, transplanted WT and NOD EPCs homed to the 
damaged pancreas and engrafted in the islets and spleen.  
4) Transdifferentiation of EPCs into endothelial cells occurs very infrequently. 
5) EPCs may have a role in β-cell regeneration but neovascularization is not the major 
mechanism.  
 
Parallel to the EPC transplantation study, fresh whole BM was transplanted into pre-
diabetic mice and monitored for 14 weeks (Chapter 6). I could draw the following 
conclusions: 
 
1) The majority of enrolled mice had delayed β-cell destruction evidenced by better 
glycaemic control, reduced inflammation and increased number of proliferating β-cells. 
2) Diabetes intervention is best performed before the complete destruction of β-cells. 
 
In addition to promoting endogenous β-cell regeneration using EPCs, I investigated an 
alternative strategy to block β-cell destruction via apoptosis by injecting intraperitonally, a 
protease peptide inhibitor for JNK domain (XG-102) into early diabetic NOD mice 
(Chapter 4). I could draw the following conclusions: 
 
1) Blocking the interaction between JNK1 and c-Jun substrate using XG-102 had very 
little effect on blocking β-cell apoptosis in early diabetic NOD mice. 
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2) XG-102 may have a role in reducing lymphocyte homing into the pancreas. 
3) JNK1 may not have an important role in β-cell apoptosis. 
 
8.2. GENERAL DISCUSSION 
 
Our data demonstrated the potential of both BM stem cells and protease peptide inhibitor 
in delaying diabetes and promoting pancreatic repair. Following are a number of issues and 
limitations which need to be studied in more detail before stem cell or drug therapy for 
diabetes can be applied to the clinical setting: 
 
8.2.1. Issues to be addressed before EPC transplantation therapy can become a reality 
 
Research has demonstrated the potential of EPCs for future therapeutic applications in 
improving angiogenesis/vasculogenesis. Successful neovascularization has been 
demonstrated in various disease models using EPCs, however to translate the knowledge 
obtained from these experiments to clinical therapy, several issues need to be considered 
and addressed: 
 
i) EPC source – EPCs from patients with endothelial dysfunction have limited 
proliferative potential and are reduced in numbers. Therefore, EPCs from a 
healthy donor is required for successful cell transplantation. 
ii) Recipient – Patients need to be assessed of their suitability, such as their age 
and other cardiovascular risk factors which may reduce the availability and 
function of EPCs. Additionally, unfavourable microenvironment present in the 
ischaemic tissue might impair the effectiveness of cell transplantation. 
iii) Ex vivo expansion of EPCs - A standard source and use of gold-standard 
markers need to be established to avoid any variation in therapeutic efficacy. 
iv) Transplantation – Dosage of cells for transplantation needs to be optimised to 
overcome problem of loss of EPCs during early stage of transplantation. Choice 
of EPC delivery also needs to be considered for successful initiation of 
vascularization and tissue regeneration in vivo. 
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Figure 8.1 Issues needing to be addressed before vascular therapy becomes an 
everyday occurrence. Newly derived EPCs need to be isolated and characterized using 
a standard procedure to avoid any variations. Additionally, it is important to optimize 
transplantation procedures such as the technique of delivery and number of cells to 
initiate vascularization in vivo. (Abbreviation: EPC, Endothelial progenitor cell). 
8.2.2. Cultured EPCs versus fresh EPCs 
 
Assessments of EPC contribution in this study were performed on cultured EPCs because 
they are low in numbers when freshly isolated, but this is how they are currently defined 
and isolated. The culture process can result in maturation of EPCs to more mature 
endothelial cells therefore limiting the efficacy of the EPC contribution. This therefore 
poses a risk when transplanted into patients. Additionally, Li et al. reported low senescence 
in ex vivo expansion of c-Kit+ cells which may thus affect the low potential for inducing 
therapeutic angiogenesis in their animal model (Li et al., 2004). In our study, the majority 
of cells were viable as ascertained using the trypan blue exclusion test when counting cells 
for culture or transplantation. This technique however is not very sensitive and just gives  
an overview of the viability of cells. This problem can be addressed by first isolating viable 
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cells using magnetic cell sorting or flow cytometry for cell viability markers such as 
propidium iodide (PI) and 7-actinomycin D (7-AAD), before enriching with a lineage 
positive antibody (Lu et al., 2008). Caution therefore is warranted as cell loss can occur 
after several separation steps by magnetic beads or flow cytometry. 
 
8.2.3. Practical uses and limitations of cell-permeable peptides 
 
Drug delivery is an important aspect in achieving a therapeutic effect in human or animal 
models. Previous therapeutic approaches such as protein and gene therapy have limited 
success due to poor permeability of peptides and oligonucleotides through the cell 
membrane. Other delivery methods include invasive methods such as microinjection and 
application of membrane disrupting agents which can result in high toxicity, 
immunogenicity and low delivery yield to the desired site (Morris et al., 2008). Substantial 
progress has been made with the development of cell-penetrating peptide (CPP), a delivery 
system that overcomes previous limitations of entry restriction into the cell. A commonly 
used CPP is TAT discovered in 1988, a transcription activator of the human 
immunodeficiency virus type 1 (HIV-1) viral genome (Frankel et al., 1988). Target 
molecules can be linked to the TAT, be delivered to the desired site in a highly efficient 
manner. In our study, we used XG-102 or D-JNK1 inhibitory peptide which was created by 
linking the 20-amino acid JNK-binding motif of JIP-1 to 10-amino acid HIV TAT 
transported sequence (Borsello et al., 2003). This peptide was designed to competitively 
block interaction between JNK1 to c-Jun and other substrates, thereby disrupting the 
MAPK/JNK cell death signal cascade. In addition to our study using XG-102, previous 
studies have shown the ability of this peptide to protect neurons against cell death in both  
rat model of middle cerebal artery occlusion and cerebal ischaemia (Borsello et al., 2003; 
Hirt et al., 2004). Although XG-102 has produced therapeutic results in animal models, its 
translation to use in human therapy is hampered by the cost of the molecule. For example 
the XG-102 dose used by Borsello and colleagues was 11mg/kg which corresponds to 
approximately 1g for the successful treatment in humans (Borsello et al., 2003).  
Additionally, as XG-102 has a long-lived biological activity inside cells and the TAT-
linked design prevents leakage from cells, it could potentially be toxic and thus further 
investigations are warranted prior to its introduction for clinical use, especially in small 
organs like the pancreas (Barr et al., 2002). 
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8.2.4. NOD mouse versus human T1D 
 
The NOD mouse is the most commonly used animal model of human T1D to date due to 
the ability to spontaneously develop diabetes, with shared immunological features such as 
defective central and peripheral tolerance. Therefore, the NOD mouse is commonly used to 
improve our understanding of diabetes pathogenesis and extensively used as a preclinical 
tool for the development of new therapeutic strategies. Agents such as insulin, anti-CD3 
and TNF-α  have all been shown at various stages of diabetes in the NOD mouse to protect 
β-cells from damage (Harrison et al., 1996; Hayward and Shreiber, 1989; Seino et al., 
1991). Such strategies are highly motivating, but caution is often warranted as therapies 
that worked in NOD mice may not be suitable for humans. For example oral injections of 
insulin protected pre-diabetic mice from developing diabetes whereas this strategy did not 
delay or prevent T1D in non-diabetic relatives at risk of developing T1D (Diabetes 
Prevention Trial of oral and subcutaneous insulin)(Skyler et al., 2005). This discrepancy 
could be due to the fact that the NOD mouse only represents one pathogenic mechanism of 
diabetes which may be relevant only to a small number of human patients (Raz et al., 
2005). The time course of diabetes development between the NOD mouse and humans are 
also quite different, where humans develop diabetes at or before puberty whereas NOD 
mice develop the disease much later. Additionally, the incidence of diabetes is equal in 
human females and males; however this is not the case in NOD mice where female NOD 
mice predominantly develop diabetes. Future preclinical therapeutic strategies need to take 
the differences between the NOD mouse and human T1D into consideration, to improve 
future translational efforts. 
 
8.2.5. Variation in clinical measurements 
 
Many studies have successfully demonstrated the delay or prevention of disease using 
therapeutic agents and biomolecules. Recently Shoda et al. analyzed past studies and 
discovered there is a wide variability of the definition of diabetes and treatment efficacy  
for the treatment of diabetes using animal models (Shoda et al., 2005). For example Akashi 
et al. defined Akita mice to be diabetic based on fed glucose levels of above 250 mg/dl. 
Treatment efficacy however was only based on two factors, reduction in blood glucose 
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level and donor chimaerism (GFP+) cells in the peripheral blood and pancreas (Akashi et 
al., 2008). In all my experiments, diabetic status of the mice was diagnosed by monitoring 
urinary glucose levels for glycosuria and then confirming by measuring blood glucose 
levels exceeding 11.5 mmol/l (i.e. 207 mg/dl) with multiple hyperglycaemic measurements 
since first diagnosis. Treatment efficacy was determined based on blood glucose levels, 
survival rate, chimaerism using Y-FISH technique, insulitis, proliferating β-cells and 
insulin staining. Our clinical measurements are similar to the study by Zorina and 
colleagues, where they defined diabetes using glycosuria and blood glucose measurements 
and efficacy based on blood glucose levels, chimaerism in blood using FACS, evaluation 
of islet destruction, proliferating β-cells and insulin staining (Zorina et al., 2003). The 
variability that exists among current studies in terms of clinical measurements and 
outcomes may complicate the translation of results from mice to humans. For example the 
definition of diabetes in animals may reflect different states of diabetes progression, thus 
effecting therapeutic intervention. A standard definition for diabetes and treatment efficacy 
thus needs to be established for utility for future human clinical trials. 
 
8.2.6. Paracrine growth factors for augmentation of vasculogenesis 
 
In our study, EPCs were isolated from BM and cultured for 3-4 weeks in standard 
endothelial growth media. Some studies have demonstrated that EPCs transfected with 
VEGF or preconditioning of cells with G-CSF growth factors can augment 
neovascularization in rat myocardial ischaemia and mouse hindlimb ischaemia models 
(Iwaguro et al., 2002; Kocher et al., 2001). Following these studies, Chen et al., implanted 
a layered scaffold in a mouse model of hindlimb ischaemia. The implant delivered spatially 
controlled gradients of VEGF in the mouse, resulting in increased blood vessel density and  
rapid restoration of hindlimb blood flow (Chen et al., 2007). Interestingly, Di Santo and 
colleagues recently demonstrated that EPCs are not necessary to augment 
neovascularization, instead conditioned media from EPCs grown in hypoxia for 72 hours 
can achieve the same effect in rat hindlimb ischaemia (Di Santo et al., 2009). This cell-free 
based therapy offers great potential for therapeutic applications. 
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8.2.7. Limitations in established techniques for the assessment of chimaerism 
 
Analysis of chimaerism after allogeneic BM cell transplantation is important for assessing 
engraftment and the early detection of graft failure. In sex mis-matched transplanted mice, 
where male cells were transplanted into female mice, the obvious method in distinguishing 
donor cells from host cells is the detection of the Y-chromosome in the recipient mice. In 
our BM and EPC transplanted studies, Y-chromosome fluorescent in situ hybridization (Y-
FISH) technique was used to identify Y-chromosomes in the female mice. In the first batch 
of BM transplanted mice, very few Y-chromosomes were detected in the spleen and 
pancreas. Similarly, de Weger and colleagues identified very low numbers of Y-
chromosomes in the host tissue, which did not correlate with the numbers they had 
transplanted (de Weger et al., 2008). Although the degree of injury/stimulus may possibly 
be the reason for low BM engraftment, the authors suggested that this discrepancy could be 
due to technical factors, where the apparent lack of a demonstrable Y-chromosome in half 
of the sections could be due to the location of the Y-chromosome outside the plane of the 
section. Analysis of polymorphic DNA sequences, i.e. short tandem repeats (STR) or 
variable number of tandem repeats (VNTR), is another widely used procedure used in the 
assessment of chimaerism. Although STR-PCR and Y-FISH method allow rapid and 
quantitative evaluation of engraftment, their use is limited in the monitoring of minimal 
residual disease due to its sensitivity of 0.1-5% (Elmaagacli et al., 2001). In recent years, 
other sensitive methods such as real time PCR on the analysis of Y-chromosome (Y-PCR) 
and single nucleotide polymorphism PCR (SNP-PCR) have been developed. Based on 
Koldehoff et al. study, they demonstrated the SNP-PCR method using 10 different SNP 
loci and were able to detect patients with a high risk of relapse after transplant significantly 
earlier than the STR-PCR method (Koldehoff et al., 2006). Additionally, the authors 
suggested that Y-PCR is a more sensitive method than interphase XY-FISH method where 
Y-PCR could detect 3 times more relapses by mixed chimaerism compared to XY-FISH. 
 
8.2.8. Effect of endothelial dysfunction  
 
EPC number is reduced and functionally impaired in patients with diabetes, rheumatoid 
arthritis and cardiovascular disease. When BM-derived progenitor cells (Sca-1+ cells) from 
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type 2 diabetic Leprdb mice were injected into skin wounds of diabetic mice, these cells 
failed to enhance wound vascularization and were unable to form tubules and incorporate 
efficiently in wound structures (Stepanovic et al., 2003). Non-diabetic cells from Leprdb 
mice however were able to promote neovascularization compared to diabetic cells, 
suggesting that although there is a numerical dysfunction of EPCs in Leprdb mice, the 
remaining EPCs may still have some angiogenic function. In our study, we observed that 
transplanted wild type EPCs can promote revascularization in early diabetic NOD mice 
based on increased islet blood vessel density compared to when non-diabetic NOD EPCs 
were transplanted. When these observations are gathered together, the wild type or healthy 
EPCs have the best efficacy in promoting neovascularization, followed by non-diabetic and 
diabetic cells. This warrants the need to investigate whether endothelial dysfunction exists 
from birth or onset of the disease which may affect future intervention strategies. 
 
8.3. FUTURE DIRECTIONS  
8.3.1. Investigate the mechanisms involved in β-cell regeneration 
 
It has not been shown before that EPCs may have a role in β-cell regeneration. In light of 
the observations made in this thesis, the mechanism by which EPCs promote β-cell 
regeneration needs to be identified and studied more extensively. For example, EPCs can 
release paracrine factors that could recruit and mobilize stem cells and simulate tissue 
repair. Different EPC subtypes should be studied and growth factors released need to be 
identified to allow direct use in future therapy. As EPCs are mainly derived from the BM, 
they may also have immunosuppressive activity as shown for BM-derived MSCs.  
 
8.3.2. Strategies to promote mobilization and homing 
Stimuli such as tissue injury, ischaemia and hypoxia can initiate mobilization of stem cells 
and EPCs from the BM. EPC mobilization and homing properties are impaired in diabetic 
mice. The introduction of growth factors such as GM-CSF & SDF-1 and IL-1β has been 
shown to promote mobilization and homing of endogenous EPCs. Therefore the 
combination of EPC transplantation and growth factors would be able to further augment 
neovascularization in the mice. Additional procedures to improve the mobilization and 
 
Chapter 8                                                             General summary and future directions 
 
 
 
Cheen Khoo                                                                                                                           154           
 
homing of EPCs to the damaged site could also include inducing ischaemia prior to 
transplantation. 
 
8.2.3. Strategies to improve EPC function 
 
Hypoxia is a well known stimulatory factor to mobilize EPCs into the circulation (Shintani 
et al., 2001; Takahashi et al., 1999). Recent studies have shown that EPCs grown in 
hypoxic condition of 1% oxygen concentration have an effect on EPC proliferation, 
differentiation, tubule formation and paracrine release. The culture of EPCs in reduced 
oxygen concentrations before transplantation into animal models would allow the 
evaluation of whether hypoxic preconditioning can enhance therapeutic vasculogenesis. 
 
8.2.4. Optimising treatment efficacy 
 
XG-102 and BM-derived EPCs were injected into newly diabetic NOD mice with the aim 
of delaying or preventing diabetes in the NOD mice, but very few residual β-cells were 
left. Data collected in these studies, demonstrate that treatment timing is therefore 
important. As NOD mice develop diabetes spontaneously, future intervention therefore 
should be carried out not only at one time point but several other time points in the 
development of diabetes of the NOD mouse. Additionally, other factors such as the dose 
and length of post-treatment also need to be considered and optimized. 
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